0000950170-22-014809.txt : 20220804 0000950170-22-014809.hdr.sgml : 20220804 20220804163732 ACCESSION NUMBER: 0000950170-22-014809 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Relay Therapeutics, Inc. CENTRAL INDEX KEY: 0001812364 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39385 FILM NUMBER: 221137267 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-370-8837 MAIL ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-Q 1 rlay-20220630.htm 10-Q 10-Q
--12-31falsehttp://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMemberhttp://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMemberhttp://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMemberhttp://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMemberQ200018123640001812364rlay:OtherthirdPartiesMember2021-01-012021-06-300001812364us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001812364us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001812364rlay:EQRxIncMember2022-01-012022-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberrlay:InvestmentsWithMaturityOfOneToTwoYearsMember2021-12-310001812364rlay:DEShawResearchMember2022-04-012022-06-300001812364rlay:DEShawResearchMember2021-01-012021-06-300001812364us-gaap:CommonStockMember2022-03-310001812364us-gaap:RetainedEarningsMember2021-04-012021-06-300001812364us-gaap:FairValueInputsLevel3Memberrlay:ZebiaiMember2021-04-220001812364us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-3000018123642022-03-310001812364us-gaap:LicenseMemberrlay:GenentechIncMember2022-04-012022-06-300001812364us-gaap:CommonStockMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001812364rlay:OtherthirdPartiesMember2021-04-012021-06-300001812364rlay:ZebiaiMember2022-01-012022-06-300001812364us-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001812364us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-3000018123642021-01-012021-03-310001812364us-gaap:CommonStockMember2022-04-012022-06-300001812364rlay:DEShawResearchMember2022-01-012022-06-300001812364us-gaap:RetainedEarningsMember2022-04-012022-06-300001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001812364us-gaap:RetainedEarningsMember2021-12-3100018123642021-04-012021-06-300001812364rlay:UndesignatedpreferredstockMember2022-06-300001812364rlay:InvestmentsWithMaturityOfOneYearOrLessMemberus-gaap:USTreasurySecuritiesMember2021-12-310001812364us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-3000018123642022-06-3000018123642022-01-012022-06-300001812364us-gaap:LicenseMemberrlay:GenentechIncMember2021-01-012021-06-300001812364us-gaap:RetainedEarningsMember2021-01-012021-03-310001812364us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364rlay:DEShawResearchMember2021-12-310001812364us-gaap:AdditionalPaidInCapitalMember2021-12-310001812364us-gaap:FairValueInputsLevel2Memberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001812364us-gaap:USTreasurySecuritiesMember2022-06-300001812364us-gaap:USTreasurySecuritiesMemberrlay:InvestmentsWithMaturityOfOneToTwoYearsMember2022-06-300001812364rlay:GenentechIncMember2022-01-012022-06-300001812364us-gaap:RetainedEarningsMember2021-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001812364us-gaap:USTreasurySecuritiesMember2021-12-310001812364us-gaap:OtherLiabilitiesMember2022-06-300001812364us-gaap:RetainedEarningsMember2022-06-300001812364rlay:LeaseAgreementMemberrlay:DEShawResearchMember2021-12-310001812364us-gaap:EmployeeStockOptionMember2022-01-012022-06-3000018123642021-12-3100018123642021-06-300001812364us-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:CommonStockMember2022-01-012022-03-310001812364us-gaap:CommonStockMember2020-12-310001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-3000018123642022-07-290001812364us-gaap:AdditionalPaidInCapitalMember2020-12-310001812364us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:CommonStockMember2022-06-300001812364us-gaap:USTreasurySecuritiesMemberrlay:InvestmentsWithMaturityOfOneToTwoYearsMember2021-12-310001812364us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001812364rlay:InvestmentsWithMaturityOfOneYearOrLessMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001812364us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001812364rlay:DEShawResearchMember2022-06-3000018123642021-03-310001812364us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:AdditionalPaidInCapitalMember2022-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberrlay:InvestmentsWithMaturityOfOneYearOrLessMember2022-06-300001812364us-gaap:FairValueInputsLevel2Memberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:CommonStockMember2021-03-3100018123642021-01-012021-06-300001812364us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001812364us-gaap:LicenseAgreementTermsMemberrlay:OtherthirdPartiesMember2021-12-310001812364us-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:CommonStockMember2021-01-012021-03-310001812364us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001812364us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364rlay:InvestmentsWithMaturityOfOneToTwoYearsMember2021-12-310001812364us-gaap:CommonStockMember2021-06-3000018123642022-04-012022-06-300001812364us-gaap:AdditionalPaidInCapitalMember2021-03-310001812364us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001812364us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-3000018123642022-01-012022-03-310001812364us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001812364rlay:OtherthirdPartiesMember2022-01-012022-06-300001812364us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001812364us-gaap:USTreasurySecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:LicenseAgreementTermsMemberrlay:OtherthirdPartiesMember2022-06-300001812364us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001812364rlay:InvestmentsWithMaturityOfOneYearOrLessMember2022-06-300001812364rlay:OtherthirdPartiesMember2022-04-012022-06-3000018123642020-12-310001812364us-gaap:RetainedEarningsMember2022-03-310001812364us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberrlay:InvestmentsWithMaturityOfOneToTwoYearsMember2022-06-300001812364us-gaap:RetainedEarningsMember2021-03-310001812364us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001812364us-gaap:RetainedEarningsMember2022-01-012022-03-310001812364us-gaap:LicenseMemberrlay:GenentechIncMember2022-01-012022-06-300001812364us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001812364us-gaap:USTreasurySecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001812364us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001812364rlay:ZebiaiMember2022-06-260001812364us-gaap:LicenseMemberrlay:GenentechIncMember2021-04-012021-06-300001812364us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001812364us-gaap:USGovernmentAgenciesDebtSecuritiesMemberrlay:InvestmentsWithMaturityOfOneYearOrLessMember2021-12-310001812364rlay:LeaseAgreementMemberrlay:DEShawResearchMember2022-06-300001812364us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001812364us-gaap:OtherLiabilitiesMember2021-12-310001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001812364us-gaap:RetainedEarningsMember2020-12-310001812364rlay:InvestmentsWithMaturityOfOneYearOrLessMemberus-gaap:USTreasurySecuritiesMember2022-06-300001812364rlay:DEShawResearchMember2021-04-012021-06-300001812364us-gaap:CommonStockMember2021-04-012021-06-300001812364us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001812364us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:InvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001812364us-gaap:AdditionalPaidInCapitalMember2022-03-310001812364rlay:InvestmentsWithMaturityOfOneToTwoYearsMember2022-06-300001812364rlay:UndesignatedpreferredstockMember2021-12-310001812364us-gaap:AdditionalPaidInCapitalMember2021-06-30rlay:DebtSecurityiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

 

06-30-202s

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2022

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

Commission File Number: 001-39385

 

RELAY THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

47-3923475

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

399 Binney Street, 2nd Floor

Cambridge, MA

 

02139

(Address of principal executive offices)

 

(Zip Code)

 

(617) 370-8837

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

 

RLAY

 

Nasdaq Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

As of July 29, 2022, the registrant had 108,898,083 shares of common stock, $0.001 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

 

Page

PART I.

 

FINANCIAL INFORMATION

 

 

Item 1.

 

Financial Statements (Unaudited)

 

1

 

 

Condensed Consolidated Balance Sheets

 

1

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

 

2

 

 

Condensed Consolidated Statements of Stockholders’ Equity

 

3

 

 

Condensed Consolidated Statements of Cash Flows

 

4

 

 

Notes to Condensed Consolidated Financial Statements

 

5

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

11

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

21

Item 4.

 

Controls and Procedures

 

21

PART II.

 

OTHER INFORMATION

 

23

Item 1.

 

Legal Proceedings

 

23

Item 1A.

 

Risk Factors

 

23

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

67

Item 5.

 

Other Information

 

67

Item 6.

 

Exhibits

 

68

Signatures

 

69

 

i


 

SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS

We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
Positive data from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive data from our preclinical or early clinical studies of our product candidates in our future clinical trials, we will be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.
Our current or future clinical trials may reveal significant adverse events not seen in our preclinical or other nonclinical studies or early clinical data and may result in a safety profile that would inhibit regulatory approval or market acceptance of any of our product candidates.
Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.
The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
If we are not able to obtain, or if delays occur in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.
Under our Amended and Restated Collaboration and License Agreement, or the DESRES Agreement, with D. E. Shaw Research, LLC, or D. E. Shaw Research, we collaborate with D. E. Shaw Research to rapidly develop various protein models, a process that depends on D. E. Shaw Research’s use of their proprietary supercomputer, Anton 2. A termination of the DESRES Agreement could have a material adverse effect on our business, financial condition, results of operations, and prospects.
We rely on third parties to conduct our ongoing clinical trials of RLY-1971, RLY-4008 and RLY-2608 and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
We contract with third parties for the manufacture of our product candidates for preclinical development, clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.
We have and may enter into other collaborations with third parties for the research, development, manufacture and commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.
We are a biopharmaceutical company with a limited operating history. We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. We have no products approved for commercial sale and have not generated any revenue from product sales.
We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.
The ongoing COVID-19 pandemic has impacted our business and any future pandemic, epidemic, or outbreak of an infectious disease could similarly affect our business and our financial results and could cause further disruption to the development of our product candidates.

ii


 

Global economic uncertainty or political instability could adversely affect our business, financial condition or results of operations.
If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products will be impaired.
Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.

iii


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;
the identification of research priorities and application of a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities;
the potential safety and efficacy of our product candidates and the therapeutic implications of clinical and preclinical data;
the manufacture of our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;
our relationships with our third-party strategic collaborators and their ability to continue research and development activities relating to our development candidates and product candidates;
the funding for our operations necessary to complete further development and commercialization of our product candidates;
our plans to seek regulatory approval of our product candidates;
the pricing and reimbursement of our product candidates, if approved;
the implementation of our business model, and strategic plans for our business, product candidates, and technology;
the scope of protection for intellectual property rights covering our product candidates and technology;
estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;
the potential benefits of strategic collaboration agreements with collaborators with development, regulatory and commercialization expertise;
future agreements with third parties in connection with the commercialization of product candidates and any other approved product;
the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
our financial performance;
the rate and degree of market acceptance of our product candidates;
regulatory developments in the United States and foreign countries;
our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;
the success of competing therapies that are or may become available;
our ability to attract and retain key scientific or management personnel;
the impact of laws and regulations on our business and programs;
developments relating to our competitors and our industry;

iv


 

the effect of the ongoing COVID-19 pandemic and the current conflict between Russia and Ukraine, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and
other risks and uncertainties, including those listed under the caption “Risk Factors.”

In some cases, you can identify forward-looking statements by terminology such as “may,” “can,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “projects,” “will,” “might,” “could,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed above under “Summary of the Material Risks Associated with Our Business”, those listed below under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

v


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Relay Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

June 30,
2022

 

 

December 31,
2021

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

107,736

 

 

$

280,119

 

Investments

 

 

730,254

 

 

 

677,954

 

Accounts receivable

 

 

288

 

 

 

403

 

Contract asset

 

 

4,764

 

 

 

4,537

 

Prepaid expenses and other current assets

 

 

12,751

 

 

 

13,229

 

Total current assets

 

 

855,793

 

 

 

976,242

 

Property and equipment, net

 

 

8,922

 

 

 

6,543

 

Operating lease assets

 

 

19,828

 

 

 

20,780

 

Restricted cash

 

 

2,578

 

 

 

2,578

 

Intangible asset

 

 

2,300

 

 

 

2,300

 

Total assets

 

$

889,421

 

 

$

1,008,443

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

4,296

 

 

$

8,276

 

Accrued expenses

 

 

22,108

 

 

 

13,557

 

Operating lease liabilities

 

 

2,002

 

 

 

1,844

 

Deferred revenue

 

 

83

 

 

 

248

 

Other current liabilities

 

 

15,413

 

 

 

396

 

Total current liabilities

 

 

43,902

 

 

 

24,321

 

Operating lease liabilities, net of current portion

 

 

20,019

 

 

 

21,056

 

Contingent consideration liability

 

 

45,863

 

 

 

50,258

 

Other liabilities

 

 

 

 

 

15,000

 

Total liabilities

 

 

109,784

 

 

 

110,635

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of
   June 30, 2022 and December 31, 2021;
no shares issued and outstanding at June 30,
   2022 and December 31, 2021

 

 

 

 

 

 

Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized
   at June 30, 2022 and December 31, 2021, respectively;
108,810,478 and 108,210,318
   shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

 

109

 

 

 

109

 

Additional paid-in capital

 

 

1,698,368

 

 

 

1,666,887

 

Accumulated other comprehensive loss

 

 

(11,906

)

 

 

(1,088

)

Accumulated deficit

 

 

(906,934

)

 

 

(768,100

)

Total stockholders’ equity

 

 

779,637

 

 

 

897,808

 

Total liabilities and stockholders’ equity

 

$

889,421

 

 

$

1,008,443

 

See accompanying notes.

1


 

Relay Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

License and other revenue

 

$

365

 

 

$

844

 

 

$

784

 

 

$

1,796

 

Total revenue

 

 

365

 

 

 

844

 

 

 

784

 

 

 

1,796

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

$

60,511

 

 

$

45,147

 

 

$

112,178

 

 

$

75,769

 

In-process research and development expenses

 

 

 

 

 

123,000

 

 

 

 

 

 

123,000

 

Loss on initial consolidation of variable interest entity

 

 

 

 

 

11,855

 

 

 

 

 

 

11,855

 

Change in fair value of contingent consideration liability

 

 

200

 

 

 

 

 

 

(4,395

)

 

 

 

General and administrative expenses

 

 

17,465

 

 

 

14,422

 

 

 

33,533

 

 

 

27,156

 

Total operating expenses

 

 

78,176

 

 

 

194,424

 

 

 

141,316

 

 

 

237,780

 

Loss from operations

 

 

(77,811

)

 

 

(193,580

)

 

 

(140,532

)

 

 

(235,984

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

1,005

 

 

 

180

 

 

 

1,701

 

 

 

406

 

Other income (expense)

 

 

18

 

 

 

1

 

 

 

(3

)

 

 

(4

)

Total other income, net

 

 

1,023

 

 

 

181

 

 

 

1,698

 

 

 

402

 

Net loss

 

$

(76,788

)

 

$

(193,399

)

 

$

(138,834

)

 

$

(235,582

)

Net loss per share, basic and diluted

 

$

(0.71

)

 

$

(2.10

)

 

$

(1.28

)

 

$

(2.58

)

Weighted average shares of common stock, basic and diluted

 

 

108,644,329

 

 

 

91,939,439

 

 

 

108,469,760

 

 

 

91,188,160

 

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized holding loss

 

 

(2,688

)

 

 

(76

)

 

 

(10,818

)

 

 

(128

)

Total other comprehensive loss

 

 

(2,688

)

 

 

(76

)

 

 

(10,818

)

 

 

(128

)

Total comprehensive loss

 

$

(79,476

)

 

$

(193,475

)

 

$

(149,652

)

 

$

(235,710

)

See accompanying notes.

2


 

Relay Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share data)

(Unaudited)

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Par value

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2021

 

 

108,210,318

 

 

$

109

 

 

$

1,666,887

 

 

$

(1,088

)

 

$

(768,100

)

 

$

897,808

 

Issuance of common stock upon exercise of stock options

 

 

195,799

 

 

 

 

 

 

883

 

 

 

 

 

 

 

 

 

883

 

Vesting of restricted stock units

 

 

27,233

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

13,455

 

 

 

 

 

 

 

 

 

13,455

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

(8,130

)

 

 

 

 

 

(8,130

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(62,046

)

 

 

(62,046

)

Balances at March 31, 2022

 

 

108,433,350

 

 

$

109

 

 

$

1,681,225

 

 

$

(9,218

)

 

$

(830,146

)

 

$

841,970

 

Issuance of common stock upon exercise of stock options

 

 

182,113

 

 

 

 

 

 

859

 

 

 

 

 

 

 

 

 

859

 

Issuance of common stock under ESPP

 

 

79,859

 

 

 

 

 

 

1,137

 

 

 

 

 

 

 

 

 

1,137

 

Vesting of restricted stock units

 

 

115,156

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

15,147

 

 

 

 

 

 

 

 

 

15,147

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

(2,688

)

 

 

 

 

 

(2,688

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(76,788

)

 

 

(76,788

)

Balances at June 30, 2022

 

 

108,810,478

 

 

$

109

 

 

$

1,698,368

 

 

$

(11,906

)

 

$

(906,934

)

 

$

779,637

 

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Par value

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2020

 

 

89,906,835

 

 

$

90

 

 

$

1,167,367

 

 

$

64

 

 

$

(404,228

)

 

$

763,293

 

Issuance of common stock upon exercise of stock options

 

 

437,230

 

 

 

 

 

 

2,055

 

 

 

 

 

 

 

 

 

2,055

 

Vesting of restricted common stock

 

 

84,489

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

3

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

9,671

 

 

 

 

 

 

 

 

 

9,671

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

(52

)

 

 

 

 

 

(52

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(42,184

)

 

 

(42,184

)

Balances at March 31, 2021

 

 

90,428,554

 

 

$

90

 

 

$

1,179,096

 

 

$

12

 

 

$

(446,412

)

 

$

732,786

 

Issuance of common stock upon exercise of stock options

 

 

218,365

 

 

 

 

 

 

1,123

 

 

 

 

 

 

 

 

 

1,123

 

Vesting of restricted stock units

 

 

22,239

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

16,147

 

 

 

 

 

 

 

 

 

16,147

 

Shares issued in connection with acquisition of ZebiAI

 

 

1,883,487

 

 

 

2

 

 

 

61,946

 

 

 

 

 

 

 

 

 

61,948

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

(76

)

 

 

 

 

 

(76

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(193,399

)

 

 

(193,399

)

Balances at June 30, 2021

 

 

92,552,645

 

 

$

92

 

 

$

1,258,312

 

 

$

(64

)

 

$

(639,811

)

 

$

618,529

 

See accompanying notes.

3


 

Relay Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

 

(138,834

)

 

$

(235,582

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

 

 

 

Stock-based compensation expense

 

 

28,602

 

 

 

25,818

 

Depreciation expense

 

 

1,931

 

 

 

1,879

 

Net amortization of premiums and discounts on investments

 

 

1,227

 

 

 

701

 

Acquired in-process research and development

 

 

 

 

 

123,000

 

Loss on initial consolidation of variable interest entity

 

 

 

 

 

11,855

 

Change in fair value of contingent consideration liability

 

 

(4,395

)

 

 

 

Changes in assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

115

 

 

 

74,801

 

Contract asset

 

 

(227

)

 

 

3,462

 

Prepaid expenses and other current assets

 

 

478

 

 

 

4,964

 

Operating lease assets and liabilities, net

 

 

73

 

 

 

186

 

Other assets

 

 

 

 

 

22

 

Accounts payable

 

 

(4,611

)

 

 

(867

)

Accrued expenses and other liabilities

 

 

9,540

 

 

 

8,261

 

Deferred revenue

 

 

(165

)

 

 

 

Net cash (used in) provided by operating activities

 

 

(106,266

)

 

 

18,500

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(4,651

)

 

 

(855

)

Purchases of investments

 

 

(151,945

)

 

 

(646,239

)

Proceeds from maturities of investments

 

 

87,600

 

 

 

464,673

 

Cash paid for acquisition of ZebiAI, net of cash acquired

 

 

 

 

 

(25,132

)

Net cash used in investing activities

 

 

(68,996

)

 

 

(207,553

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from issuance of common stock upon exercise of stock options

 

 

1,742

 

 

 

3,176

 

Proceeds from issuance of common stock under ESPP

 

 

1,137

 

 

 

 

Net cash provided by financing activities

 

 

2,879

 

 

 

3,176

 

Net decrease in cash, cash equivalents and restricted cash

 

 

(172,383

)

 

 

(185,877

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

282,697

 

 

 

448,524

 

Cash, cash equivalents and restricted cash at end of period

 

 

110,314

 

 

 

262,647

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

Property and equipment additions included in accounts payable and accrued expenses

 

 

669

 

 

$

1,077

 

Reclassification of restricted stock liability to additional paid-in capital

 

 

 

 

$

3

 

Assets obtained in asset acquisition of ZebiAI

 

 

 

 

$

662

 

Liabilities assumed in asset acquisition of ZebiAI

 

 

 

 

$

2,330

 

Fair value of equity issued in asset acquisition of ZebiAI

 

 

 

 

$

62,990

 

Reconciliation of Cash, Cash Equivalents and Restricted Cash from Balance Sheets to Statement of Cash Flows

 

 

 

June 30,
2022

 

 

June 30,
2021

 

Cash and cash equivalents

 

$

107,736

 

 

$

260,069

 

Restricted cash

 

 

2,578

 

 

 

2,578

 

Total cash, cash equivalents and restricted cash as shown on condensed consolidated
   statements of cash flows

 

$

110,314

 

 

$

262,647

 

See accompanying notes.

4


 

Relay Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(In thousands, except share and per share data)

(Unaudited)

1. Nature of Business and Basis of Presentation

Relay Therapeutics, Inc. (the “Company”) was incorporated in Delaware on May 4, 2015 and is headquartered in Cambridge, Massachusetts. The Company is a clinical-stage, precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the Company believes it is among the first of a new breed of biotech created at the intersection of disparate technologies, the Company aims to push the boundaries of what’s possible in drug discovery. The Company’s Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s lead product candidates, RLY-4008, RLY-2608 and RLY-1971, are in clinical development. The Company also has over five discovery stage programs across both precision oncology and genetic disease indications.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.

The Company’s product candidates are in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.

The Company has devoted substantially all of its resources to developing its product candidates, including RLY-4008, RLY-2608 and RLY-1971, by developing its computation and experimental approaches, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations.

The Company has incurred net operating losses since inception and had an accumulated deficit of $906.9 million as of June 30, 2022. The Company expects that its existing cash, cash equivalents and investments as of June 30, 2022 will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue its business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into license or collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all.

2. Significant Accounting Policies

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The Company’s condensed consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiaries, Relay Therapeutics Securities Corporation and Relay ML Discovery, LLC.

All intercompany balances and transactions have been eliminated.

Certain prior period amounts, specifically including certain current liabilities, have been reclassified to conform to current period presentation. Such reclassifications have no impact on the Company’s condensed consolidated statement of operations and comprehensive loss, as previously reported.

5


 

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of June 30, 2022, the condensed consolidated results of its operations for the three and six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The condensed consolidated financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The condensed consolidated results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. (“ZebiAI”), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments thereto require that credit losses be reported as an allowance using an expected losses model, representing the entity’s current estimate of credit losses expected to be incurred. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company’s condensed consolidated financial statements or disclosures as of and for the three and six months ended June 30, 2022.

Recently Issued Accounting Pronouncements Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of any recently issued standards have or may have a material impact on its condensed consolidated financial statements and disclosures.

3. Fair Value Measurements

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

 

 

Fair Value Measurements as of
June 30, 2022:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

80,153

 

 

$

 

 

$

 

 

$

80,153

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

 

 

 

478,880

 

 

 

 

 

 

478,880

 

U.S. agency securities

 

 

 

 

 

251,374

 

 

 

 

 

 

251,374

 

Total investments

 

 

 

 

 

730,254

 

 

 

 

 

 

730,254

 

Total assets

 

$

80,153

 

 

$

730,254

 

 

$

 

 

$

810,407

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Milestone Payments

 

$

 

 

$

 

 

$

40,863

 

 

$

40,863

 

Total liabilities

 

$

 

 

$

 

 

$

40,863

 

 

$

40,863

 

 

6


 

 

 

 

Fair Value Measurements as of
December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

251,891

 

 

$

 

 

$

 

 

$

251,891

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

 

 

 

469,386

 

 

 

 

 

 

469,386

 

U.S. agency securities

 

 

 

 

 

208,568

 

 

 

 

 

 

208,568

 

Total investments

 

 

 

 

 

677,954

 

 

 

 

 

 

677,954

 

Total assets

 

$

251,891

 

 

$

677,954

 

 

$

 

 

$

929,845

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Milestone Payments

 

$

 

 

$

 

 

$

45,258

 

 

$

45,258

 

Total liabilities

 

$

 

 

$

 

 

$

45,258

 

 

$

45,258

 

In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data.

Fair Value of Contingent Consideration Liability

In April 2021, the Company acquired ZebiAI.

The Company’s Level 3 contingent consideration liability is related to $85.0 million of platform and program-related milestones (“Contingent Milestone Payments”) potentially payable to ZebiAI’s former equity holders. The contingent consideration liability for the Contingent Milestone Payments is measured at fair value at each reporting date pursuant to FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company determines the fair value of the Contingent Milestone Payments based on the probability of achieving the milestones, the related timing, and, to a lesser extent, an appropriate discount rate. Significant judgment is used in determining these assumptions. Due to the uncertainties associated with the development of platforms and drug candidates in the pharmaceutical industry and the effects of changes in assumptions including probability of success and related timing, the Company expects its estimates regarding the fair value of Contingent Milestone Payments to continue to change in the future, resulting in adjustments to the fair value of the Company’s Contingent Milestone Payments, and the effect of any such adjustments could be material.

 

The Company also has a contingent consideration liability related to the fair value of $100.0 million in earnout payments (“Contingent Earnout Payments”). Because the Contingent Earnout Payments were not accounted for as derivatives under FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"), they were only measured at fair value as of the acquisition date and are not re-assessed at fair value at each reporting period. The Contingent Earnout Payments will be adjusted when the contingency is resolved and the consideration is paid or becomes payable.

The following table reconciles the change in fair value of the contingent consideration liability (in thousands):

 

 

 

 

Six Months Ended June 30, 2022

 

Balance at December 31, 2021

$

50,258

 

Change in fair value of Contingent Milestone Payments

 

(4,395

)

Balance at June 30, 2022

$

45,863

 

The “Change in fair value of Contingent Milestone Payments” in the table above was attributable to changes in the assumptions noted above between December 31, 2021 and June 30, 2022, primarily changes in timing and interest rates.

The Contingent Milestone Payments are payable in shares of common stock based on a fixed amount assigned to each milestone and the average closing price of the Company’s common stock for the 5-day period prior to the milestone achievement. Accordingly, the number of shares of common stock to be issued upon a milestone achievement vary dependent on the Company’s common stock price. The settlement amounts of Contingent Milestone Payments are predominantly fixed. If the milestones were achieved in full on June 30, 2022, the number of shares of common stock to be issued would be 4,751,258 based on an average closing price of the Company's common stock of $17.89 for the 5-day period prior to June 30, 2022.

7


 

4. Investments

The fair value of available-for-sale investments by type of security was as follows:

 

 

June 30, 2022

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

332,729

 

 

$

 

 

$

(4,150

)

 

$

328,579

 

U.S. agency securities

 

 

165,061

 

 

 

 

 

 

(1,462

)

 

 

163,599

 

Total investments with a maturity of one year or less

 

 

497,790

 

 

 

 

 

 

(5,612

)

 

 

492,178

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

154,076

 

 

 

 

 

 

(3,775

)

 

 

150,301

 

U.S. agency securities

 

 

90,294

 

 

 

 

 

 

(2,519

)

 

 

87,775

 

Total investments with a maturity of one to two years

 

 

244,370

 

 

 

 

 

 

(6,294

)

 

 

238,076

 

Total investments

 

$

742,160

 

 

$

 

 

$

(11,906

)

 

$

730,254

 

 

 

 

December 31, 2021

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

189,406

 

 

$

 

 

$

(228

)

 

$

189,178

 

U.S. agency securities

 

 

108,895

 

 

 

 

 

 

(138

)

 

 

108,757

 

Total investments with a maturity of one year or less

 

 

298,301

 

 

 

 

 

 

(366

)

 

 

297,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

280,743

 

 

 

 

 

 

(535

)

 

 

280,208

 

U.S. agency securities

 

 

99,998

 

 

 

 

 

 

(187

)

 

 

99,811

 

Total investments with a maturity of one to two years

 

 

380,741

 

 

 

 

 

 

(722

)

 

 

380,019

 

Total investments

 

$

679,042

 

 

$

 

 

$

(1,088

)

 

$

677,954

 

Pursuant to the Company’s adoption of ASU 2016-13 and the related amendments thereto on January 1, 2022, the Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive (loss) income. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.

The Company held 112 and 88 debt securities that were in an unrealized loss position as of June 30, 2022 and December 31, 2021, respectively. The unrealized losses at June 30, 2022 and December 31, 2021 were attributable to changes in interest rates and the unrealized losses do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis.

The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at June 30, 2022, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

 

 

Less than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

478,880

 

 

$

(7,925

)

 

$

 

 

$

 

 

$

478,880

 

 

$

(7,925

)

U.S. agency securities

 

 

251,374

 

 

 

(3,981

)

 

 

 

 

 

 

 

 

251,374

 

 

 

(3,981

)

Total

 

$

730,254

 

 

$

(11,906

)

 

$

 

 

$

 

 

$

730,254

 

 

$

(11,906

)

 

8


 

The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2021, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

 

 

Less than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

469,386

 

 

$

(763

)

 

$

 

 

$

 

 

$

469,386

 

 

$

(763

)

U.S. agency securities

 

 

208,568

 

 

 

(325

)

 

 

 

 

 

 

 

 

208,568

 

 

 

(325

)

Total

 

$

677,954

 

 

$

(1,088

)

 

$

 

 

$

 

 

$

677,954

 

 

$

(1,088

)

 

5. Collaboration and License Arrangements

Discovery Collaboration Agreement with EQRx, Inc.

During the three and six months ended June 30, 2022, there were no changes to the Company’s Discovery and Collaboration Agreement (“Collaboration Agreement”) with EQRx, Inc. (“EQRx”) from August 2021. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.

During the three and six months ended June 30, 2022, expenses related to the Collaboration Agreement were immaterial.

Collaboration and License Agreement with Genentech, Inc.

During the three and six months ended June 30, 2022 and 2021, there were no material changes to the Company’s Collaboration and License Agreement (“License Agreement”) with Genentech, Inc. (“Genentech”) from December 2020. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.

During the three months ended June 30, 2022 and 2021, the Company recognized $0.3 million and $0.8 million of revenue from the License Agreement, respectively.

During the six months ended June 30, 2022 and 2021, the Company recognized $0.5 million and $1.7 million of revenue from the License Agreement, respectively.

As of June 30, 2022 and December 31, 2021, the Company recorded a contract asset of $4.8 million and $4.5 million, respectively, both of which are classified as current assets on the condensed consolidated balance sheet. The contract asset relates to the amount of revenue recognized for which the right to payment is contingent upon conditions other than the passage of time, such as the completion of future milestone activities.

As of June 30, 2022 and December 31, 2021, the Company recorded an other liability in the amount of $15.0 million. The liability represents the cash received for a milestone payment in 2021 under the License Agreement. The amount has been excluded from the transaction price at both June 30, 2022 and December 31, 2021 and, therefore, excluded from amounts recognized as revenue, since the amount is subject to repayment to Genentech if the Company exercises its option to participate in the profit/cost share under the License Agreement.

6. Stock Compensation

Stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development expenses

 

$

8,139

 

 

$

10,145

 

 

$

15,249

 

 

$

14,296

 

General and administrative expenses

 

 

7,008

 

 

 

6,002

 

 

 

13,353

 

 

 

11,522

 

 

 

$

15,147

 

 

$

16,147

 

 

$

28,602

 

 

$

25,818

 

 

9


 

7. Net Loss Per Share

The following table summarizes the computation of basic and diluted net loss per share of the Company:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net loss

 

$

(76,788

)

 

$

(193,399

)

 

$

(138,834

)

 

$

(235,582

)

Net loss per share, basic and diluted

 

$

(0.71

)

 

$

(2.10

)

 

$

(1.28

)

 

$

(2.58

)

Weighted average shares of common stock, basic and diluted

 

 

108,644,329

 

 

 

91,939,439

 

 

 

108,469,760

 

 

 

91,188,160

 

The Company’s potentially dilutive securities, which include outstanding options to purchase common stock and restricted stock units summarized below, have been excluded from the computation of diluted net loss per share for the periods indicated below, as the effect would be anti-dilutive and reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same.

 

 

Three and Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

Options to purchase common stock

 

 

11,526,322

 

 

 

8,906,194

 

Restricted stock units

 

 

1,681,891

 

 

 

505,393

 

 

 

 

13,208,213

 

 

 

9,411,587

 

 

8. Commitments and Contingencies

Intellectual Property License

During the six months ended June 30, 2022, the Company amended the Amended and Restated Collaboration and License Agreement (“DESRES Agreement”) with D.E. Shaw Research, LLC (“D.E. Shaw Research”), specifically to update certain of the Category 1, Category 2, and Category 3 Target lists thereunder. However, there was no change to the Company’s accounting treatment or incremental amounts recognized in connection therewith for the three and six months ended June 30, 2022.

The Company assessed the milestones under the DESRES Agreement at June 30, 2022 and December 31, 2021, concluding no such milestone payments were due.

The Company recorded research and development expenses of $2.3 million and $2.1 million under the DESRES Agreement for the three months ended June 30, 2022 and 2021, respectively.

The Company recorded research and development expenses of $4.7 million and $3.9 million under the DESRES Agreement for the six months ended June 30, 2022 and 2021, respectively.

As of June 30, 2022 and December 31, 2021, the Company had accrued expense balances of $0.3 million and $0, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.

As of June 30, 2022 and December 31, 2021, the Company had prepaid balances of $0 and $4.4 million, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.

Other Significant Arrangements

The Company has certain other research and license arrangements with third parties, which provide the Company with research services with the goal of identifying and developing product candidates, and the Company is obligated to pay certain development milestone payments pursuant to these arrangements upon the achievement of certain specified contingent events. The Company assessed such milestones at June 30, 2022 and December 31, 2021, concluding no such milestone payments were due. The Company incurred approximately $1.6 million and $0.7 million of research and development expenses under these agreements for the three months ended June 30, 2022 and 2021, respectively. The Company incurred approximately $2.6 million and $1.1 million of research and development expenses under these agreements for the six months ended June 30, 2022 and 2021, respectively.

9. Subsequent Events

In preparing the consolidated interim financial statements as of June 30, 2022 and for the three and six month periods then ended, the Company evaluated subsequent events for recognition and measurement purposes. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.

10


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As we believe we are among the first of a new breed of biotech created at the intersection of disparate technologies, we aim to push the boundaries of what’s possible in drug discovery. Our Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Our initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

We are advancing a pipeline of medicines to address targets in precision oncology, including our lead product candidates, RLY-4008, RLY-2608 and RLY-1971.

RLY-4008. In the third quarter of 2020, we initiated a first-in-human clinical trial for RLY-4008, a potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2, or FGFR2, for patients with advanced or metastatic FGFR2-altered solid tumors. In October 2021, we announced initial clinical data from this trial, which suggested robust inhibition of FGFR2 in the first 49 subjects that was not observed to be limited by off-target toxicities, including hyperphosphatemia and diarrhea, as of the data cut-off date of September 9, 2021. In December 2021, we initiated expansion cohorts at a continuous 70 mg once-daily, or QD, dose, and in January 2022, the U.S. Food and Drug Administration, or FDA, granted orphan drug designation to RLY-4008 for the treatment of cholangiocarcinoma, or CCA. In the first half of 2022, we conducted an end-of-phase 1 meeting with the FDA to discuss next steps for the clinical development of RLY-4008. Based on discussions with the FDA, we have decided to move forward with a single arm trial design for pan-FGFR, or FGFRi, treatment-naïve FGFR2-fusion CCA to potentially support accelerated approval. In June 2022, we announced the anticipated registrational path for RLY-4008 in CCA and the interim clinical data with a data cut-off date of April 19, 2022 that was shared with the FDA to support such path. The interim clinical data included a safety database of 115 patients, with 58 patients treated with the QD dosing schedule, and 13 of these patients were FGFRi treatment-naïve FGFR2-fusion CCA patients treated with the QD dosing schedule ranging from 20 mg up to 70 mg. The interim clinical data from the QD dosing schedule shared with the FDA demonstrated confirmed partial responses in eight out of thirteen, or 62%, FGFRi-naïve FGFR2-fusion CCA patients, including all four of the patients treated at the registrational trial dose of 70 mg QD. The safety analysis of this interim clinical data was consistent with our analysis of the initial clinical data as of September 9, 2021.
RLY-2608. In December 2021, we dosed the first patient in a first-in-human clinical trial for RLY-2608, the first known allosteric, pan-mutant (H1047X, E542X and E545X) and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor in clinical development. In April 2022, we initiated the second arm of the dose escalation part of this trial, evaluating RLY-2608 in combination with fulvestrant for patients with HR+, HER2–, PI3Kα-mutated, locally advanced or metastatic breast cancer. RLY-2608 is the lead program of multiple efforts in our PI3Kα franchise to discover and develop mutant selective inhibitors of PI3Kα. In the fourth quarter of 2021, we announced preclinical data for RLY-2608, in which we observed that RLY-2608 preferentially bound to mutant PI3Kα at a novel allosteric site discovered by the Dynamo platform. The data also suggest that projected clinically relevant doses of RLY-2608 achieved tumor regression in PIK3CA mutant in vivo xenograft mouse models representing H1047R and E545K mutations with significantly reduced impact on glucose metabolism compared to non-mutant selective active site inhibitors. The data further suggest that in preclinical models, RLY-2608 combined with standard of care therapies facilitated regressions in ER+/HER2- breast cancer.
RLY-1971. We initiated a Phase 1 clinical trial for RLY-1971, our inhibitor of Src homology region 2 domain-containing phosphatase-2, or SHP2, in patients with advanced solid tumors in the first quarter of 2020. In December 2020, we entered into a global collaboration and license agreement, or the License Agreement, with Genentech, Inc., a member of the Roche Group, or Genentech, for the development and commercialization of RLY-1971. In July 2021, Genentech initiated the cohort of RLY-1971 in combination with GDC-6036, its KRAS G12C inhibitor, in a Phase 1b trial.

While our initial focus is on precision oncology, we believe our Dynamo platform may also be broadly applied to other areas of precision medicine, such as genetic disease indications. In addition to the three product candidates described above, we have over five discovery stage programs across both precision oncology and genetic disease. We announced three of these discovery stage programs in June 2022 as part of our HR+/HER2- breast cancer franchise, including a selective cyclin dependent kinase 2, or CDK2, inhibitor, a rationally designed estrogen receptor alpha, or ERα, degrader and a selective and chemically distinct pan-mutant PI3Kα inhibitor, RLY-5836. We are focused on using the novel insights derived from our approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of our therapies.

11


 

We were incorporated in May 2015. We have devoted substantially all of our resources to developing our lead product candidates, developing our innovative computational and experimental approaches on protein motion, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have principally financed our operations through private placements of preferred stock, convertible debt and proceeds from public offerings of our common stock. Additionally, in 2021, we received an aggregate of $95.0 million in connection with the License Agreement with Genentech.

In October 2021, we completed a public offering, or the October 2021 Offering, of 15,188,679 shares of common stock, including the exercise in full of the underwriters’ option to purchase an additional 1,981,132 shares, at an offering price of $26.50 per share, for net proceeds of $382.2 million, after deducting underwriting discounts and commissions and other offering expenses. In July 2020, we closed our initial public offering, or IPO, and issued 23,000,000 shares of our common stock at a price of $20.00 per share for net proceeds of $425.3 million, after deducting underwriting discounts and commissions and offering expenses. Prior to our IPO, we had received gross proceeds of approximately $520.0 million from sales of our preferred stock and our issuance of convertible debt.

In August 2021, we entered into the Discovery and Collaboration Agreement, or Collaboration Agreement, with EQRx, Inc., or EQRx, to discover, develop, and commercialize novel medicines against validated oncology targets. Under the terms of the agreement, we will be responsible for the discovery phase through to filing of the application for an Investigational New Drug, or IND, while EQRx will be responsible for clinical development, regulatory and commercialization efforts of the product candidates developed pursuant to the collaboration. Subject to certain opt-out rights, we and EQRx will equally share in the discovery, development and commercialization costs and the net profits from sales of any collaboration medicines, if approved. We retain the right to develop any collaboration medicines in combination with our wholly-owned pipeline.

On April 15, 2021, we entered into an Agreement and Plan of Merger, or the Merger Agreement, and on April 22, 2021, we acquired ZebiAI Therapeutics, Inc., or ZebiAI. Pursuant to the Merger Agreement, we were required to pay ZebiAI’s former stockholders, option holders and warrant holders, or the ZebiAI Holders, upfront consideration in an aggregate amount of approximately $85.0 million, excluding customary purchase price adjustments, composed of approximately $20.0 million payable in cash and approximately $65.0 million payable in shares of our common stock. In addition, (i) the ZebiAI Holders will be eligible to receive up to an additional $85.0 million in milestone payments upon the achievement of certain platform or program-related milestones, payable in our common stock and (ii) we will pay to the ZebiAI Holders 10% of the payments we receive within three years of the closing date of the Merger Agreement from partnering, collaboration or other agreements related to ZebiAI’s platform up to an aggregate maximum amount of $100.0 million, payable in cash.

In December 2020, we entered into the License Agreement with Genentech for the development and commercialization of RLY-1971. Under the terms of the License Agreement, we received $75.0 million in an upfront payment and $20.0 million in milestone payments from Genentech in 2021. We are eligible to receive an additional $5.0 million in near-term payments; and, if we do not opt into a U.S. profit/cost share, up to $695.0 million in additional development, commercialization and sales-based milestones for RLY-1971; and tiered royalties on annual global net sales (on a country-by-country basis), anticipated to be in the low-to-mid-teens, subject to reductions in certain circumstances. Additionally, we are eligible to receive additional royalties in the event of regulatory approval of RLY-1971 and Genentech’s compound, GDC-6036, that directly binds to and inhibits KRAS G12C, in combination. We have the right to opt-in to a 50/50 U.S. profit/cost share and if we do opt into the U.S. profit/cost share, we are eligible to receive up to $410.0 million in additional commercialization and sales-based milestones for RLY-1971 outside of the U.S. and tiered royalties on annual net sales outside of the U.S. (on a country-by-country basis), anticipated to be in the low-to-mid-teens, subject to reduction in certain circumstances. We also retain the right to develop RLY-1971 in combination with our FGFR2 and PI3Kα programs.

The ongoing COVID-19 pandemic has presented a substantial public health and economic challenge around the world and continues to affect our employees, patients, communities and business operations. The extent to which the COVID-19 pandemic may continue to affect our operations or those of our third-party partners, including our preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the severity and duration of additional variant outbreaks, vaccination rates where we or our third party partners conduct operations, and the actions to contain COVID-19 or treat its impact, among others. The continued spread of COVID-19 globally could adversely impact our preclinical or clinical trial operations in the United States, including our ability to obtain slots for IND-enabling studies, recruit and retain patients, principal investigators and site staff in our clinical trials, obtain sufficient clinical trial supply of our product candidates due to supply chain disruptions or interruptions in global shipping, as well as activate new clinical trial sites. To date, we have been able to continue to enroll our patients in first-in-human clinical trials for RLY-1971, RLY-4008, and RLY-2608, and we currently do not anticipate any interruptions in clinical enrollment or any material adverse impact on our financial condition or results of operations due to the ongoing COVID-19 pandemic. However, we are continuing to assess the potential impact of the ongoing COVID-19 pandemic on our current and future business and operations, including our expenses and clinical trials, as well as on our industry and the healthcare system. See “—The ongoing COVID-19 pandemic has impacted our business and any future pandemic, epidemic, or outbreak of an infectious disease could similarly affect our business and our financial results and could cause further disruption to the development of our product candidates” for a more detailed discussion of the risks related to the ongoing COVID-19 pandemic.

Additionally, inflation generally affects us by increasing our employee-related costs and clinical trial expenses, as well as other operating expenses. Our financial condition and results of operations may also be impacted by other factors we may not be able to control, such as global supply chain disruptions, uncertain global economic conditions, global trade disputes or political instability as further discussed in the section “Risk Factors” in this Quarterly Report. We do not believe that such factors had a material adverse impact on our results of operations during the three and six months ended June 30, 2022.

12


 

Since our inception, we have incurred significant operating losses on an aggregate basis. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $138.8 million and $235.6 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, we had an accumulated deficit of $906.9 million. These losses have resulted primarily from costs incurred in connection with research and development activities, licensing and patent investment and general and administrative costs associated with our operations. We expect to continue to incur significant expenses, including the costs of operating as a public company, and generate increasing operating losses for at least the next several years.

We anticipate that our expenses will increase substantially if and as we:

conduct our current and future clinical trials of RLY-4008 and RLY-2608;
conduct additional preclinical research and development of RLY-5836, our PI3Kα mutant selective inhibitor, CDK2 inhibitor and ERα degrader programs and other early-stage programs;
initiate and continue research and preclinical and clinical development of our other product candidates;
seek to identify additional product candidates;
pursue marketing approvals for any of our product candidates that successfully complete clinical trials, if any;
establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;
obtain, maintain, expand and protect our intellectual property portfolio;
acquire or in-license other drugs and technologies;
hire and retain additional clinical, regulatory, quality and scientific personnel;
build out new facilities or expand existing facilities to support our ongoing development activity; and
add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our operations as a public company.

In addition, if we obtain marketing approval for any of our lead product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.

As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed, on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates.

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce or terminate our operations.

We believe our cash, cash equivalents and investments of $838.0 million as of June 30, 2022, will enable us to fund our operating expenses and capital expenditure requirements into at least 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will need to raise additional capital in the future to continue developing the drugs in our pipeline and to commercialize any approved drug. We may seek to obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan.

13


 

Components of our Results of Operations

Revenue

To date, our revenue consists primarily of amounts related to the License Agreement with Genentech. We recognize our revenue as the performance obligations are satisfied under the agreement.

Operating Expenses

Research and Development Expenses

Research and development expenses include:

salaries, benefits and other employee related costs, including stock-based compensation expense, for personnel engaged in research and development functions;
costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, and other vendors that conduct our clinical trials and preclinical activities;
costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;
costs related to compliance with regulatory requirements; and
facility costs, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies. We do not allocate certain internal costs, facilities, or overhead costs to specific development programs.

We expense research and development costs as the services are performed or the goods are received. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid expenses or accrued research and development expenses.

Our most advanced development programs, RLY-1971, RLY-4008 and RLY-2608, are in first-in-human clinical trials. We have over five discovery stage programs across both precision oncology and genetic disease indications. Costs incurred for these programs include costs incurred to support our discovery research and translational science efforts up to the initiation of first-in-human clinical development. Platform research and other research and development activities include costs that are not specifically allocated to active product candidates, including facilities costs, depreciation expense and other costs. Employee related expenses includes salary, wages, stock-based compensation and other costs related to our personnel, which are not allocated to specific programs or activities.

We cannot determine with certainty the duration and costs of future clinical trials and future development costs, if, when or to what extent we will generate revenue from the commercialization and sale of any of our product candidates for which we obtain marketing approval or our other research and development costs. We may never succeed in obtaining marketing approval for any of our product candidates.

The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:

the scope, rate of progress, expense and results of our preclinical development activities, any future clinical trials of RLY-4008, RLY-2608 or other product candidates and other research and development activities that we may conduct;
uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates;
establishing an appropriate safety and efficacy profile with IND-enabling studies;
the initiation and completion of future clinical trial results;
the timing, receipt and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;
significant and changing government regulation and regulatory guidance;

14


 

potential additional studies requested by regulatory agencies;
establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;
the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers or other vendors resulting from the ongoing COVID-19 pandemic or a similar public health crisis or the changing political conditions such as the current conflict between Russia and Ukraine and related global economic sanctions;
the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and
maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue to conduct clinical trials of RLY-4008 and RLY-2608, as well as identify and develop additional product candidates.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.

In-Process Research and Development Expenses

In-process research and development expenses consist of the cost of acquiring in-process research and development assets that have no alternative future use, specifically in connection with our acquisition of ZebiAI. We do not expect to record incremental expenses in connection therewith in future periods.

Loss on Initial Consolidation of Variable Interest Entity

Loss on initial consolidation of variable interest entity consists of the difference between total consideration transferred and the fair value of net assets acquired and liabilities assumed in connection with our acquisition of ZebiAI. We do not expect to record incremental losses in connection therewith in future periods.

Change in Fair Value of Contingent Consideration Liability

Change in fair value of contingent consideration liability consists of fluctuations in the estimated fair value of contingent milestone payments under the Merger Agreement with ZebiAI. In future periods, we expect the fair value of such contingent milestone payments to increase or decrease based on, among other things, our estimates of the probability of achieving and timing of the contingent milestone payments, as well as changes in market interest rates and the time value of money.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; other expenses associated with operating as a public company, including compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We expect that our general and administrative expenses will increase in the future as we increase our general and administrative personnel headcount to support personnel in research and development and to support our operations generally as we increase our research and development activities and activities related to the potential commercialization of our product candidates.

Other Income, Net

Other income, net primarily consists of interest income related to interest earned on our cash, cash equivalents and investments.

15


 

Income Taxes

Since our inception in 2015, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items.

Results of Operations

Comparison of the three months ended June 30, 2022 and 2021

The following table summarizes our results of operations for the three months ended June 30, 2022 and 2021:

 

 

Three Months Ended
June 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

 

 

 

 

(in thousands)

 

License and other revenue

 

$

365

 

 

$

844

 

 

$

(479

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development expenses

 

$

60,511

 

 

$

45,147

 

 

$

15,364

 

In-process research and development expenses

 

 

 

 

 

123,000

 

 

 

(123,000

)

Loss on initial consolidation of variable interest entity

 

 

 

 

 

11,855

 

 

 

(11,855

)

Change in fair value of contingent consideration liability

 

 

200

 

 

 

 

 

 

200

 

General and administrative expenses

 

 

17,465

 

 

 

14,422

 

 

 

3,043

 

Total operating expenses

 

 

78,176

 

 

 

194,424

 

 

 

(116,248

)

Loss from operations

 

 

(77,811

)

 

 

(193,580

)

 

 

115,769

 

Other income, net

 

 

1,023

 

 

 

181

 

 

 

842

 

Net loss

 

$

(76,788

)

 

$

(193,399

)

 

$

116,611

 

Revenue

We recognized revenue of approximately $0.4 million and $0.8 million for the three months ended June 30, 2022 and 2021, respectively. The decrease of $0.4 million was primarily due to the decrease in research and development services provided under the License Agreement with Genentech, as we are nearing completion of the Phase 1a clinical trial of RLY-1971.

Research and Development Expenses

The following summarizes our research and development expenses for the three months ended June 30, 2022 and 2021:

 

 

Three Months Ended
June 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

 

 

 

 

(in thousands)

 

External costs for programs in clinical trials

 

$

12,275

 

 

$

4,244

 

 

$

8,031

 

External costs for preclinical programs

 

 

20,453

 

 

 

17,023

 

 

 

3,430

 

Employee related expenses

 

 

23,536

 

 

 

20,088

 

 

 

3,448

 

Other expenses

 

 

4,247

 

 

 

3,792

 

 

 

455

 

Total research and development expenses

 

$

60,511

 

 

$

45,147

 

 

$

15,364

 

Research and development expenses were $60.5 million for the three months ended June 30, 2022 compared to $45.1 million for the three months ended June 30, 2021. The increase of $15.4 million was primarily due to $3.4 million of additional employee related costs due to increased headcount, $8.0 million related to additional clinical trial expenses in connection with the ongoing enrollment of our clinical trial for RLY-4008 and the initiation of our clinical trial for RLY-2608 in the fourth quarter of 2021, and $3.4 million related to preclinical programs.

In-Process Research and Development Expenses

In-process research and development expenses of $123.0 million were recognized for the three months ended June 30, 2021 in connection with the in-process research and development asset pursuant to the asset acquisition of ZebiAI in the second quarter of 2021. No such expenses were incurred during the three months ended June 30, 2022.

Loss on Initial Consolidation of Variable Interest Entity

Loss on initial consolidation of variable interest entity of $11.9 million was recognized for the three months ended June 30, 2021 in connection with the acquisition of ZebiAI in the second quarter of 2021. No such expenses were incurred during the three months ended June 30, 2022.

16


 

Change in Fair Value of Contingent Consideration Liability

The fair value of our contingent consideration liability for milestones under the Merger Agreement with ZebiAI increased by $0.2 million during the three months ended June 30, 2022. The increase was primarily attributable to changes in the assumptions underlying the fair value measurement between March 31, 2022 and June 30, 2022. Because the Merger Agreement with ZebiAI was only executed during the three months ended June 30, 2021, there were no similar amounts in the prior period. In future periods, we expect the fair value of contingent consideration to increase or decrease based on, among other things, our estimates of the probability of achieving and the timing of the contingent milestone payments, as well as changes in market interest rates and the time value of money.

General and Administrative Expenses

General and administrative expenses were $17.5 million for the three months ended June 30, 2022 compared to $14.4 million for the three months ended June 30, 2021. The increase of $3.0 million was primarily due to $3.0 million of additional employee related costs due to increased headcount, including an increase in stock-based compensation expense of $1.0 million.

Other Income, Net

Other income, net, was $1.0 million for the three months ended June 30, 2022 compared to $0.2 million for the three months ended June 30, 2021. The increase of $0.8 million was primarily a result of changes in interest rates.

Comparison of the six months ended June 30, 2022 and 2021

The following table summarizes our results of operations for the six months ended June 30, 2022 and 2021:

 

 

Six Months Ended
June 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

 

 

 

 

(in thousands)

 

License and other revenue

 

$

784

 

 

$

1,796

 

 

$

(1,012

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development expenses

 

$

112,178

 

 

$

75,769

 

 

$

36,409

 

In-process research and development expenses

 

 

 

 

 

123,000

 

 

 

(123,000

)

Loss on initial consolidation of variable interest entity

 

 

 

 

 

11,855

 

 

 

(11,855

)

Change in fair value of contingent consideration liability

 

 

(4,395

)

 

 

 

 

 

(4,395

)

General and administrative expenses

 

 

33,533

 

 

 

27,156

 

 

 

6,377

 

Total operating expenses

 

 

141,316

 

 

 

237,780

 

 

 

(96,464

)

Loss from operations

 

 

(140,532

)

 

 

(235,984

)

 

 

95,452

 

Other income, net

 

 

1,698

 

 

 

402

 

 

 

1,296

 

Net loss

 

$

(138,834

)

 

$

(235,582

)

 

$

96,748

 

Revenue

We recognized revenue of approximately $0.8 million and $1.8 million for the six months ended June 30, 2022 and 2021, respectively. The decrease of $1.0 million was primarily related to revenue recognized upon the transfer of active pharmaceutical ingredient during the six months ended June 30, 2021, for which no revenue was recognized during the six months ended June 30, 2022.

Research and Development Expenses

The following summarizes our research and development expenses for the six months ended June 30, 2022 and 2021:

 

 

Six Months Ended
June 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

 

 

 

 

(in thousands)

 

External costs for programs in clinical trials

 

$

20,991

 

 

$

6,967

 

 

$

14,024

 

External costs for preclinical programs

 

 

37,874

 

 

 

29,829

 

 

 

8,045

 

Employee related expenses

 

 

44,619

 

 

 

31,819

 

 

 

12,800

 

Other expenses

 

 

8,694

 

 

 

7,154

 

 

 

1,540

 

Total research and development expenses

 

$

112,178

 

 

$

75,769

 

 

$

36,409

 

Research and development expenses were $112.2 million for the six months ended June 30, 2022 compared to $75.8 million for the six months ended June 30, 2021. The increase of $36.4 million was primarily due to $12.8 million of additional employee related costs due to increased headcount, including an increase in stock-based compensation of $1.0 million, $14.0 million related to additional clinical trial expenses in connection with the ongoing enrollment of our clinical trial for RLY-4008 and the initiation of our clinical trial for RLY-2608 in the fourth quarter of 2021, and $8.0 million related to preclinical programs.

17


 

In-Process Research and Development Expenses

In-process research and development expenses of $123.0 million were recognized for the six months ended June 30, 2021 in connection with the in-process research and development asset pursuant to the asset acquisition of ZebiAI in the second quarter of 2021. No such expenses were incurred during the six months ended June 30, 2022.

Loss on Initial Consolidation of Variable Interest Entity

Loss on initial consolidation of variable interest entity of $11.9 million was recognized for the six months ended June 30, 2021 in connection with the acquisition of ZebiAI in the second quarter of 2021. No such expenses were incurred during the six months ended June 30, 2022.

Change in Fair Value of Contingent Consideration Liability

The fair value of our contingent consideration liability for milestones under the Merger Agreement with ZebiAI decreased by $4.4 million during the six months ended June 30, 2022. The decrease was primarily attributable to changes in the assumptions underlying the fair value measurement between December 31, 2021 and June 30, 2022. Because the Merger Agreement with ZebiAI was only executed during the six months ended June 30, 2021, there were no similar amounts in the prior period. In future periods, we expect the fair value of contingent consideration to increase or decrease based on, among other things, our estimates of the probability of achieving and the timing of the contingent milestone payments, as well as changes in market interest rates and the time value of money.

General and Administrative Expenses

General and administrative expenses were $33.5 million for the six months ended June 30, 2022 compared to $27.2 million for the six months ended June 30, 2021. The increase of $6.4 million was primarily due to $6.1 million of additional employee related costs due to increased headcount, including an increase in stock-based compensation expense of $1.8 million.

Other Income, Net

Other income, net, was $1.7 million for the six months ended June 30, 2022 compared to $0.4 million for the six months ended June 30, 2021. The increase of $1.3 million was primarily a result of changes in interest rates.

Liquidity and Capital Resources

Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several years, if ever. To date, we have principally financed our operations through private placements of preferred stock, convertible debt and proceeds from public offerings of our common stock. In July 2020, we closed our IPO and issued 23,000,000 shares of common stock for net proceeds of $425.3 million. Prior to our IPO, we received gross proceeds of $520.0 million from sales of our preferred stock and our issuance of convertible debt. We received an upfront payment of $75.0 million from Genentech pursuant to the License Agreement with Genentech in January 2021 and $20.0 million in milestone payments in 2021. As of June 30, 2022, we had cash, cash equivalents and investments of $838.0 million.

In August 2021, we filed a universal shelf registration statement on Form S-3ASR with the SEC, or the 2021 Shelf, to register for sale an amount of our common stock, preferred stock, debt securities, warrants and/or units in one or more offerings, which became effective upon filing with the SEC (File No. 333-258768).

In August 2021, we entered into a sales agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we may offer and sell shares of our common stock having aggregate gross proceeds of up to $300.0 million from time to time in “at-the-market” offerings through Cowen, as our sales agent. We agreed to pay Cowen a commission of up to 3.0% of the gross proceeds of any shares sold by Cowen under the Sales Agreement. There have been no shares of our common stock sold under the Sales Agreement as of June 30, 2022.

In October 2021, we completed the October 2021 Offering of 15,188,679 shares of common stock, including the exercise in full of the underwriters’ option to purchase an additional 1,981,132 shares, at an offering price of $26.50 per share. We received net proceeds of $382.2 million, after deducting underwriting discounts and commissions and other offering expenses.

18


 

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

 

(in thousands)

 

Cash (used in) provided by operating activities

 

$

(106,266

)

 

$

18,500

 

Cash used in investing activities

 

 

(68,996

)

 

 

(207,553

)

Cash provided by financing activities

 

 

2,879

 

 

 

3,176

 

Net decrease in cash, cash equivalents and restricted cash

 

$

(172,383

)

 

$

(185,877

)

Operating Activities

During the six months ended June 30, 2022, we used $106.3 million of cash on operating activities, primarily resulting from our net loss of $138.8 million, offset by non-cash charges of $27.4 million and cash provided by changes in our operating assets and liabilities of $5.1 million.

During the six months ended June 30, 2021, operating activities provided $18.5 million of cash, primarily resulting from changes in our operating assets and liabilities of $90.8 million, offset by our net loss excluding non-cash charges of $72.3 million.

Investing Activities

During the six months ended June 30, 2022, investing activities used $69.0 million of cash, consisting of $64.3 million of net purchases of investments and $4.7 million for the acquisition of property and equipment.

During the six months ended June 30, 2021, investing activities used $207.6 million of cash, consisting of $181.6 million of net purchases of investments, $25.1 million in cash paid for the acquisition of ZebiAI, and $0.9 million for the acquisition of property and equipment.

Financing Activities

During the six months ended June 30, 2022, net cash provided by financing activities was $2.9 million, consisting of proceeds from the exercise of stock options and purchases under our Employee Stock Purchase Plan, or ESPP.

During the six months ended June 30, 2021, net cash provided by financing activities was $3.2 million, consisting of proceeds from the exercise of stock options.

Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing clinical development activities related to the potential clinical development activities of RLY-4008 and RLY-2608 and the ongoing preclinical development activities of our other programs. In addition, we continue to incur additional costs associated with operating as a public company. We expect that our expenses will increase substantially as discussed in more detail in “¾ Overview” above.

As of June 30, 2022, we had cash, cash equivalents and investments of $838.0 million. We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into at least 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

Because of the numerous risks and uncertainties associated with the development of RLY-4008, RLY-2608 and our other product candidates and programs, and because the extent to which we may enter into collaborations with third parties for the development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:

the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers or other vendors, resulting from the ongoing COVID-19 pandemic or similar public health crisis or the changing political conditions such as the current conflict between Russia and Ukraine and related global economic sanctions;
the scope, progress, results and costs of our current and future clinical trials of RLY-4008 and RLY-2608 and additional preclinical research of our other programs;

19


 

the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for our other product candidates;
the number of future product candidates that we pursue and their development requirements;
the costs, timing and outcome of regulatory review of our product candidates;
our ability to establish and maintain collaborations on favorable terms, if at all;
the success of any existing or future collaborations that we may enter into with third parties;
the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, such as our collaboration with Genentech;
the achievement of milestones or occurrence of other developments that trigger payments under any existing or future collaboration agreements, if any;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under any existing or future collaboration agreements, if any;
the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;
the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
our headcount growth and associated costs as we expand our business operations and our research and development activities; and
the costs of operating as a public company.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any product candidate for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.

Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. Additional debt or preferred equity financing, if available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute your ownership interest.

If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual Obligations and Commitments

There were no material changes to our contractual obligations and commitments during the three and six months ended June 30, 2022. For more information on our contractual obligations and commitments, please refer to “Management’s Discussion and Analysis of Financial

20


 

Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 and Note 8, Commitments and Contingencies, of the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Critical Accounting Policies and Use of Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

For a discussion of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 24, 2022, the notes to our audited financial statements appearing in our Annual Report on Form 10-K and the notes to the financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. There have been no material changes to these critical accounting policies and estimates through June 30, 2022 from those discussed in our Annual Report on Form 10-K for the year ended December 31, 2021.

Recently Issued and Adopted Accounting Pronouncements

A description of recently issued accounting pronouncements that we have adopted is disclosed in Note 2 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. None of these pronouncements had a material impact on our financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest rate risk

We are exposed to market risk related to changes in interest rates of our investment portfolio of cash equivalents and short-term investments. As of June 30, 2022, our cash equivalents consisted of money market funds. As of June 30, 2022, our investments consisted of investments in U.S. treasury bills and United States agency securities that have contractual maturities of less than two years. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes in federal interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of June 30, 2022, we estimate that such hypothetical 100 basis point adverse movement would not result in a material impact on our condensed consolidated results of operations.

As of June 30, 2022, we had no debt outstanding and are therefore not exposed to interest rate risk with respect to debt.

Foreign currency exchange risk

All of our employees and our operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services that permit us to satisfy our payment obligations in U.S. dollars (at prevailing exchange rates) but have underlying payment obligations denominated in foreign currencies, including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements and we have not had a formal hedging program with respect to foreign currency. We estimate that a 10% increase or decrease in current exchange rates would not have a material effect on our financial results for the three and six months ended June 30, 2022. While we have not engaged in the hedging of our foreign currency transactions to date, we are evaluating the costs and benefits of initiating such a program and may in the future hedge selected significant transactions denominated in currencies other than the U.S. dollar as we expand our international operations and our risk grows.

Item 4. Controls and Procedures.

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of

21


 

disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our management has evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

22


 

PART II—OTHER INFORMATION

From time to time, we may become involved in litigation or other legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of June 30, 2022, we were not a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. We believe the risks described below include risks that are material to us as well as other risks that may adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, financial condition, results of operations and growth prospects and could result in a complete loss of your investment.

Risks Related to Our Product Candidates

Risks Related to Clinical Development

We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop.

We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. We have three product candidates, RLY-1971, RLY-4008 and RLY-2608, in first-in-human clinical development. We may not be able to file INDs for any of our other product candidates on the timelines we expect, if at all. For example, we may experience manufacturing delays with IND-enabling studies. Moreover, we cannot be sure that once we have submitted an IND, the FDA will allow further clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. The FDA or other regulatory authorities may impose a clinical hold before or after a trial begins for a number of reasons outlined in FDA regulations, including if the FDA believes the study drug raises a significant risk of illness or injury. If the FDA imposes a clinical hold, trials may not commence or recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, the submission of an IND does not mean the FDA will allow clinical trials to begin and, if and when clinical trials do commence under an active IND, issues may arise that require suspension or termination of such trials. Further, commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. Regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a new drug application, or NDA, to the FDA and a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for each product candidate and, consequently, the ultimate approval and commercial marketing of each product candidate. Our RLY-1971, RLY-4008 and RLY-2608 first-in-human clinical trials are ongoing, but we do not know whether any of our future clinical trials will begin on time or ever be completed on schedule, if at all.

If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

be delayed in obtaining marketing approval for our product candidates;
not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
be subject to post-marketing testing requirements; or
have the product removed from the market after obtaining marketing approval.

 

23


 

Clinical product development involves a lengthy and expensive process, with an uncertain outcome.

It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct the required clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical and other nonclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Our preclinical and other nonclinical studies and future clinical trials may not be successful.

From time to time, we may publish interim, top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as more participants enroll and as data mature. Preliminary or top-line data also remain subject to cleaning and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.

We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

We may experience delays in completing our preclinical studies and initiating or completing clinical trials, and we may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:

regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
existing clinical trial sites may drop out of the clinical trial, which may require that we add new clinical trial sites or investigators;
clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials or we may decide to abandon product development programs;
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;
our third party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol;
we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
the cost of clinical trials of our product candidates may be greater than we anticipate;
we may not be able to adequately project the timing and quantity of our product candidates or other materials necessary to conduct clinical trials of our product candidates or the supply or quality of these materials may be insufficient or inadequate; and
our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the clinical trials, or reports may arise from nonclinical studies or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates.

24


 

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials.

Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused by the ongoing COVID-19 pandemic, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any delays in our preclinical or current or future clinical development programs may harm our business, financial condition and prospects significantly.

If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, because we will be deploying our drug discovery platform across a broad target space, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ product candidates. Furthermore, our ability to enroll patients may be significantly delayed by the ongoing COVID-19 pandemic and we do not know the extent and scope of such delays at this point.

In addition to the competitive clinical trial environment, the eligibility criteria of our planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed.

We may also engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, furthering the difficulty in identifying patients with the targeted genetic mutations for our clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA’s expedited review and development programs, including Breakthrough Therapy Designation and Fast Track Designation, or otherwise to seek to accelerate clinical development and regulatory timelines. The FDA has indicated that if we continue RLY-4008 and RLY-2608 in a specific biomarker-defined population, a companion diagnostic device will be required to ensure their safe and effective use.

Clinical trial enrollment may be affected by other factors including:

the severity of the disease under investigation;
the eligibility criteria for the clinical trial in question;
the availability of an appropriate genomic screening test;
the perceived risks and benefits of the product candidate under study;
the efforts to facilitate timely enrollment in clinical trials;
the availability of approved products that treat the same indications as our product candidates;

25


 

the patient referral practices of physicians;
the ability to monitor patients adequately during and after treatment;
the proximity and availability of clinical trial sites for prospective patients; and
factors we may not be able to control, such as uncertain geopolitical conditions or current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (e.g., complications due to the current conflict between Russia and Ukraine or the ongoing COVID-19 pandemic).

Positive data from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive data from our preclinical or early clinical studies of our product candidates in our future clinical trials, we will be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.

Any positive data from our preclinical or early clinical studies of our product candidates may not necessarily be predictive of the results of later clinical studies and any future clinical trials of our product candidates. Similarly, even if we are able to complete our planned preclinical and clinical studies or any future clinical trials of our product candidates according to our current development timeline, the positive data from such preclinical or early clinical studies and clinical trials of our product candidates may not be replicated in subsequent nonclinical studies or clinical trial results.

Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, other nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or other regulatory authority approval.

Our current or future clinical trials or those of our future collaborators may reveal significant adverse events not seen in our preclinical or other nonclinical studies or early clinical data and may result in a safety profile that would inhibit regulatory approval or market acceptance of any of our product candidates.

Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical or other nonclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical or other nonclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through preclinical or other nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates.

We may develop future product candidates, in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials.

As is the case with many treatments for cancer and rare diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our clinical trials, or we may be required to abandon the clinical trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage clinical trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.

26


 

Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.

Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. For example, pursuant to the DESRES Agreement, we collaborate with D. E. Shaw Research to develop various protein models and make predictions as to how molecules might move, with subsequent validation efforts in our and our CROs’ labs. There can be no assurance that we will find potential additional targets using this approach, that any such targets will be tractable, or that such clinical validations will be successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:

the research methodology used may not be successful in identifying potential indications and/or product candidates;
potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products; or
it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio.

Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.

We intend to develop our current product candidates and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.

We intend to develop our current product candidates, and may develop future product candidates, for use in combination with one or more currently approved cancer therapies. Even if any product candidate we develop was to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to bear the risks that the FDA or similar regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.

We may also evaluate our current product candidates or any other future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities. We will not be able to market and sell any of our product candidates we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. Pursuant to the License Agreement with Genentech, as further described above, Genentech will assume the development of RLY-1971, including developing RLY-1971 in combination with Genentech’s KRAS G12C program.

If the FDA or similar regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with our current product candidates or any product candidate we develop, we may be unable to obtain approval of or market any of the product candidates we develop.

Our product candidates utilize a novel mechanism of action and novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.

Our product candidates utilize novel mechanisms of action and novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. Our Dynamo platform uses advanced computational models in tight integration with our medicinal chemistry, structural biology, enzymology and biophysics capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects

27


 

in our abilities to expand our Dynamo platform, and we cannot predict whether we will continue to have access to these capabilities in the future to support our Dynamo platform. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development of this novel mechanism will not arise in the future, which may cause significant delays, or we raise problems we may not be able to resolve.

Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies’ lack of experience with them. The novelty of our mechanism of action may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. Because our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more well-known product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical or other nonclinical studies and clinical trials. Any such events could adversely impact our business prospects, financial condition and results of operations.

We are conducting, or have filed clinical trial applications to conduct, clinical trials for our product candidates outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials.

We are conducting, or have filed clinical trial applications to conduct, additional clinical trials outside the United States, including Australia, the United Kingdom, Europe and Asia and may conduct, or file clinical trial applications to conduct, additional clinical trials in other foreign jurisdictions in the future. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; (ii) the trials were performed by clinical investigators of recognized competence and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from clinical trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.

Risks Related to Obtaining Regulatory Approvals

If we are not able to obtain, or if delays occur in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.

Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by similar authorities in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. Currently, all of our product candidates are in development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have only limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive nonclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates.

The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a similar foreign regulatory authority requires that we perform additional nonclinical studies or clinical trials, approval, if obtained at all, may be delayed. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty

28


 

of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted NDA, 510(k), premarket approval application, or PMA, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and similar authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:

the FDA or similar foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
we may not be able to enroll a sufficient number of patients in our clinical studies;
we may be unable to demonstrate to the satisfaction of the FDA or similar foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations;
the results of clinical trials may not meet the level of statistical significance required by the FDA or similar foreign regulatory authorities for approval;
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the FDA or similar foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;
the FDA or similar foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA or similar foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval.

Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.

Risks Related to Commercialization

The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.

We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation/dose expansion study in patients with advanced or metastatic solid tumors and pursuant to the License Agreement with Genentech entered into in December 2020, future development for RLY-1971, including the potential to conduct multiple combination studies, is governed by a joint development team between us and Genentech. In July 2021, Genentech initiated the cohort of RLY-1971 in combination with GDC-6036, its KRAS G12C inhibitor, in a Phase 1b trial. We estimate there are approximately 38,000 patients annually in the United States with advanced lung cancer or colorectal cancer who might benefit from a combination of RLY-1971 with another targeted inhibitor. In the future, if RLY-1971 advances to earlier lines of combination treatment for lung cancer or colorectal cancer, we believe it could be applied in the treatment of approximately 70,000 patients annually in the United States. The subset of patients with KRAS G12C mutations in lung cancer and colorectal cancer who could potentially benefit from the combination of RLY-1971 with GDC-6036 is approximately 17,000 to 32,000 annually in the United States.

We are also evaluating the safety and tolerability of RLY-4008 in a first-in-human clinical trial initiated in September 2020 in patients with advanced or metastatic FGFR2-altered solid tumors with a single arm, potentially registration-enabling cohort for FGFRi treatment-naïve

29


 

FGFR2-fusion CCA. We believe FGFR2-mediated cancers affect approximately 8,000 late-line patients annually in the United States. In the future, if RLY-4008 advances to earlier lines of treatment, it could potentially address approximately 20,000 patients annually in the United States.

In December 2021, we dosed the first patient in a first-in-human clinical trial for RLY-2608, the first known allosteric, pan-mutant (H1047X, E542X and E545X) and isoform-selective PI3Kα inhibitor in clinical development. We believe RLY-2608 has the potential to address approximately 50,000 to 156,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine.

Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with RLY-1971, RLY-4008 or RLY-2608 or our other product candidates, are based on estimates.

The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label, if our product candidates are approved for sale for these indications, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with cancers and solid tumors may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be the wrong choice and may adversely affect our business.

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.

The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the pharmaceutical, biotechnology, and other related markets that address computationally focused structure-based drug design in cancer and genetic diseases. There are other companies focusing on structure-based drug design to develop therapies in the fields of cancer and other diseases. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue precision medicines. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, the accuracy of our computations and predictions, ability to integrate computational and experimental capabilities, ability to successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business.

Many of the companies that we compete against or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or earlier stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, we cannot predict whether our current competitive advantages, such as our ability to leverage our Dynamo platform and our relationship with D. E. Shaw Research, will remain in place in the future. If these or other barriers to entry do not remain in place, other companies may be able to more directly or effectively compete with us.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.

30


 

The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.

In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments. Sales of these or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.

There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or similar foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree.

Factors payors consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.

Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower.

Risks Related to Our Reliance on Third Parties

Under the DESRES Agreement, as amended, we collaborate with D. E. Shaw Research to rapidly develop various protein models, a process that depends on D. E. Shaw Research’s use of their proprietary supercomputer, Anton 2. A termination of the DESRES Agreement could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Under the DESRES Agreement, we collaborate with D. E. Shaw Research to develop various protein models to make predictions as to how molecules might move in connection with identifying potential new biological targets and prospective drug compounds. There can be no assurance these protein models, or the technology used by D. E. Shaw Research to develop them (including the Anton 2 supercomputer), will provide reliable data or target information, or that the findings from these activities and our subsequent validation efforts will translate into the ability to develop therapeutically effective compounds. Our collaboration with D. E. Shaw Research is our key computational collaboration, and there can be no assurance that this collaboration will continue past the current term of the DESRES Agreement, on

31


 

favorable terms or at all, or that at any time while the collaboration is in effect D. E. Shaw Research will provide a level of service that benefits our programs in a meaningfully positive manner. While we also have other computational collaborations, mostly focused on developing machine learning models, such collaborations do not provide a substitute for the technology made available through our collaboration with D. E. Shaw Research. The termination of the DESRES Agreement or any reduction in our collaboration with D. E. Shaw Research would require us to rely more heavily on these other collaborations and our own internal resources, and may delay or impair our development efforts.

Furthermore, while the termination of the DESRES Agreement would not directly impact the development of our lead product candidates, we cannot predict the effects such termination could have on our preclinical studies and development efforts and our ability to discover and develop additional product candidates. In particular, the technologies accessed through D. E. Shaw Research, including the Anton 2 supercomputer, are important aspects of our Dynamo platform, and we do not currently have access to another source of computational power comparable to that provided by the Anton 2 supercomputer. Currently, not only is our collaboration with D. E. Shaw Research for a limited time period, but it is also limited with respect to the number of target proteins available under the collaboration (with such number subject to increases or decreases from year to year, and with the number of total targets across categories capped at twenty, subject to some limitations), which could restrict our ability to broaden our platform across a larger number of targets and programs.

Under the DESRES Agreement, D. E. Shaw Research controls the rights to its technology, we control the rights to certain compounds, and we jointly own with D. E. Shaw Research any other work product created by D. E. Shaw Research and us. Any work product we jointly own with D. E. Shaw Research and any other information that we or D. E. Shaw Research share is subject to a non-exclusive cross-license between us and D. E. Shaw Research, subject to certain exceptions. In some instances, D. E. Shaw Research is required to assign to us some of the work product created by D. E. Shaw Research. Disputes may arise between us and D. E. Shaw Research, as well as any future potential collaborators, regarding intellectual property subject to the DESRES Agreement. If disputes over intellectual property that we co-own or we own individually prevent or impair our ability to maintain our current collaboration arrangements on acceptable terms, or undermine our ability to successfully control the intellectual property necessary to protect our product candidates, we may be unable to successfully develop and commercialize the affected product candidates. Uncertainties or disagreements around our rights under any such intellectual property may undermine our ability to partner our programs with third parties.

In addition, the DESRES Agreement is complex and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could be adverse to us, for example by narrowing what we believe to be the scope of our rights to certain intellectual property, or increasing what we believe to be our financial or other obligations under the DESRES Agreement, and any such outcome could have a material adverse effect on our business, financial condition, results of operations, and prospects.

We are generally also subject to all of the same risks with respect to protection of intellectual property that we co-own, as we are for intellectual property that we own, which are described below. If we or D. E. Shaw Research fail to adequately protect this intellectual property, our ability to commercialize products could suffer.

Moreover, we are subject to certain payment obligations under the DESRES Agreement, including payments to D. E. Shaw Research in connection with certain transactions, including our collaboration with Genentech pursuant to the License Agreement with Genentech. These payment obligations may decrease the value to us of certain transactional opportunities or otherwise burden our ability to enter into such transactions.

We rely on third parties to conduct our ongoing clinical trials of RLY-1971, RLY-4008 and RLY-2608 and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates. We may also rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.

Such arrangements will likely provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates.

32


 

Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.

We rely and expect to continue to rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.

We, our principal investigators and our CROs are required to comply with regulations, including Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and similar foreign regulatory authorities for any products in clinical development, including the EMA and the Medicines and Healthcare Products Regulatory Agency. These regulatory authorities enforce GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or similar foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, these regulatory authorities will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Although we designed our first-in-human clinical trials of RLY-1971, RLY-4008 and RLY-2608 and intend to design the future clinical trials for the product candidates that we develop, we expect that CROs will conduct all of our clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:

have staffing difficulties;
fail to comply with contractual obligations;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed; or
form relationships with other entities, some of which may be our competitors.

These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development program materially and irreversibly harmed. If we are unable to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.

If any of our relationships with these third-party principal investigators or CROs terminate, we may not be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.

33


 

We contract with third parties for the manufacture of our product candidates for preclinical development, clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.

We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products if any of our product candidates receive marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.

The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a similar foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Further, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates.

We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

reliance on the third party for regulatory compliance and quality assurance;
the possible breach of the manufacturing agreement by the third party;
the possible misappropriation of our proprietary information, including our trade secrets and know-how; and
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Due to capacity constraints at cGMP manufacturers relating to the ongoing COVID-19 pandemic, we have been required to forecast the amount of clinical trial supply needed for our clinical trials further in advance than had typically been required, and there is limited flexibility to adjust our manufacturing needs as our clinical trials progress, which may lead to added costs or delays in our clinical trials.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We are also unable to predict how the ongoing COVID-19 pandemic or the current conflict between Russia and Ukraine may affect our third-party manufacturers, including any potential disruptions to our global supply chain. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers, which we may not be able to do on reasonable terms, if at all, or manufacture the materials ourselves, for which we may not have the capabilities or resources. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original contract manufacturing organization, or CMO, and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. Changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. We may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates.

34


 

Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.

The third parties upon whom we rely for the supply of the active pharmaceutical ingredient, drug product and starting materials used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.

The active pharmaceutical ingredients, or API, drug product and starting materials used in our product candidates are supplied to us primarily from single-source suppliers. Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API, drug product and starting materials for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization. We do not currently have arrangements in place for a redundant or second-source supply of any such API, drug product or starting materials in the event any of our current suppliers of such API, drug product or starting materials cease their operations for any reason. If any of our third-party suppliers or manufacturers ceases its operations for any reason or is unable or unwilling to supply API, drug product or starting material in sufficient quantities, on the timelines necessary, or at acceptable prices, to meet our needs, it could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. We are also unable to predict how changing global economic or political conditions, such as the current conflict between Russia and Ukraine and related global economic sanctions, or potential global health concerns, such as the ongoing COVID-19 pandemic, will affect our third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.

For all of our product candidates, we intend to identify and qualify additional manufacturers to provide such API, drug product and starting materials prior to or after submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.

Establishing additional or replacement suppliers for the API, drug product and starting materials used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API, drug product and starting materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API, drug product or starting materials from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects.

We have and may enter into other collaborations with third parties for the research, development, manufacture and commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.

We have entered into and may enter into collaborations with third parties for one or more of our programs or product candidates, such as our License Agreement with Genentech to develop and commercialize RLY-1971. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that any future collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them.

Any collaborations we have entered into or will enter into may pose several risks, including the following:

Collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;
Collaborators may not perform their obligations as expected;
The clinical trials conducted as part of these collaborations may not be successful;
Collaborators may not pursue development and/or commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;
Collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

35


 

We may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates;
Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
Product candidates developed in collaboration with us may be viewed by any collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;
A collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product candidate;
Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any programs or product candidates, may cause delays or termination of the research, development, manufacture or commercialization of such programs or product candidates, may lead to additional responsibilities for us with respect to such programs or product candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive;
Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation. For example, Genentech has the first right to enforce or defend certain of our intellectual property rights under our collaboration, and although we may have the right to assume the enforcement and defense of such intellectual property rights if Genentech does not, our ability to do so may be compromised by Genentech’s actions;
Disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;
Collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
Collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, Genentech may terminate its collaboration with us for convenience after a specified notice period.

If our collaborations do not result in the successful development and commercialization of products, or if one of any future collaborators terminates its agreement with us, we may not receive any milestone or royalty payments under the collaboration. If we do not receive the payments we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization summarized and described in this report also apply to the activities of our collaborators.

In addition, if any collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation among the business and financial communities could be adversely affected.

We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans.

Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a

36


 

collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.

We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.

We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.

We may be required to pay certain milestones and royalties under our license or collaboration agreements with third-party licensors or collaborators.

Under our current and future license or collaboration agreements, including our DESRES Agreement, we may be required to pay milestones, royalties and other payments based on our revenues, including revenues from product sales, and these milestones and royalty payments could adversely affect the overall profitability of any products that we may seek to commercialize. In order to maintain our rights under these agreements, we may need to meet certain specified milestones in the development of our product candidates. Further, our licensors (or their licensors), licensees or other strategic collaborators may dispute the terms, including amounts, that we are required to pay under the respective license or collaboration agreements. If these claims result in a material increase in the amounts that we are required to pay to our licensors or collaborators, or in a claim of breach of the license, our ability to research, develop and obtain approval of product candidates or to commercialize our products could be significantly impaired.

Risks Related to Our Financial Position and Ability to Raise Additional Capital

Risks Related to Our Operating History

We are a biopharmaceutical company with a limited operating history.

We are a biopharmaceutical company with a limited operating history and have incurred net losses in each year since our inception. Our net losses were $138.8 million and $235.6 million for the six months ended June 30, 2022 and 2021, respectively. We had an accumulated deficit of $906.9 million as of June 30, 2022. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We commenced operations in May 2015. Since inception, we have focused substantially all of our efforts and financial resources on developing our drug discovery platform and initial product candidates. We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates and there is no assurance that we will obtain approvals in the future. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital.

We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.

Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development expenses to significantly increase in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced-manufacturing expenses. We will also continue to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.

The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual

37


 

operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:

the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;
our ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;
our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive;
the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;
the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;
our ability to attract, hire and retain qualified personnel;
expenditures that we will or may incur to develop additional product candidates;
the level of demand for our product candidates should they receive approval, which may vary significantly;
the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates;
the changing and volatile U.S. and global economic environments or political instability, including as a result of the ongoing COVID-19 pandemic or the current conflict between Russia and Ukraine; and
future accounting pronouncements or changes in our accounting policies.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.

We have no products approved for commercial sale and have not generated any revenue from product sales.

Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our product sales and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant revenue unless and until we obtain marketing approval of, and begin to sell one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:

successfully complete preclinical studies;
successfully enroll subjects in, and complete, clinical trials;
have our IND applications go into effect for our planned clinical trials or future clinical trials;
receive regulatory approvals from applicable regulatory authorities;
initiate and successfully complete all safety studies required to obtain U.S. and foreign marketing approval for our product candidates;
establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing;
obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;

38


 

launch commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;
obtain and maintain acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;
effectively compete with other therapies;
obtain and maintain healthcare coverage and adequate reimbursement;
enforce and defend intellectual property rights and claims;
take precautionary measures to help minimize the risk of COVID-19 or any future pandemics or similar outbreaks to our employees; and
maintain a continued acceptable safety profile of the product candidates following approval.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.

Risks Related to Raising Additional Capital

We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.

The development of pharmaceutical products is capital-intensive. We are continuing our clinical trials of our lead product candidates, RLY-4008, RLY-2608 and RLY-1971, and advancing our other product candidates through preclinical development. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, depending on the status of regulatory approval or, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our research and development programs or future commercialization efforts.

We expect that our existing cash and cash equivalents and investments will be sufficient to fund our operations through at least the next 12 months. Our future capital requirements will depend on and could increase significantly as a result of many factors, including:

the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors, resulting from the ongoing COVID-19 pandemic or similar public health crisis or the changing political conditions such as the current conflict between Russia and Ukraine and related global economic sanctions;
the scope, progress, results and costs of our current and future clinical trials of RLY-4008 and RLY-2608 and additional preclinical research of our other programs;
the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for our other product candidates;
the number of future product candidates that we pursue and their development requirements;
the costs, timing and outcome of regulatory review of our product candidates;
our ability to establish and maintain collaborations on favorable terms, if at all;
the success of any existing or future collaborations that we may enter into with third parties;
the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, such as our collaboration with Genentech;

39


 

the achievement of milestones or occurrence of other developments that trigger payments under any existing or future collaboration agreements, if any;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under any existing or future collaboration agreements, if any;
the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;
the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
our headcount growth and associated costs as we expand our business operations and our research and development activities; and
the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.

Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets may make equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.

If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that materially adversely affect your rights as a common stockholder. We may offer and sell up to an aggregate amount of $300.0 million of our common stock from time to time in “at the market” offerings pursuant to the sales agreement, or the Sales Agreement, with Cowen and Company, LLC, subject to the limitations thereof. As of June 30, 2022, no shares of common stock have been sold under the Sales Agreement. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

40


 

If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Risks Related to COVID-19 and the Global Economy

The ongoing COVID-19 pandemic has impacted our business and any future pandemic, epidemic, or outbreak of an infectious disease could similarly affect our business and our financial results and could cause further disruption to the development of our product candidates.

Public health crises such as pandemics or similar outbreaks could adversely impact our business. While progress has been made in the fight against the ongoing COVID-19 pandemic, including the broad dissemination and administration of vaccines in certain countries, the COVID-19 pandemic has continued to spread globally, including in all 50 states within the United States, including Cambridge, Massachusetts where our primary office and laboratory space is located. The COVID-19 pandemic has continued to evolve as new variants of COVID-19 have been identified and spread, which have led to various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the ongoing COVID-19 pandemic may continue to affect our operations or those of our third-party partners, including our preclinical or other nonclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the severity and duration of additional variant outbreaks, vaccination rates where we or our third party partners conduct operations, and the actions to contain COVID-19 or treat its impact, among others. The continued spread of COVID-19 globally could adversely impact our preclinical, other nonclinical or clinical trial operations in the United States, including our ability to obtain slots for IND-enabling studies and recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if infection rates remain high. For example, similar to other biopharmaceutical companies, we may experience delays in initiating IND-enabling studies, protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials as well as in activating new trial sites. COVID-19 may also affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. In addition, if any patients enrolled in our clinical trials are infected with COVID-19, they may not be able to complete these trials. Further, since the beginning of the COVID-19 pandemic, three vaccines for COVID-19 have received Emergency Use Authorization by the FDA and two of those later received marketing approval. Additional vaccines may be authorized or approved in the future. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Any negative impact COVID-19 has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.

Additionally, timely enrollment in ongoing and planned future clinical trials is dependent upon clinical trial sites which could be adversely affected by global health matters, such as pandemics. We conduct clinical trials for our product candidates in geographies which continue to be affected by COVID-19. Some factors from the ongoing COVID-19 pandemic that will delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include:

the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our clinical trials;
the potential negative effect on the operations of our third-party manufacturers, suppliers or other collaboration partners, including issues due to worker shortages, supply chain disruptions such as delays in procurement of manufacturing equipment and any related parts, facilities and production suspensions and a sudden increase in demand for certain goods and services, such as medical services and supplies;
interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our clinical trials; and

41


 

business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.

We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the SEC or FDA.

These and other factors arising from the ongoing COVID-19 pandemic could worsen as the pandemic continues to evolve. Any of these factors, and other factors related to any unforeseen disruptions, have had and could continue to have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates.

Global economic uncertainty or political instability could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions and uncertainty in the global economy and in the global financial markets. The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, significant volatility in commodity prices, declines in consumer confidence, declines in economic growth, supply chain interruptions, uncertainty about economic stability and record inflation globally. Economic uncertainty in various global markets caused by political instability, changes in trade agreements and conflicts, such as the current conflict between Russia and Ukraine, and related sanctions as well as a severe or prolonged economic downturn or continued extreme economic volatility and disruptions could result in a variety of risks to our business, including difficulty in enrolling participants in our clinical trials, difficulty in forecasting our financial results and managing inventory levels and negatively impacting our ability to raise additional capital when needed on acceptable terms, if at all. Political developments impacting government spending and international trade, including potential government shutdowns and trade disputes and tariffs, may negatively impact markets and cause weaker macro-economic conditions. The effects of these events may continue due to potential U.S. government shutdowns and the transition in administrations, and the United States’ ongoing trade disputes with China and other countries. Additionally, the ongoing COVID-19 pandemic has resulted in economic slowdown and caused significant volatility and uncertainty in U.S. and international markets. See “—The COVID-19 pandemic has impacted our business and any future pandemic, epidemic, or outbreak of an infectious disease could similarly affect our business and our financial results and could cause further disruption to the development of our product candidates.” Global economic uncertainty or political instability, including the current conflict between Russia and Ukraine, has also strained, and could continue to strain, certain of our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions, including the global economic uncertainty resulting from the conflict between Russia and Ukraine and otherwise, could adversely impact our business.

Risks Related to Our Intellectual Property

Risks Related to Protecting Our Intellectual Property

If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products will be impaired.

Our commercial success will depend in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our product candidates, and our core technologies, including our novel target discovery technology and our proprietary compound library and other know-how. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the United States and abroad related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Other than our U.S. patent relating to RLY-1971 composition of matter, we do not own or in-license any issued patents relating to our platform or our lead product candidates under clinical development.

Pursuant to the License Agreement with Genentech, we have granted an exclusive, worldwide, royalty-bearing license to Genentech, with the right to sublicense, develop and commercialize RLY-1971 and any other SHP2 inhibitors developed under the License Agreement with Genentech. Genentech has the first right, but not the obligation, to file, prosecute and maintain any patents licensed to it, as well as to enforce infringement of or defend claims against such patents that relate to RLY-1971 or other SHP2 inhibitors. See “Risks Related to Our Reliance on Third Parties We have and may enter into collaborations with third parties for the research, development, manufacture and

42


 

commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.” for a discussion of risks related to the protection of our intellectual property rights under our collaborations.

Most of the research and development for our programs has been performed under the DESRES Agreement. Under the DESRES Agreement, D. E. Shaw Research controls the rights to its technology (including its supercomputer and software, each of which are important aspects of our Dynamo platform), we control the rights to certain compounds, and we jointly own with D. E. Shaw Research any other work product created by D. E. Shaw Research and us. Subject to certain limits, we have the right to have the following work product assigned to us: the composition of matter, method of use, and method of manufacture of certain compounds directed to a Category 1 Target, as set forth in the DESRES Agreement.

We have not yet designated all of the compounds for which we will have this right of assignment, and thus, we do not yet know the scope of exclusivity we will enjoy under our patent rights for our product candidates.

After any work product is assigned to us, we will have the right to prepare, file, prosecute and maintain patents that cover such assigned work product. We also have the implicit right to defend patents that cover work product owned by us.

To date, much of the work product created under our agreement with D. E. Shaw Research has been created by D. E. Shaw Research and us, together, and is thus co-owned. We have the first right to prepare, file, prosecute, maintain and defend patents that cover work product created by D. E. Shaw Research and us, together. If we choose not to exercise those rights with respect to patents and patent applications that cover joint work product, D. E. Shaw Research will have the right to take over such activities, unless such rights are waived, as is the case for our co-owned SHP2 patent applications. The party that is preparing, filing, prosecuting and maintaining a patent that covers joint work product also has the right to enforce such patent against infringers.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation.

The degree of patent protection we require to successfully commercialize our product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our pending patent applications will issue, or that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect our lead product candidates under clinical development, RLY-1971, RLY-4008, RLY-2608, or our other product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned patent portfolio and any patent portfolio we may license in the future may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to our product candidates, including generic versions of such products.

We have licensed patent rights, and in the future may license additional patent rights, to or from third parties. For example, we have licensed our patent rights to our SHP2 program to Genentech. These licensed patent rights may be valuable to our business, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or medicines underlying such licenses. We cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors or licensees fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected.

Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications, with respect to either the same methods or formulations or the same subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty.

In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to most of the pending patent applications covering our product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office, or USPTO, have been significantly narrowed by the time they issue, if at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is

43


 

too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

Even if we acquire patent protection that we expect should enable us to maintain such competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO challenging the priority of an invention claimed within one of our patents, which submissions may also be made prior to a patent’s issuance, precluding the granting of any of our pending patent applications. We may become involved in opposition, derivation, reexamination, inter parties review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others from whom we have obtained licenses to such rights.

Competitors may claim that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing on their patents and that we therefore cannot practice our technology as claimed under our patents, if issued. Competitors may also contest our patents, if issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.

In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. With respect to intellectual property arising in the course of our collaboration with D. E. Shaw Research, disagreements between us and D. E. Shaw Research may impact our exclusive control of intellectual property important for protecting our product candidates and proprietary position. A loss of exclusivity, in whole or in part, could allow others to compete with us and harm our business.

An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, without payment to us, or could limit the duration of the patent protection covering our technology and product candidates. Such challenges may also result in our inability to manufacture or commercialize our product candidates without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

Even if they are unchallenged, our owned patent portfolio and any patent portfolio we may license in the future may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our business.

44


 

Our failure to secure trademark registrations could adversely affect our business and our ability to market our products and product candidates.

Our trademark applications in the United States and any other jurisdictions where we may file may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in corresponding foreign agencies, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our applications and/or registrations, and our applications and/or registrations may not survive such proceedings. Failure to secure such trademark registrations in the United States and in foreign jurisdictions could adversely affect our business and our ability to market our products and product candidates.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.

In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. With respect to the building of our proprietary compound library, we consider trade secrets and know-how to be our primary intellectual property. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our consultants and employees. We may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.

Our trade secrets could otherwise become known or be independently discovered by our competitors. Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors’ products, our competitive position could be adversely affected, as could our business.

Risks Related to Intellectual Property Litigation

Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings before the USPTO. Our competitors or other third parties may assert infringement claims against us, alleging that our products or technologies are covered by their patents. Given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Many companies have filed, and continue to file, patent applications related to SHP2 inhibitors, FGFR2 inhibitors, and PI3K inhibitors. Some of these patent applications have already been allowed or issued, and others may issue in the future. Since these areas are competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates, or the practice of our technology. If a patent holder believes our product or product candidate infringes on its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our owned patent portfolio and any patent portfolio we may license in the future may thus have no deterrent effect.

If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our product candidates and technology. We may choose to obtain a license, even in the absence of an

45


 

action or finding of infringement. In either case, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed to us. Without such a license, we could be forced, including by court order, to cease developing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed such third-party patent rights. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. If we lose a foreign patent lawsuit, alleging our infringement of a competitor’s patents, we could be prevented from marketing our products in one or more foreign countries, which would have a materially adverse effect on our business.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.

We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate such technologies or features would have a material adverse effect on our business, and may prevent us from successfully commercializing our product candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which would have an adverse effect on our business, results of operations and financial condition.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.

Competitors and other third parties may infringe, misappropriate or otherwise violate our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims. A court may disagree with our allegations, however, and may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the third-party technology in question. Further, such third parties could counterclaim that we infringe their intellectual property or that a patent we have asserted against them is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. In addition, third parties may initiate legal proceedings against us to assert such challenges to our intellectual property rights. The outcome of any such proceeding is generally unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Patents may be unenforceable if someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. It is possible that prior art of which we and the patent examiner were unaware during prosecution exists, which could render any patents that may issue invalid. Moreover, it is also possible that prior art may exist that we are aware of but do not believe is relevant to our future patents, should they issue, but that could nevertheless be determined to render our patents invalid.

An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our product candidates, we would lose at least part, and perhaps all, of the patent protection covering such product candidate. Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.

46


 

We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

Risks Related to Enforcement of Our Intellectual Property Rights

We may not be able to effectively enforce our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the patent laws of some foreign countries do not afford intellectual property protection to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in the major markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.

If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.

Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.

Risks Related to Third Party Intellectual Property

We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.

A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. Although we believe that licenses to these patents are available from these third parties on commercially reasonable terms, if we were not able to obtain a license, or were not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly materially.

47


 

If we fail to comply with our obligations in the agreements under which we collaborate with or license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we could lose rights that are important to our business.

We expect our future license agreements will impose, various development, diligence, commercialization, and other obligations on us in order to maintain the licenses. In spite of our efforts, a future licensor might conclude that we have materially breached our obligations under such license agreements and seek to terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patent rights licensed thereunder fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;
the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
the priority of invention of patented technology.

The agreements under which we may license intellectual property or technology from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

These and similar issues may arise with respect to our collaboration agreements, such as our DESRES Agreement, as amended. Our collaboration with D. E. Shaw Research is our key computational collaboration, and there can be no assurance that this collaboration will continue past the current term of the DESRES Agreement, on favorable terms or at all, or that at any time while the collaboration is in effect D. E. Shaw Research will provide any particular level of services or that the parties will operate under the agreement without disputes. These disputes may involve ownership or control of intellectual property rights, exclusivity obligations, diligence and payment obligations, for example.

The DESRES Agreement imposes certain exclusivity obligations on us during the term of the agreement with respect to Category 2 targets, and certain exclusivity obligations on D. E. Shaw Research during and after the term of the agreement. While we have some degree of control over how we designate various targets under the DESRES Agreement, D. E. Shaw Research has some degree of control over such designations as well, and our exclusivity obligations limit or delay our ability to conduct research on selected targets with third parties.

Under the DESRES Agreement, D. E. Shaw Research controls the rights to its technology, we control the rights to certain compounds, and we jointly own with D. E. Shaw Research any other work product created by D. E. Shaw Research and us. Any work product we jointly own with D. E. Shaw Research and any other information that we or D. E. Shaw Research share is subject to a non-exclusive cross-license between us and D. E. Shaw Research, subject to certain exceptions. In some instances, D. E. Shaw Research is required to assign to us some of the work product created by D. E. Shaw Research. Disputes may arise between us and D. E. Shaw Research, as well as any future potential collaborators, regarding intellectual property subject to the DESRES Agreement. If disputes over intellectual property that we co-own or we own individually prevent or impair our ability to maintain our current collaboration arrangements on acceptable terms, or undermine our ability to successfully control the intellectual property necessary to protect our product candidates, we may be unable to successfully develop and commercialize the affected product candidates. Uncertainties or disagreements around our rights under any such intellectual property may undermine our ability to partner our programs with third parties.

48


 

In addition, the DESRES Agreement is complex and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could be adverse to us, for example by narrowing what we believe to be the scope of our rights to certain intellectual property, or increasing what we believe to be our financial or other obligations under the DESRES Agreement, and any such outcome could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Risks Related to Intellectual Property Laws

Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law on September 16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a “first to file” system. The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.

The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce rights in our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that we may obtain in the future.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own;
we or our licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;
we or our licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;
it is possible that our present or future pending patent applications (whether owned or licensed) will not lead to issued patents;
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;
our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable;
the patents of others may harm our business; and

49


 

we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.

Risks Related to Government Regulation

Risks Related to Regulatory Approval

Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.

If the FDA or a similar foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval and applicable product tracking and tracing requirements. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;
clinical trial holds;
fines, warning letters or other regulatory enforcement action;
refusal by the FDA to approve pending applications or supplements to approved applications filed by us;
product seizure or detention, or refusal to permit the import or export of products; and
injunctions or the imposition of civil or criminal penalties.

The FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about approved prescription drug products. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of regulated products for off-label uses and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

 

50


 

European data collection is governed by restrictive regulations governing the processing and cross-border transfer of personal information.

In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional data collection restrictions. For example, the collection, use, storage, disclosure, transfer, or other processing of personal data of individuals in the EEA, including personal health data, is subject to the GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, providing notice to the individuals to whom the personal data relates regarding data processing activities, implementing safeguards to protect the privacy and security of personal data, providing notification of data breaches in certain circumstances, and taking certain measures when engaging third-party processors or sub-processors. The GDPR focuses on accountability of data controllers (such as us) and requires us to put in place all technical and organizational measures (privacy by design and by default) to ensure that we meet our obligations. It also increases substantially the penalties to which we could be subject in the event of any non-compliance, including fines of up to €10,000,000 or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to €20,000,000 or up to 4% of our total worldwide annual turnover for more serious offenses. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our activities in the EEA. In addition, further to the UK’s exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK’s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK’s data protection regime, which is independent from but aligned to the EU’s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to £17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU’s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.

We must also ensure that we maintain adequate safeguards or have other legal bases to enable the transfer of personal data outside of the EEA and UK in compliance with the EU GDPR and UK GDPR, in particular for transfers to the United States. In 2020, in a ruling about the EU-U.S. Privacy Shield, the Court of Justice of the EU raised questions about whether the European Commission’s Standard Contractual Clauses, or SCCs, can lawfully be used for personal data transfers from the EU to the United States or most other countries. Furthermore, on June 4, 2021, the European Commission issued new forms of SCCs for data transfers of personal data from controllers or processors in the EU (or otherwise subject to the GDPR) to controllers or processors established outside the EU. The new form of SCCs has replaced the SCCs that were adopted previously under the EU Data Protection Directive. We will be required to transition to the new form of SCCs when these safeguards are used as the basis for transferring personal data out of the EEA and doing so may require significant effort and cost. The new SCCs may also impact our business as companies based in Europe may be reluctant to utilize the new SCCs to legitimize transfers of personal data to third countries given the burdensome requirements of transfer impact assessments and the substantial obligations that the new SCCs impose upon exporters.

Additionally, with respect to the UK, the Information Commissioner’s Office, or ICO, has recently introduced new mechanisms for international transfers of personal data originating from the UK (an International Data Transfer Agreement, or IDTA, along with a separate addendum to the EU SCCs), which are in force as of March 21, 2022, to replace the old form EU SCCs for UK transfers. The new IDTA or the UK addendum must be used for any new contract entered into after September 21, 2022 and implemented in existing contracts that incorporate the prior version of the SCCs by March 21, 2024. We will be required to implement these new safeguards when these safeguards are used as the basis for transferring personal data out of the UK and doing so may require significant effort and cost.

If we are investigated by a European or UK data protection authority, we may face fines and other penalties. Any such investigation or charges by European or UK data protection authorities could have a negative effect on our business and on our ability to commercialize our products in the future, including with European, UK-based or multi-national pharmaceutical partners.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

51


 

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, similar regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval.

If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.

In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or obtain access to in vitro companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Further, the FDA has indicated that if we continue RLY-4008 and RLY-2608 in a specific biomarker-defined population, a companion diagnostic device will be required to ensure their safe and effective use. Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and similar foreign regulatory authorities regulate in vitro companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization.

We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic candidates.

Risks Related to Anti-bribery, Anti-corruption and Other Government Regulations

Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.

If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

52


 

Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions.

We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.

Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.

Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.

Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and governments of foreign jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:

the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties;
the federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims Act, or FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery. In addition, the government may assert that a claim including items and services

53


 

resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
the federal physician payment transparency requirements, sometimes referred to as the “Sunshine Act” under the Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report to the Department of Health and Human Services information related to transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective January 1, 2022, these reporting obligations were extended to include transfers of value made to certain non-physician providers (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified-nurse midwives);
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH and its implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the creation, maintenance, receipt, or other use or disclosure of individually identifiable health information, including mandatory contractual terms with business associates, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;
federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and
analogous state laws and regulations, such as state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America’s Code on Interactions with Healthcare Professionals. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. State and foreign laws, including for example the EU GDPR, which became effective May 2018 also govern the privacy and security of health information and other personal information in some circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state and foreign requirements and if we fail to comply with an applicable state or foreign law requirement we could be subject to penalties. Further, many state laws governing the privacy and security of health information in certain circumstances, differ from each other in significant ways, thus complicating compliance efforts.

Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, reputational harm, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they

54


 

may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.

Risks Related to Regulatory Review of Certain Drug Development Designations

We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.

If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.

We have obtained orphan drug designation for one of our product candidates. We may seek orphan drug designation for certain of our other product candidates as well, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

In January 2022, the FDA granted orphan drug designation to RLY-4008 for the treatment of cholangiocarcinoma. As part of our business strategy, we may seek orphan drug designation for certain of our other product candidates as well, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.

Similarly, in the EU, the European Commission, upon the recommendation of the EMA’s Committee for Orphan Medicinal Products, grants orphan designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized for marketing in the EU (or, if a method exists, the product would be of a significant benefit to those affected by the condition). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the product in the EU would generate sufficient return to justify the necessary investment in developing the product. In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers.

Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified.

Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition or if another drug with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. We have obtained orphan drug designation for one of our product candidates and while we may seek orphan drug designation for our other product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations. In addition, the FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.

55


 

Breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive marketing approval in the United States.

We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

We may seek fast track designation for some of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA’s priority review procedures.

We may seek approval of our product candidates, where applicable, under the FDA's accelerated approval pathway. This pathway, even if granted for our FGFR2 program or our PI3K program or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek accelerated approval of our FGFR2 program or our PI3K program and for future product candidates. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. Thus, even if we do seek to utilize the accelerated approval pathway, we may not be able to obtain accelerated approval and, even if we do, we may not experience a faster development, regulatory review or approval process for that product. In addition, receiving accelerated approval does not assure that the product’s accelerated approval will eventually be converted to a traditional approval.

Risks Related to Healthcare Legislative Reform

The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict.

The FDA, the EMA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and

56


 

could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.

Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.

The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements, (ii) additions or modifications to product labeling, (iii) the recall or discontinuation of our products or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act, or the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the United States pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D. Since then, the ACA risk adjustment program payment parameters have been updated annually.

Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On December 20, 2019, the Further Consolidated Appropriations Act (H.R. 1865) was signed into law, which repealed the so called “Cadillac” tax on certain high cost employer sponsored insurance plans, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future. The Bipartisan Budget Act of 2018, also amended the ACA, effective January 1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole.” CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has recently published a final rule that would give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken; however, pursuant to the CARES Act and subsequent legislation, these reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. A 1% payment reduction occurred from April 1, 2022 through June 30, 2022, and the 2% payment reduction resumed on July 1, 2022. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its product candidates available to eligible patients as a result of the Right to Try Act. In May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020.

There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration’s policy to (i) support legislative

57


 

reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs the U.S. Department of Health and Human Services, or HHS, to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA’s implementing regulations. The FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for “best price” or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. However, on December 29, 2021, CMS rescinded the MFN rule. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors have been delayed until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as local state Medicaid programs could have a significant impact on our business in light of the higher proportion of SCD patients that utilize Medicare and Medicaid programs to pay for treatments.

Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

the demand for our current or future product candidates, if we obtain regulatory approval;
our ability to set a price that we believe is fair for our products;
our ability to obtain coverage and reimbursement approval for a product;
our ability to generate revenue and achieve or maintain profitability;
the level of taxes that we are required to pay; and
the availability of capital.

Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.

 

 

58


 

Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.

We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists’ and wholesalers’ ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public’s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the Secretary of the HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for “best price” or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.

Risks Related to the Regulatory Agency Review Process

Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, global health concerns, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical government employees and stop critical activities. Separately, in response to the ongoing COVID-19 pandemic, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA’s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities. Additionally, as of May 26, 2021, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and any travel restrictions, the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

59


 

Risks Related to Employee Matters and Managing Growth

Risks Related to Employee Matters

Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.

We are highly dependent on the research and development, clinical and business development expertise of the principal members of our management, scientific and clinical team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel.

In particular, we have experienced a very competitive hiring environment in Cambridge, Massachusetts, where we are headquartered. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited.

Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical or other nonclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

 

 

 

60


 

Risks Related to Growth and Acquisitions

We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

As of June 30, 2022, we had 305 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of pharmaceutical and clinical development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.

Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies.

As a part of our growth strategy, we may make selected acquisitions of complementary products and/or businesses, such as our acquisition of ZebiAI in April 2021. Any acquisition involves numerous risks and operational, financial, and managerial challenges, including the following, any of which could adversely affect our business, financial condition, or results of operations:

difficulties in integrating new operations, technologies, products, and personnel;
challenges maintaining uniform procedures, controls and policies with respect to our financial accounting systems;
lack of synergies or the inability to realize expected synergies and cost-savings;
underperformance of any acquired technology, product, or business relative to our expectations and the price we paid;
negative near-term impacts on financial results after an acquisition, including acquisition-related earnings charges;
the potential loss of key employees, customers, and strategic partners of acquired companies;
claims by terminated employees and shareholders of acquired companies or other third parties related to the transaction;
the assumption or incurrence of additional debt obligations or expenses, or use of substantial portions of our cash;
the issuance of equity securities to finance or as consideration for any acquisitions that dilute the ownership of our stockholders;
the issuance of equity securities to finance or as consideration for any acquisitions may not be an option if the price of our common stock is low or volatile which could preclude us from completing any such acquisitions;
any collaboration, strategic alliance and licensing arrangement may require us to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us;
diversion of management’s attention and company resources from existing operations of the business;
inconsistencies in standards, controls, procedures, and policies;
the impairment of intangible assets as a result of technological advancements, or worse-than-expected performance of acquired companies;

61


 

assumption of, or exposure to, historical liabilities of the acquired business, including unknown contingent or similar liabilities that are difficult to identify or accurately quantify; and
risks associated with acquiring intellectual property, including potential disputes regarding acquired companies’ intellectual property.

In addition, the successful integration of acquired businesses requires significant efforts and expense across all operational areas. There can be no assurance that any of the acquisitions we may make, including our acquisition of ZebiAI, will be successful or will be, or will remain, profitable. Our failure to successfully address the foregoing risks may prevent us from achieving the anticipated benefits from any acquisition in a reasonable time frame, or at all.

Risks Related to Business Disruptions

Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our or related parties’ cyber security.

Given our limited operating history, we are still in the process of implementing our internal security measures. Our internal computer systems and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses, ransomware attacks and other unauthorized access. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. The risk of cyber incidents could also be increased by cyberwarfare in connection with the current conflict between Russia and Ukraine, including potential proliferation of malware into systems unrelated to the conflict. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, the further development and commercialization of our product candidate or any future product candidates could be hindered or delayed, we could be required to expend significant amounts of money and other resources to repair or replace our information systems or networks, the market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. In addition, in response to the ongoing COVID-19 pandemic, part of our workforce is currently working remotely. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

 

Our current operations are located in Massachusetts; however, we rely on third parties, including those that are located outside the United States, and we or the third parties upon whom we depend may be adversely affected by natural disasters or other unplanned events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our current operations are located in Massachusetts. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, including any potential effects from the current global spread of COVID-19, global conflicts such as the current conflict between Russia and Ukraine, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the facilities of our third-party contract manufacturers or CROs, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative

62


 

consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.

Natural disasters or pandemics such as the ongoing COVID-19 pandemic could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the facilities of our third-party contract manufacturers or CROs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the facilities of our third-party contract manufacturers or CROs are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.

Risks Related to Our Common Stock

Risks Related to Trading Our Common Stock

The trading price of our common stock historically has been volatile, which may affect the price at which you could sell any shares of our common stock. Securities class action or other litigation involving our company or members of our management team could also substantially harm our business, financial condition and results of operations.

The market price for our common stock historically has been volatile and could continue to be subject to wide fluctuations in response to various factors. Since shares of our common stock were sold in our initial public offering, or IPO, in July 2020 at a price of $20.00 per share, our stock price has fluctuated significantly, ranging from an intraday low of $12.65 to an intraday high of $64.37 through July 29, 2022. This volatility may affect the price at which you could resell the common stock. Our stock price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors, including the factors described below. The stock market in general and Nasdaq and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated or disproportionate to the operating performance of these companies.

Our stock price is likely to be volatile. The market price for our common stock may be influenced by many factors, including:

the success of competitive products or technologies;
results of clinical trials of our product candidates or those of our competitors;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to any of our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares;
variations in our financial results or those of companies that are perceived to be similar to us;
changes in the structure of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors;

63


 

general economic, industry and market conditions; and
the other factors described in this “Risk Factors” section.

In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

An active trading market for our common stock may not be sustained.

If an active market for our common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.

Risks Related to Dividends

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

General Risk Factors

Risks Related to Insider Control

Our executive officers, directors, principal stockholders and their affiliates exercise significant control over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.

As of June 30, 2022, the holdings of our executive officers, directors, principal stockholders and their affiliates, represented beneficial ownership, in the aggregate, of approximately 56.3% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and control the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These stockholders may have interests, with respect to their common stock, that are different from those of our public market investors and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by:

delaying, deferring or preventing a change of control of us;
impeding a merger, consolidation, takeover or other business combination involving us; or
discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

Risks Related to Tax

Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

Under Section 382 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value) in the ownership of its equity over a three year period), the corporation’s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2021, we had federal net operating loss carryforwards of approximately $466.2 million, and our ability to utilize those net operating loss carryforwards could be limited by an “ownership change” as described above.

 

 

64


 

Comprehensive tax reform legislation could adversely affect our business and financial condition.

The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made and changes are likely to continue to occur in the future.

Additional changes to U.S. federal income tax law are currently being contemplated, and future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders’ tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. You are urged to consult your tax advisor regarding the implications of potential changes in tax laws on an investment in our common stock.

Risks Related to Operating as a Public Company

We have incurred increased costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives.

As a public company, and particularly since we are no longer an “emerging growth company,” we have incurred and expect to incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. Because we are no longer an emerging growth company, we are required to include with our annual reports an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have been and will continue to be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404 or that we will not be able to comply with the requirements of Section 404 in a timely manner. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

65


 

Risks Related to Our Charter and Bylaws

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Our fourth amended and restated certificate of incorporation, as amended, and our amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:

a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;
a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;
a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons;
advance notice requirements for stockholder proposals and nominations for election to our board of directors;
a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds (2/3) of all outstanding shares of our voting stock then entitled to vote in the election of directors;
a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any bylaws by stockholder action and not less than two-thirds (2/3) of all outstanding shares of our voting stock to amend specific provisions of our fourth amended and restated certificate of incorporation; and
the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.

Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (3) any action asserting a claim pursuant to any provision of the Delaware General Corporation Law, our fourth amended and restated certificate of incorporation or our amended and restated bylaws; or (4) any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

We recognize that the Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, the forum selection clauses in our amended and restated bylaws may limit

66


 

our stockholders’ ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are “facially valid” under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.

Risks Related to Market Analysts

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our stock downgrade their evaluations of our stock or publishes inaccurate or unfavorable research about our business, the trading price of our stock may decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 5. Other Information

 

As previously reported in our Current Report on Form 8-K filed with the SEC on May 27, 2022, in a non-binding advisory vote held at the 2022 Annual Meeting of Stockholders on the frequency of future say-on-pay votes regarding the compensation of our named executive officers, our stockholders expressed their preference for a say-on-pay vote to be conducted every one year. After taking into consideration the voting results and the prior recommendation of our board of directors in favor of an annual stockholder advisory vote on the compensation of our named executive officers, our board of directors intends to hold future advisory votes on the compensation of our named executive officers every year. Our board of directors will re-evaluate this determination after the next stockholder advisory vote on the frequency of say-on-pay votes (which will be at the 2028 Annual Meeting of Stockholders, unless presented earlier).

67


 

Item 6. Exhibits.

 

Exhibit
Number

 

Description

 

 

 

 

 

3.1

 

Fourth Amended and Restated Certificate of Incorporation of Relay Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K (File No. 001-39385) filed on July 21, 2020).

 

 

3.2

 

Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of Relay Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K (File No. 001-39385) filed on May 27, 2022).

 

 

3.3

 

Amended and Restated Bylaws of Relay Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 8-K (File No. 001-39385) filed on July 21, 2020).

 

 

 

31.1*

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

31.2*

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

32.1**

 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

101.INS*

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

104*

 

Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)

 

* Filed herewith.

** The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

68


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

RELAY THERAPEUTICS, INC.

 

 

Date: August 4, 2022

 

By:

/S/ SANJIV K. PATEL

 

 

 

Sanjiv K. Patel, M.D.

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

Date: August 4, 2022

 

By:

/S/ THOMAS CATINAZZO

 

 

 

Thomas Catinazzo

 

 

 

Chief Financial Officer

 

 

 

(Principal Accounting Officer and Principal Financial Officer)

 

69


EX-31.1 2 rlay-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sanjiv K. Patel, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Relay Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 4, 2022

 

By:

 

 /s/ SANJIV K. PATEL

 

 

 

 

Sanjiv K. Patel

 

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 


EX-31.2 3 rlay-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas Catinazzo, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Relay Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 4, 2022

 

By:

 

/s/ THOMAS CATINAZZO

 

 

 

 

Thomas Catinazzo

 

 

 

 

Chief Financial Officer

(Principal Accounting Officer and Principal Financial Officer)

 


EX-32.1 4 rlay-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Relay Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 4, 2022

 

By:

 

 /s/ SANJIV K. PATEL

 

 

 

 

Sanjiv K. Patel

 

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

Date: August 4, 2022

 

By:

 

 /s/ THOMAS CATINAZZO

 

 

 

 

Thomas Catinazzo

 

 

 

 

Chief Financial Officer

(Principal Accounting Officer and Principal Financial Officer)

 


EX-101.PRE 5 rlay-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.CAL 6 rlay-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 7 rlay-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Acquisition of ZebiAI link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Collaboration and License Arrangements link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Stock Compensation link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Acquisition of ZebiAI (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Stock Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Investments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Acquisition of ZebiAI - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Acquisition of ZebiAI - Summary of Net Assets Acquired Based on Estimated Fair Values (Detail) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Collaboration and License Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Common Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Stock Compensation - Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Leases - Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 8 rlay-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 rlay-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Unrealized holding loss Operating Expenses [Abstract] Operating expenses: Investments, Fair Value Disclosure Total investments Investments, Fair Value Disclosure, Total Asset Class [Domain] Asset Class Operating Income (Loss) Loss from operations Entity Emerging Growth Company Entity Emerging Growth Company Financial Instrument [Axis] Financial Instrument Proceeds from issuance of common stock under ESPP Proceeds from Stock Plans Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Cowen. Cowen [Member] Cowen [Member] Geographical [Axis] Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively; 108,810,478 and 108,210,318 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Entity Address, State or Province Entity Address, State or Province Summary of operating lease presentation in consolidated statements of operations and comprehensive loss. Summary Of Operating Lease Presentation In Consolidated Statements Of Operations And Comprehensive Loss Table [Text Block] Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss Liabilities Total liabilities Class of Stock [Domain] Class of Stock Proceeds from Sale and Maturity of Other Investments Proceeds from maturities of investments Proceeds from Sale and Maturity of Other Investments, Total License Agreement Terms [Member] License Agreement Terms [Member] Milestone payments. Milestone Payments Milestone payments Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Other income: Other Income and Expenses [Abstract] Schedule of operating lease presentation in consolidated balance sheet. Schedule Of Operating Lease Presentation In Consolidated Balance Sheet Table [Text Block] Schedule of Operating Leases Presentation in Consolidated Balance Sheets Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares of common stock, basic and diluted Business Combinations [Abstract] Less than 12 Months, Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Less than 12 Months, Unrealized Losses Change in fair value of Contingent Milestone Payments Change in fair value of Contingent Milestone Payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in fair value of contingent consideration liability Business Acquisition [Line Items] Business Acquisition [Line Items] General and administrative expenses [Member] General and Administrative Expense [Member] General and Administrative Expense [Member] Restricted Cash Restricted cash Restricted Cash, Total Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current, Total Change in fair value of contingent consideration liabilities Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement. Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Significant Accounting Policies [Text Block] Significant Accounting Policies Other Liabilities, Current, Total Other Liabilities, Current Other current liabilities City Area Code City Area Code Investments with maturity of one year or less. Investments With Maturity Of One Year Or Less [Member] Investments with a maturity of one year or less [Member] Schedule of Investments [Abstract] US Treasury Securities [Member] US treasury bills [Member] U.S treasury bills [Member] Revenues [Abstract] Revenue: Sale of Stock, Consideration Received Per Transaction Aggregate gross proceeds from the sale of shares Expense related to accelerated stock options. Expense Related To Accelerated Stock Options Expense related to accelerated stock options as a result of Zebi AI Commitments and Contingencies Commitments and contingencies (Note 8) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share Finite-Lived Intangible Assets, Net Intangible asset Finite-Lived Intangible Assets, Net, Total Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net, Ending Balance Stock Issued During Period, Shares, New Issues Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares Common stock shares sold Debt Securities, Available-for-sale Fair Value Debt Securities, Available-for-sale, Total Business Combination Disclosure [Text Block] Acquisition of ZebiAI Liabilities, Fair Value Disclosure [Abstract] Liabilities Issuance of common stock under ESPP, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Total cash, cash equivalents and restricted cash as shown on condensed consolidated statements of cash flows Milestone payment due upon specified regulatory milestone achievement. Milestone Payment Due Upon Specified Regulatory Milestone Achievement Milestone payment Due Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of convertible preferred stock into common stock upon initial public offering Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Capital Expenditures Incurred but Not yet Paid Property and equipment additions included in accounts payable and accrued expenses Other Liabilities [Member] General and Administrative Expense General and administrative expenses General and Administrative Expense, Total Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Contract with Customer, Liability, Current Deferred revenue Common Stock, Shares, Issued Common stock shares issued Common Stock, Shares, Issued, Total Investments Investments Investments, Total Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Intangible asset Debt Securities, Available-for-sale, Amortized Cost Amortized Cost Operating Lease, Right-of-Use Asset Operating lease assets Right of use asset Reclassification of restricted stock liability to additional paid in capital Reclassification Of Restricted Stock Liability To Additional Paid In Capital Reclassification of restricted stock liability to additional paid-in capital Security Exchange Name Security Exchange Name Statistical Measurement [Domain] Statistical Measurement Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders Other Liabilities, Noncurrent, Total Other Liabilities, Noncurrent Other liabilities Cash and Cash Equivalents, Fair Value Disclosure Assets, fair value Subsequent Event Type [Domain] Subsequent Event Type Document Period End Date Document Period End Date Cash received for milestone payment. Cash Received for Milestone Payment Cash received for milestone payment Restricted Cash, Noncurrent Restricted cash Income Statement Location [Axis] Income Statement Location Investments [Domain] Investments Accrued Liabilities, Current Accrued expenses and other current liabilities Accrued expenses Accrued Liabilities, Current, Total Investments with maturity of one to two years. Investments With Maturity Of One To Two Years [Member] Investments with a maturity of one to two years [Member] Related Party Transaction [Axis] Related Party Transaction Common Stock, Shares Authorized Common stock shares authorized Use of Estimates, Policy [Policy Text Block] Use of Estimates Vesting of restricted common stock shares. Vesting Of Restricted Common Stock Shares Vesting of restricted common stock, shares Current operating lease liabilities Operating Lease, Liability, Current Operating lease liabilities Accretion (Amortization) of Discounts and Premiums, Investments Net amortization of premiums and discounts on investments Contract with Customer, Asset, after Allowance for Credit Loss Contract asset Contract with Customer, Asset, after Allowance for Credit Loss, Total Supplemental Cash Flow Information [Abstract] Supplemental disclosure of non-cash investing and financing activities: Class of Stock [Axis] Class of Stock Research and Development Expense (Excluding Acquired in Process Cost) Research and development expenses Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Assets obtained in asset acquisition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive effect Stock issued during period value preferred stock net of issuance costs. Stock Issued During Period Value Preferred Stock Net Of Issuance Costs Issuance of Series C preferred stock, net of issuance costs Letter of credit expiration date Debt Instrument, Maturity Date Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy Entity Address, Address Line Two Entity Address, Address Line Two Current Fiscal Year End Date Current Fiscal Year End Date Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash, cash equivalents and restricted cash Operating lease costs Operating Lease, Cost BMR Hampshire, LLC [Member] BMR-Hampshire, LLC. [Member] BMR-Hampshire, LLC. [Member] Increase decrease in operating lease assets and liabilities net. Increase decrease in operating lease assets and liabilities net Operating lease assets and liabilities, net Operating lease assets and liabilities, net Stock issued during period additional shares issued. Stock issued during period additional shares issued Additional shares issued DE shaw research. D E Shaw Research [Member] DE Shaw Research [Member] Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Other Operating Assets, Total Operating lease renewal option Lessee, Operating Lease, Existence of Option to Extend [true false] Nonfinancial Liabilities Fair Value Disclosure Total liabilities Counterparty Name [Axis] Counterparty Name Assets [Abstract] Assets Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of convertible preferred stock into common stock upon initial public offering, shares Assets, Fair Value Disclosure [Abstract] Assets Business Description and Basis of Presentation [Text Block] Nature of Business and Basis of Presentation 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Liabilities assumed in asset acquisition of ZebiAI Liabilities Assumed Liabilities assumed in asset acquisition US Government Agencies Debt Securities [Member] US agency securities [Member] U.S agency securities [Member] Common Stock, Par or Stated Value Per Share Common stock par value Shares, Outstanding Ending balance, shares Beginning balance, shares Investments, Debt and Equity Securities [Abstract] Business combination, contingent milestone payments. Business Combination, Contingent Milestone Payments Contingent milestone payments Investments [Member] Investments [Member] Stockholders' Equity Note [Abstract] Operating Leased Assets [Line Items] Document Type Document Type Schedule of Held-to-maturity Securities [Line Items] Schedule of Held-to-maturity Securities [Line Items] Business Combination, Consideration Transferred Consideration transferred Business Combination, Consideration Transferred, Total Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021 Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Assets, Current Total current assets BMR-Hampshire, LLC. B M R Hampshire L L C [Member] BMR Hampshire, LLC [Member] Schedule of changes in fair value of contingent consideration liability. Schedule Of Changes In Fair Value Of Contingent Consideration Liability [Table Text Block] Schedule of Changes in Fair Value of Contingent Consideration Liability Share-based Payment Arrangement, Option [Member] Options to purchase common stock [Member] ZebiAI Therapeutics, Inc. Zebi A I Therapeutics Inc [Member] ZebiAI Therapeutics, Inc. [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Investments, Fair Value Disclosure [Abstract] Investments: Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs Net of discounts and issuance costs Increase (Decrease) in Deferred Revenue Deferred revenue Earnings Per Share, Basic and Diluted Net loss per share, basic and diluted Earnings Per Share, Basic and Diluted, Total Area of land Area of Land Leases [Abstract] Antidilutive Securities [Axis] Antidilutive Securities Transfer of active pharmaceutical ingredients. Transfer Of Active Pharmaceutical Ingredients [Member] Transfer of Active Pharmaceutical Ingredients [Member] Description of new accounting pronouncements not yet adopted. Description Of New Accounting Pronouncements Not Yet Adopted Policy [Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Fair value of equity issued in asset acquisition of ZebiAI Stock Issued Fair value of equity issued in connection with asset acquisition Common Stock, Shares, Outstanding Common stock shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Business Combination, Contingent Consideration Arrangements, Description Contingent consideration payment description Cash paid for acquisition of ZebiAI, net of cash acquired Cash paid for acquisition of ZebiAI, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired, Total Operating Expenses Total operating expenses Investment Secondary Categorization [Axis] Investment Secondary Categorization Financial Instruments [Domain] Financial Instruments Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Losses Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Research and Development in Process In-process research and development expenses Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Available-for-sale Debt Securities in an Unrealized Loss Position Summary of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Earnings Per Share [Abstract] Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Debt securities unrealized loss position 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Liabilities assumed in asset acquisition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total Net Income (Loss) Attributable to Parent Net loss Net loss Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Research and Development Expense [Member] Research and development expenses [Member] Document Fiscal Period Focus Document Fiscal Period Focus Undesignated preferred stock. Undesignatedpreferredstock [Member] Undesignated Preferred Stock [Member] Accounting Policies [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss 399 Binney Street, Cambridge, Massachusetts. Binney Street Cambridge Massachusetts [Member] 399 Binney Street [Member] Entity Address, Address Line One Entity Address Address Line1 Liabilities, Current Total current liabilities Restricted cash and cash equivalents at carrying value abstract. Restricted Cash And Cash Equivalents At Carrying Value [Abstract] Restricted Cash And Cash Equivalents At Carrying Value [Abstract] Commitments Disclosure [Text Block] Commitments and Contingencies Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible List] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Potential development milestone payments. Potential Development Milestone Payments Potential development milestone payments Total lease payments Lessee, Operating Lease, Liability, to be Paid Subsequent Event [Table] Subsequent Event [Table] Product and Service [Domain] Product and Service Loss on extinguishment and reissuance of preferred stock. Loss On Extinguishment And Reissuance Of Preferred Stock Extinguishment upon modification of series C preferred stock Operating lease option to terminate Lessee, Operating Lease, Existence of Option to Terminate [true false] Revenues Total revenue Investments by Secondary Categorization [Domain] Investments by Secondary Categorization Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative EQRx, Inc. E Q Rx Inc [Member] EQRx, Inc [Member] Net Cash Provided by (Used in) Operating Activities Net cash (used in) provided by operating activities Closing price of common stock Business Acquisition, Share Price Average share value of 5-day Debt Securities, Available-for-sale, Unrealized Loss Position Total, Fair Value Total, Fair Value Equity Components [Axis] Equity Components Assets, Current [Abstract] Current assets: Entity Registrant Name Entity Registrant Name Common Stock [Abstract] Common Stock [Abstract] Stockholders' Equity Note Disclosure [Text Block] Common Stock Text Block [Abstract] Entity Interactive Data Current Entity Interactive Data Current Entity Address, City or Town Entity Address, City or Town Cash and cash equivalents fair value disclosure. Cash And Cash Equivalents Fair Value Disclosure [Abstract] Cash equivalents: Trading Symbol Trading Symbol Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Less: interest Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Upfront consideration payable. Upfront Consideration Payable Upfront consideration payable Local Phone Number Local Phone Number ZebiAI. ZebiAI [Member] ZebiAI [Member] Lease expiration month and year. Lease Expiration Month And Year Operating lease agreement expiration date Sale of Stock, Percentage of Ownership after Transaction Percentage of commission of shares sold Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders’ equity Subsequent Event Type [Axis] Subsequent Event Type Share-based Payment Arrangement, Accelerated Cost Stock-based compensation expense associated with accelerated vesting for certain stock options Fixed lease payments Operating Lease, Payments Preferred Stock, Shares Issued Preferred stock shares issued Preferred Stock, Shares Issued, Total Assets, Fair Value Disclosure Total assets Investment [Text Block] Investments Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table] Statistical Measurement [Axis] Statistical Measurement Entity Small Business Entity Small Business Preferred Stock, Shares Outstanding Preferred stock shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Organization, Consolidation and Presentation of Financial Statements [Abstract] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Collaboration and license arrangement. Collaboration And License Arrangement [Line Items] Collaboration And License Arrangement [Line Items] Business Acquisition [Axis] Business Acquisition Balance Sheet Location [Axis] Vesting of restricted common stock value. Vesting Of Restricted Common Stock Value Vesting of restricted common stock Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Summary of Fair Value of Available-for-Sale Investments by Type of Security Basis of presentation. Basis Of Presentation Policy [Text Block] Basis of presentation Sales agreement. Sales Agreement [Member] Sales Agreement [Member] Land subject to ground leases Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Lease, Description [Table] Depreciation Depreciation expense Depreciation, Total Term of the lease Lessee, Operating Lease, Term of Contract Prepaid Expense, Current Prepaid balance Prepaid Expense, Current, Total Stock Issued During Period, Value, New Issues Issuance of common stock in public offering, net of discounts and issuance costs of $34,707 Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Less than 12 Months, Fair Value Share-based Payment Arrangement, Noncash Expense Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Aggregate fair value consideration transferred Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Issued shares of common stock Payment related to collaboration or other agreements. Payment Related To Collaboration Or Other Agreements Payment related to collaboration or other agreements Contribution toward the cost of construction and tenant improvements for the premises Contribution toward the cost of construction and tenant improvements for the premises. Business Combination, Contingent Consideration, Liability Ending balance Beginning balance Contingent consideration liability Fair value of contingent milestone payments Business Combination, Contingent Consideration, Liability, Total Total, Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Total, Unrealized Losses Total, Unrealized Losses Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Commitments and Contingencies Disclosure [Abstract] Assets Total assets Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Series C preferred stock issuance costs. Series C Preferred Stock Issuance Costs Series C preferred stock issuance costs Leases Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, shares Statement [Line Items] Statement [Line Items] Liabilities and Equity Total liabilities and stockholders’ equity Stock Issued During Period, Value, Treasury Stock Reissued Extinguishment upon modification of Series C preferred stock Document Quarterly Report Document Quarterly Report Balance Sheet Location [Domain] Statement of Cash Flows [Abstract] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Title of 12(b) Security Title of 12(b) Security Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Interest Income, Other Interest income Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Increase (Decrease) in Prepaid Expense Prepaid expenses and other current assets Percentage of payment related to collaboration or other agreements. Percentage Of Payment Related To Collaboration Or Other Agreements Percentage of payment related to collaboration or other agreements Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Revenue from license agreement Fair Value Hierarchy and NAV [Axis] Level 2 [Member] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Lease Agreement [Member] Lease Agreement [Member] Lease Agreement Restricted Stock [Member] Unvested restricted stock [Member] Entity Current Reporting Status Entity Current Reporting Status Collaborative Arrangement Disclosure [Text Block] Collaboration and License Arrangements Investment Type [Axis] Investment Type Money Market Funds [Member] Money market funds [Member] Debt Securities, Available-for-sale [Table] Debt Securities Available For Sale [Table] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss [Member] Income Statement Location [Domain] Income Statement Location Investments [Abstract] Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items] Business Combination, Acquisition Related Costs Acquisition-related costs Preferred Stock, Shares Authorized Preferred stock shares authorized Increase (Decrease) in Accrued Liabilities Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities, Total Minimum [Member] Minimum [Member] Acquired in-process research and development Acquired research and development in process Acquired research and development in process. Measurement Frequency [Domain] Measurement Frequency Average stock price upon milestone settlement Average stock price upon milestone settlement. Other income (expense). Other Income Expense Other income (expense) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Schedule of Business Acquisitions, by Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Number of milestone targets. Number Of Milestone Targets Number of milestone targets Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Entity Filer Category Entity Filer Category Business Combination, Description [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer 12 Months or Longer, Fair Value Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Letter of credit Entity Ex Transition Period Entity Ex Transition Period Fair Value Disclosures [Abstract] Maximum [Member] Maximum [Member] Entity Central Index Key Entity Central Index Key Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree Increase (Decrease) in Commodity Contract Assets and Liabilities Contract asset Stock Issued During Period, Value, Acquisitions Shares issued in connection with acquisition of ZebiAI Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Summary of Net Assets Acquired Based on Estimated Fair Values Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component Preferred Stock, Par or Stated Value Per Share Preferred stock par value Common stock, restriction period. Common Stock Restriction Period Common Stock Restriction Period Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Unrealized gain (loss) on investments Other third parties [member]. Otherthird Parties [Member] Other Third Parties [Member] Increase (Decrease) in Accounts Receivable Accounts receivable Subsequent Events [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Business combination contingent consideration liability, contingent earnout payments. Business combination contingent consideration liability, contingent earnout payments Business combination contingent consideration liability, contingent earnout payments Unaudited interim financial information. Unaudited Interim Financial Information Policy [Text Block] Unaudited Interim Financial Information Genentech agreement. Genentech Agreement [Member] Genentech Agreement [Member] License [Member] License Agreement [Member] Statement [Table] Statement [Table] Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Cash Equivalents [Member] Cash equivalents [Member] Entity File Number Entity File Number Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Retained Earnings [Member] Accumulated Deficit [Member] Revenue from license agreement License and other revenue Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Collaboration and license arrangement. Collaboration And License Arrangement [Table] Collaboration And License Arrangement [Table] Liabilities, Current [Abstract] Current liabilities: Share-based Payment Arrangement [Text Block] Stock Compensation Subsequent Event [Member] Subsequent Event [Member] Total lease liabilities Present value of operating lease liabilities Total lease liabilities Operating Lease, Liability Common Stock [Member] Common Stock [Member] Variable Interest Entity, Initial Consolidation, Gain (Loss) Loss on initial consolidation of variable interest entity Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Net acquired assets Cover [Abstract] In Process Research and Development, Policy [Policy Text Block] Acquired In-Process Research and Development Asset Class [Axis] Asset Class Related Party Transaction [Domain] Related Party Transaction Statement of Stockholders' Equity [Abstract] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Restricted Stock Units (RSUs) [Member] Restricted stock units [Member] Document Transition Report Document Transition Report Preferred Stock Dividends and Other Adjustments Deemed dividend resulting from extinguishment upon modification of series C preferred stock Preferred Stock Dividends and Other Adjustments, Total Collaboration and license arrangement. Collaboration And License Arrangement [Abstract] Research and Development Expense Research and development expense Research and Development Expense, Total Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] Assets obtained in asset acquisition of ZebiAI Fair Value of Assets Acquired Assets obtained in asset acquisition Stock Issued During Period, Shares, Acquisitions Shares issued in connection with acquisition, shares Number of shares would be issued upon milestone achievement. Number of Shares Would Be Issued Upon Milestone Achievement Number of shares that would be issued upon milestone achievement Share-based Payment Arrangement, Expense Total share-based compensation expense Business combination recognized identifiable assets acquired and liabilities assumed assets loss on initial consolidation of variable interest entity. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Loss On Initial Consolidation Of Variable Interest Entity Loss on initial consolidation of VIE Business combination recognized identifiable assets acquired and liabilities assumed in process research and development asset. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Asset Acquired IPR&D asset Statement of Financial Position [Abstract] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Stockholders' Equity Attributable to Parent [Abstract] Stockholders’ equity: Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Unrealized loss on investments Payments to Acquire Investments Purchases of investments Payments to Acquire Investments, Total Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Computation of Basic and Diluted Net Loss Per Share Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Measurement Frequency [Axis] Measurement Frequency Entity Shell Company Entity Shell Company Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Operations and Comprehensive Loss Statement [Abstract]. Operations And Comprehensive Loss Statement [Abstract] Sale of Stock, Price Per Share Shares issue price per share Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Issuance of common stock under ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Earnings Per Share [Text Block] Net Loss Per Share Counterparty Name [Domain] Counterparty Name Amendment Flag Amendment Flag Collaborative Arrangement, Accounting Policy [Policy Text Block] Collaboration Agreements Product and Service [Axis] Product and Service Conversion of Stock, Amount Converted Conversion of preferred stock into common stock upon initial public offering Total other income, net Other Nonoperating Income (Expense) Business combination contingent consideration liability, milestones payments. Business Combination Contingent Consideration Liability Milestones Payments Business combination contingent consideration liability, milestones payments Contingent Milestone Payments Collaborative Arrangement, Rights and Obligations Collaborative arrangement, rights and obligations Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Fair Value, Recurring [Member] Fair value on a recurring basis [Member] Subsequent Events [Text Block] Subsequent Events Genentech Inc. Genentech Inc [Member] Genentech [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Geographical [Domain] Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 12 Months or Longer, Unrealized Losses Business Acquisition, Effective Date of Acquisition Acquisition date Share-based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss Fair Value Disclosures [Text Block] Fair Value Measurements Proceeds from Issuance of Common Stock Proceeds from issuance of common stock upon exercise of stock options Proceeds from issuance of shares XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2022
Jul. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Entity Registrant Name RELAY THERAPEUTICS, INC.  
Entity Central Index Key 0001812364  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Interactive Data Current Yes  
Entity Current Reporting Status Yes  
Entity Address, State or Province MA  
Entity Shell Company false  
Entity Small Business false  
Entity Emerging Growth Company false  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol RLAY  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   108,898,083
Entity File Number 001-39385  
Entity Tax Identification Number 47-3923475  
Entity Address Address Line1 399 Binney Street  
Entity Address, Address Line Two 2nd Floor  
Entity Address, City or Town Cambridge  
Entity Address, Postal Zip Code 02139  
City Area Code 617  
Local Phone Number 370-8837  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 107,736 $ 280,119
Investments 730,254 677,954
Accounts receivable 288 403
Contract asset 4,764 4,537
Prepaid expenses and other current assets 12,751 13,229
Total current assets 855,793 976,242
Property and equipment, net 8,922 6,543
Operating lease assets 19,828 20,780
Restricted cash 2,578 2,578
Intangible asset 2,300 2,300
Total assets 889,421 1,008,443
Current liabilities:    
Accounts payable 4,296 8,276
Accrued expenses 22,108 13,557
Operating lease liabilities 2,002 1,844
Deferred revenue 83 248
Other current liabilities 15,413 396
Total current liabilities 43,902 24,321
Operating lease liabilities, net of current portion 20,019 21,056
Contingent consideration liability 45,863 50,258
Other liabilities   15,000
Total liabilities 109,784 110,635
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively; 108,810,478 and 108,210,318 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively 109 109
Additional paid-in capital 1,698,368 1,666,887
Accumulated other comprehensive loss (11,906) (1,088)
Accumulated deficit (906,934) (768,100)
Total stockholders’ equity 779,637 897,808
Total liabilities and stockholders’ equity $ 889,421 $ 1,008,443
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Common stock par value $ 0.001 $ 0.001
Common stock shares authorized 300,000,000 150,000,000
Common stock shares issued 108,810,478 108,210,318
Common stock shares outstanding 108,810,478 108,210,318
Undesignated Preferred Stock [Member]    
Preferred stock par value $ 0.001 $ 0.001
Preferred stock shares authorized 10,000,000 10,000,000
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
License and other revenue $ 365 $ 844 $ 784 $ 1,796
Revenue from Contract with Customer, Product and Service [Extensible List] us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember
Total revenue $ 365 $ 844 $ 784 $ 1,796
Operating expenses:        
Research and development expenses 60,511 45,147 112,178 75,769
In-process research and development expenses   123,000   123,000
Loss on initial consolidation of variable interest entity   11,855   11,855
Change in fair value of contingent consideration liabilities 200   (4,395)  
General and administrative expenses 17,465 14,422 33,533 27,156
Total operating expenses 78,176 194,424 141,316 237,780
Loss from operations (77,811) (193,580) (140,532) (235,984)
Other income:        
Interest income 1,005 180 1,701 406
Other income (expense) 18 1 (3) (4)
Total other income, net 1,023 181 1,698 402
Net loss $ (76,788) $ (193,399) $ (138,834) $ (235,582)
Net loss per share, basic and diluted $ (0.71) $ (2.10) $ (1.28) $ (2.58)
Weighted average shares of common stock, basic and diluted 108,644,329 91,939,439 108,469,760 91,188,160
Other comprehensive loss:        
Unrealized holding loss $ (2,688) $ (76) $ (10,818) $ (128)
Total other comprehensive loss (2,688) (76) (10,818) (128)
Total comprehensive loss $ (79,476) $ (193,475) $ (149,652) $ (235,710)
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020 $ 763,293 $ 90 $ 1,167,367 $ 64 $ (404,228)
Beginning balance, shares at Dec. 31, 2020   89,906,835      
Issuance of common stock upon exercise of stock options 2,055   2,055
Issuance of common stock upon exercise of stock options, shares   437,230      
Vesting of restricted common stock 3   3    
Vesting of restricted common stock, shares   84,489      
Stock-based compensation expense 9,671   9,671    
Unrealized loss on investments (52)     (52)  
Net loss (42,184)       (42,184)
Ending balance at Mar. 31, 2021 732,786 $ 90 1,179,096 12 (446,412)
Ending balance, shares at Mar. 31, 2021   90,428,554      
Beginning balance at Dec. 31, 2020 763,293 $ 90 1,167,367 64 (404,228)
Beginning balance, shares at Dec. 31, 2020   89,906,835      
Net loss (235,582)        
Ending balance at Jun. 30, 2021 618,529 $ 92 1,258,312 (64) (639,811)
Ending balance, shares at Jun. 30, 2021   92,552,645      
Beginning balance at Mar. 31, 2021 732,786 $ 90 1,179,096 12 (446,412)
Beginning balance, shares at Mar. 31, 2021   90,428,554      
Issuance of common stock upon exercise of stock options 1,123   1,123    
Issuance of common stock upon exercise of stock options, shares   218,365      
Vesting of restricted common stock, shares   22,239      
Stock-based compensation expense 16,147   16,147    
Shares issued in connection with acquisition of ZebiAI 61,948 $ 2 61,946    
Shares issued in connection with acquisition, shares   1,883,487      
Unrealized loss on investments (76)     (76)  
Net loss (193,399)       (193,399)
Ending balance at Jun. 30, 2021 618,529 $ 92 1,258,312 (64) (639,811)
Ending balance, shares at Jun. 30, 2021   92,552,645      
Beginning balance at Dec. 31, 2021 897,808 $ 109 1,666,887 (1,088) (768,100)
Beginning balance, shares at Dec. 31, 2021   108,210,318      
Issuance of common stock upon exercise of stock options 883   883    
Issuance of common stock upon exercise of stock options, shares   195,799      
Vesting of restricted common stock, shares   27,233      
Stock-based compensation expense 13,455   13,455    
Unrealized loss on investments (8,130)     (8,130)  
Net loss (62,046)       (62,046)
Ending balance at Mar. 31, 2022 841,970 $ 109 1,681,225 (9,218) (830,146)
Ending balance, shares at Mar. 31, 2022   108,433,350      
Beginning balance at Dec. 31, 2021 897,808 $ 109 1,666,887 (1,088) (768,100)
Beginning balance, shares at Dec. 31, 2021   108,210,318      
Net loss (138,834)        
Ending balance at Jun. 30, 2022 779,637 $ 109 1,698,368 (11,906) (906,934)
Ending balance, shares at Jun. 30, 2022   108,810,478      
Beginning balance at Mar. 31, 2022 841,970 $ 109 1,681,225 (9,218) (830,146)
Beginning balance, shares at Mar. 31, 2022   108,433,350      
Issuance of common stock upon exercise of stock options 859   859    
Issuance of common stock upon exercise of stock options, shares   182,113      
Issuance of common stock under ESPP 1,137   1,137    
Issuance of common stock under ESPP, shares   79,859      
Vesting of restricted common stock, shares   115,156      
Stock-based compensation expense 15,147   15,147    
Unrealized loss on investments (2,688)     (2,688)  
Net loss (76,788)       (76,788)
Ending balance at Jun. 30, 2022 $ 779,637 $ 109 $ 1,698,368 $ (11,906) $ (906,934)
Ending balance, shares at Jun. 30, 2022   108,810,478      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (138,834) $ (235,582)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Stock-based compensation expense 28,602 25,818
Depreciation expense 1,931 1,879
Net amortization of premiums and discounts on investments 1,227 701
Acquired in-process research and development   123,000
Loss on initial consolidation of variable interest entity   11,855
Change in fair value of contingent consideration liabilities (4,395)  
Changes in assets and liabilities:    
Accounts receivable 115 74,801
Contract asset (227) 3,462
Prepaid expenses and other current assets 478 4,964
Operating lease assets and liabilities, net 73 186
Other assets   22
Accounts payable (4,611) (867)
Accrued expenses and other liabilities 9,540 8,261
Deferred revenue (165)  
Net cash (used in) provided by operating activities (106,266) 18,500
Cash flows from investing activities:    
Purchases of property and equipment (4,651) (855)
Purchases of investments (151,945) (646,239)
Proceeds from maturities of investments 87,600 464,673
Cash paid for acquisition of ZebiAI, net of cash acquired   (25,132)
Net cash used in investing activities (68,996) (207,553)
Cash flows from financing activities:    
Proceeds from issuance of common stock upon exercise of stock options 1,742 3,176
Proceeds from issuance of common stock under ESPP 1,137  
Net cash provided by financing activities 2,879 3,176
Net decrease in cash, cash equivalents and restricted cash (172,383) (185,877)
Cash, cash equivalents and restricted cash at beginning of period 282,697 448,524
Cash, cash equivalents and restricted cash at end of period 110,314 262,647
Supplemental disclosure of non-cash investing and financing activities:    
Property and equipment additions included in accounts payable and accrued expenses $ 669 1,077
Reclassification of restricted stock liability to additional paid-in capital   3
Assets obtained in asset acquisition of ZebiAI   662
Liabilities assumed in asset acquisition of ZebiAI   2,330
Fair value of equity issued in asset acquisition of ZebiAI   $ 62,990
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2022
Jun. 30, 2021
Restricted Cash And Cash Equivalents At Carrying Value [Abstract]    
Cash and cash equivalents $ 107,736 $ 260,069
Restricted cash 2,578 2,578
Total cash, cash equivalents and restricted cash as shown on condensed consolidated statements of cash flows $ 110,314 $ 262,647
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Nature of Business and Basis of Presentation
6 Months Ended
Jun. 30, 2022
Text Block [Abstract]  
Nature of Business and Basis of Presentation

1. Nature of Business and Basis of Presentation

Relay Therapeutics, Inc. (the “Company”) was incorporated in Delaware on May 4, 2015 and is headquartered in Cambridge, Massachusetts. The Company is a clinical-stage, precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the Company believes it is among the first of a new breed of biotech created at the intersection of disparate technologies, the Company aims to push the boundaries of what’s possible in drug discovery. The Company’s Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s lead product candidates, RLY-4008, RLY-2608 and RLY-1971, are in clinical development. The Company also has over five discovery stage programs across both precision oncology and genetic disease indications.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.

The Company’s product candidates are in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.

The Company has devoted substantially all of its resources to developing its product candidates, including RLY-4008, RLY-2608 and RLY-1971, by developing its computation and experimental approaches, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations.

The Company has incurred net operating losses since inception and had an accumulated deficit of $906.9 million as of June 30, 2022. The Company expects that its existing cash, cash equivalents and investments as of June 30, 2022 will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue its business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into license or collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all.

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Significant Accounting Policies

2. Significant Accounting Policies

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The Company’s condensed consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiaries, Relay Therapeutics Securities Corporation and Relay ML Discovery, LLC.

All intercompany balances and transactions have been eliminated.

Certain prior period amounts, specifically including certain current liabilities, have been reclassified to conform to current period presentation. Such reclassifications have no impact on the Company’s condensed consolidated statement of operations and comprehensive loss, as previously reported.

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of June 30, 2022, the condensed consolidated results of its operations for the three and six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The condensed consolidated financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The condensed consolidated results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. (“ZebiAI”), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments thereto require that credit losses be reported as an allowance using an expected losses model, representing the entity’s current estimate of credit losses expected to be incurred. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company’s condensed consolidated financial statements or disclosures as of and for the three and six months ended June 30, 2022.

Recently Issued Accounting Pronouncements Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of any recently issued standards have or may have a material impact on its condensed consolidated financial statements and disclosures.

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements

3. Fair Value Measurements

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

 

 

Fair Value Measurements as of
June 30, 2022:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

80,153

 

 

$

 

 

$

 

 

$

80,153

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

 

 

 

478,880

 

 

 

 

 

 

478,880

 

U.S. agency securities

 

 

 

 

 

251,374

 

 

 

 

 

 

251,374

 

Total investments

 

 

 

 

 

730,254

 

 

 

 

 

 

730,254

 

Total assets

 

$

80,153

 

 

$

730,254

 

 

$

 

 

$

810,407

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Milestone Payments

 

$

 

 

$

 

 

$

40,863

 

 

$

40,863

 

Total liabilities

 

$

 

 

$

 

 

$

40,863

 

 

$

40,863

 

 

 

 

 

Fair Value Measurements as of
December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

251,891

 

 

$

 

 

$

 

 

$

251,891

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

 

 

 

469,386

 

 

 

 

 

 

469,386

 

U.S. agency securities

 

 

 

 

 

208,568

 

 

 

 

 

 

208,568

 

Total investments

 

 

 

 

 

677,954

 

 

 

 

 

 

677,954

 

Total assets

 

$

251,891

 

 

$

677,954

 

 

$

 

 

$

929,845

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Milestone Payments

 

$

 

 

$

 

 

$

45,258

 

 

$

45,258

 

Total liabilities

 

$

 

 

$

 

 

$

45,258

 

 

$

45,258

 

In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data.

Fair Value of Contingent Consideration Liability

In April 2021, the Company acquired ZebiAI.

The Company’s Level 3 contingent consideration liability is related to $85.0 million of platform and program-related milestones (“Contingent Milestone Payments”) potentially payable to ZebiAI’s former equity holders. The contingent consideration liability for the Contingent Milestone Payments is measured at fair value at each reporting date pursuant to FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company determines the fair value of the Contingent Milestone Payments based on the probability of achieving the milestones, the related timing, and, to a lesser extent, an appropriate discount rate. Significant judgment is used in determining these assumptions. Due to the uncertainties associated with the development of platforms and drug candidates in the pharmaceutical industry and the effects of changes in assumptions including probability of success and related timing, the Company expects its estimates regarding the fair value of Contingent Milestone Payments to continue to change in the future, resulting in adjustments to the fair value of the Company’s Contingent Milestone Payments, and the effect of any such adjustments could be material.

 

The Company also has a contingent consideration liability related to the fair value of $100.0 million in earnout payments (“Contingent Earnout Payments”). Because the Contingent Earnout Payments were not accounted for as derivatives under FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"), they were only measured at fair value as of the acquisition date and are not re-assessed at fair value at each reporting period. The Contingent Earnout Payments will be adjusted when the contingency is resolved and the consideration is paid or becomes payable.

The following table reconciles the change in fair value of the contingent consideration liability (in thousands):

 

 

 

 

Six Months Ended June 30, 2022

 

Balance at December 31, 2021

$

50,258

 

Change in fair value of Contingent Milestone Payments

 

(4,395

)

Balance at June 30, 2022

$

45,863

 

The “Change in fair value of Contingent Milestone Payments” in the table above was attributable to changes in the assumptions noted above between December 31, 2021 and June 30, 2022, primarily changes in timing and interest rates.

The Contingent Milestone Payments are payable in shares of common stock based on a fixed amount assigned to each milestone and the average closing price of the Company’s common stock for the 5-day period prior to the milestone achievement. Accordingly, the number of shares of common stock to be issued upon a milestone achievement vary dependent on the Company’s common stock price. The settlement amounts of Contingent Milestone Payments are predominantly fixed. If the milestones were achieved in full on June 30, 2022, the number of shares of common stock to be issued would be 4,751,258 based on an average closing price of the Company's common stock of $17.89 for the 5-day period prior to June 30, 2022.

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Investments
6 Months Ended
Jun. 30, 2022
Schedule of Investments [Abstract]  
Investments

4. Investments

The fair value of available-for-sale investments by type of security was as follows:

 

 

June 30, 2022

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

332,729

 

 

$

 

 

$

(4,150

)

 

$

328,579

 

U.S. agency securities

 

 

165,061

 

 

 

 

 

 

(1,462

)

 

 

163,599

 

Total investments with a maturity of one year or less

 

 

497,790

 

 

 

 

 

 

(5,612

)

 

 

492,178

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

154,076

 

 

 

 

 

 

(3,775

)

 

 

150,301

 

U.S. agency securities

 

 

90,294

 

 

 

 

 

 

(2,519

)

 

 

87,775

 

Total investments with a maturity of one to two years

 

 

244,370

 

 

 

 

 

 

(6,294

)

 

 

238,076

 

Total investments

 

$

742,160

 

 

$

 

 

$

(11,906

)

 

$

730,254

 

 

 

 

December 31, 2021

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

189,406

 

 

$

 

 

$

(228

)

 

$

189,178

 

U.S. agency securities

 

 

108,895

 

 

 

 

 

 

(138

)

 

 

108,757

 

Total investments with a maturity of one year or less

 

 

298,301

 

 

 

 

 

 

(366

)

 

 

297,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

280,743

 

 

 

 

 

 

(535

)

 

 

280,208

 

U.S. agency securities

 

 

99,998

 

 

 

 

 

 

(187

)

 

 

99,811

 

Total investments with a maturity of one to two years

 

 

380,741

 

 

 

 

 

 

(722

)

 

 

380,019

 

Total investments

 

$

679,042

 

 

$

 

 

$

(1,088

)

 

$

677,954

 

Pursuant to the Company’s adoption of ASU 2016-13 and the related amendments thereto on January 1, 2022, the Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive (loss) income. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.

The Company held 112 and 88 debt securities that were in an unrealized loss position as of June 30, 2022 and December 31, 2021, respectively. The unrealized losses at June 30, 2022 and December 31, 2021 were attributable to changes in interest rates and the unrealized losses do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis.

The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at June 30, 2022, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

 

 

Less than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

478,880

 

 

$

(7,925

)

 

$

 

 

$

 

 

$

478,880

 

 

$

(7,925

)

U.S. agency securities

 

 

251,374

 

 

 

(3,981

)

 

 

 

 

 

 

 

 

251,374

 

 

 

(3,981

)

Total

 

$

730,254

 

 

$

(11,906

)

 

$

 

 

$

 

 

$

730,254

 

 

$

(11,906

)

 

The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2021, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

 

 

Less than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

469,386

 

 

$

(763

)

 

$

 

 

$

 

 

$

469,386

 

 

$

(763

)

U.S. agency securities

 

 

208,568

 

 

 

(325

)

 

 

 

 

 

 

 

 

208,568

 

 

 

(325

)

Total

 

$

677,954

 

 

$

(1,088

)

 

$

 

 

$

 

 

$

677,954

 

 

$

(1,088

)

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and License Arrangements
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration and License Arrangements

5. Collaboration and License Arrangements

Discovery Collaboration Agreement with EQRx, Inc.

During the three and six months ended June 30, 2022, there were no changes to the Company’s Discovery and Collaboration Agreement (“Collaboration Agreement”) with EQRx, Inc. (“EQRx”) from August 2021. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.

During the three and six months ended June 30, 2022, expenses related to the Collaboration Agreement were immaterial.

Collaboration and License Agreement with Genentech, Inc.

During the three and six months ended June 30, 2022 and 2021, there were no material changes to the Company’s Collaboration and License Agreement (“License Agreement”) with Genentech, Inc. (“Genentech”) from December 2020. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.

During the three months ended June 30, 2022 and 2021, the Company recognized $0.3 million and $0.8 million of revenue from the License Agreement, respectively.

During the six months ended June 30, 2022 and 2021, the Company recognized $0.5 million and $1.7 million of revenue from the License Agreement, respectively.

As of June 30, 2022 and December 31, 2021, the Company recorded a contract asset of $4.8 million and $4.5 million, respectively, both of which are classified as current assets on the condensed consolidated balance sheet. The contract asset relates to the amount of revenue recognized for which the right to payment is contingent upon conditions other than the passage of time, such as the completion of future milestone activities.

As of June 30, 2022 and December 31, 2021, the Company recorded an other liability in the amount of $15.0 million. The liability represents the cash received for a milestone payment in 2021 under the License Agreement. The amount has been excluded from the transaction price at both June 30, 2022 and December 31, 2021 and, therefore, excluded from amounts recognized as revenue, since the amount is subject to repayment to Genentech if the Company exercises its option to participate in the profit/cost share under the License Agreement.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Stock Compensation
6 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Stock Compensation

6. Stock Compensation

Stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development expenses

 

$

8,139

 

 

$

10,145

 

 

$

15,249

 

 

$

14,296

 

General and administrative expenses

 

 

7,008

 

 

 

6,002

 

 

 

13,353

 

 

 

11,522

 

 

 

$

15,147

 

 

$

16,147

 

 

$

28,602

 

 

$

25,818

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Net Loss Per Share

7. Net Loss Per Share

The following table summarizes the computation of basic and diluted net loss per share of the Company:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net loss

 

$

(76,788

)

 

$

(193,399

)

 

$

(138,834

)

 

$

(235,582

)

Net loss per share, basic and diluted

 

$

(0.71

)

 

$

(2.10

)

 

$

(1.28

)

 

$

(2.58

)

Weighted average shares of common stock, basic and diluted

 

 

108,644,329

 

 

 

91,939,439

 

 

 

108,469,760

 

 

 

91,188,160

 

The Company’s potentially dilutive securities, which include outstanding options to purchase common stock and restricted stock units summarized below, have been excluded from the computation of diluted net loss per share for the periods indicated below, as the effect would be anti-dilutive and reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same.

 

 

Three and Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

Options to purchase common stock

 

 

11,526,322

 

 

 

8,906,194

 

Restricted stock units

 

 

1,681,891

 

 

 

505,393

 

 

 

 

13,208,213

 

 

 

9,411,587

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

8. Commitments and Contingencies

Intellectual Property License

During the six months ended June 30, 2022, the Company amended the Amended and Restated Collaboration and License Agreement (“DESRES Agreement”) with D.E. Shaw Research, LLC (“D.E. Shaw Research”), specifically to update certain of the Category 1, Category 2, and Category 3 Target lists thereunder. However, there was no change to the Company’s accounting treatment or incremental amounts recognized in connection therewith for the three and six months ended June 30, 2022.

The Company assessed the milestones under the DESRES Agreement at June 30, 2022 and December 31, 2021, concluding no such milestone payments were due.

The Company recorded research and development expenses of $2.3 million and $2.1 million under the DESRES Agreement for the three months ended June 30, 2022 and 2021, respectively.

The Company recorded research and development expenses of $4.7 million and $3.9 million under the DESRES Agreement for the six months ended June 30, 2022 and 2021, respectively.

As of June 30, 2022 and December 31, 2021, the Company had accrued expense balances of $0.3 million and $0, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.

As of June 30, 2022 and December 31, 2021, the Company had prepaid balances of $0 and $4.4 million, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.

Other Significant Arrangements

The Company has certain other research and license arrangements with third parties, which provide the Company with research services with the goal of identifying and developing product candidates, and the Company is obligated to pay certain development milestone payments pursuant to these arrangements upon the achievement of certain specified contingent events. The Company assessed such milestones at June 30, 2022 and December 31, 2021, concluding no such milestone payments were due. The Company incurred approximately $1.6 million and $0.7 million of research and development expenses under these agreements for the three months ended June 30, 2022 and 2021, respectively. The Company incurred approximately $2.6 million and $1.1 million of research and development expenses under these agreements for the six months ended June 30, 2022 and 2021, respectively.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events

9. Subsequent Events

In preparing the consolidated interim financial statements as of June 30, 2022 and for the three and six month periods then ended, the Company evaluated subsequent events for recognition and measurement purposes. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The Company’s condensed consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiaries, Relay Therapeutics Securities Corporation and Relay ML Discovery, LLC.

All intercompany balances and transactions have been eliminated.

Certain prior period amounts, specifically including certain current liabilities, have been reclassified to conform to current period presentation. Such reclassifications have no impact on the Company’s condensed consolidated statement of operations and comprehensive loss, as previously reported.

Unaudited Interim Financial Information

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of June 30, 2022, the condensed consolidated results of its operations for the three and six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The condensed consolidated financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The condensed consolidated results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. (“ZebiAI”), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments thereto require that credit losses be reported as an allowance using an expected losses model, representing the entity’s current estimate of credit losses expected to be incurred. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company’s condensed consolidated financial statements or disclosures as of and for the three and six months ended June 30, 2022.

Recently Issued Accounting Pronouncements Not Yet Adopted

Recently Issued Accounting Pronouncements Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of any recently issued standards have or may have a material impact on its condensed consolidated financial statements and disclosures.

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

 

 

Fair Value Measurements as of
June 30, 2022:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

80,153

 

 

$

 

 

$

 

 

$

80,153

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

 

 

 

478,880

 

 

 

 

 

 

478,880

 

U.S. agency securities

 

 

 

 

 

251,374

 

 

 

 

 

 

251,374

 

Total investments

 

 

 

 

 

730,254

 

 

 

 

 

 

730,254

 

Total assets

 

$

80,153

 

 

$

730,254

 

 

$

 

 

$

810,407

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Milestone Payments

 

$

 

 

$

 

 

$

40,863

 

 

$

40,863

 

Total liabilities

 

$

 

 

$

 

 

$

40,863

 

 

$

40,863

 

 

 

 

 

Fair Value Measurements as of
December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

251,891

 

 

$

 

 

$

 

 

$

251,891

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

 

 

 

469,386

 

 

 

 

 

 

469,386

 

U.S. agency securities

 

 

 

 

 

208,568

 

 

 

 

 

 

208,568

 

Total investments

 

 

 

 

 

677,954

 

 

 

 

 

 

677,954

 

Total assets

 

$

251,891

 

 

$

677,954

 

 

$

 

 

$

929,845

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent Milestone Payments

 

$

 

 

$

 

 

$

45,258

 

 

$

45,258

 

Total liabilities

 

$

 

 

$

 

 

$

45,258

 

 

$

45,258

 

Schedule of Changes in Fair Value of Contingent Consideration Liability

The following table reconciles the change in fair value of the contingent consideration liability (in thousands):

 

 

 

 

Six Months Ended June 30, 2022

 

Balance at December 31, 2021

$

50,258

 

Change in fair value of Contingent Milestone Payments

 

(4,395

)

Balance at June 30, 2022

$

45,863

 

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Tables)
6 Months Ended
Jun. 30, 2022
Schedule of Investments [Abstract]  
Summary of Fair Value of Available-for-Sale Investments by Type of Security

The fair value of available-for-sale investments by type of security was as follows:

 

 

June 30, 2022

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

332,729

 

 

$

 

 

$

(4,150

)

 

$

328,579

 

U.S. agency securities

 

 

165,061

 

 

 

 

 

 

(1,462

)

 

 

163,599

 

Total investments with a maturity of one year or less

 

 

497,790

 

 

 

 

 

 

(5,612

)

 

 

492,178

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

154,076

 

 

 

 

 

 

(3,775

)

 

 

150,301

 

U.S. agency securities

 

 

90,294

 

 

 

 

 

 

(2,519

)

 

 

87,775

 

Total investments with a maturity of one to two years

 

 

244,370

 

 

 

 

 

 

(6,294

)

 

 

238,076

 

Total investments

 

$

742,160

 

 

$

 

 

$

(11,906

)

 

$

730,254

 

 

 

 

December 31, 2021

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

189,406

 

 

$

 

 

$

(228

)

 

$

189,178

 

U.S. agency securities

 

 

108,895

 

 

 

 

 

 

(138

)

 

 

108,757

 

Total investments with a maturity of one year or less

 

 

298,301

 

 

 

 

 

 

(366

)

 

 

297,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

280,743

 

 

 

 

 

 

(535

)

 

 

280,208

 

U.S. agency securities

 

 

99,998

 

 

 

 

 

 

(187

)

 

 

99,811

 

Total investments with a maturity of one to two years

 

 

380,741

 

 

 

 

 

 

(722

)

 

 

380,019

 

Total investments

 

$

679,042

 

 

$

 

 

$

(1,088

)

 

$

677,954

 

Available-for-sale Debt Securities in an Unrealized Loss Position

The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at June 30, 2022, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

 

 

Less than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

478,880

 

 

$

(7,925

)

 

$

 

 

$

 

 

$

478,880

 

 

$

(7,925

)

U.S. agency securities

 

 

251,374

 

 

 

(3,981

)

 

 

 

 

 

 

 

 

251,374

 

 

 

(3,981

)

Total

 

$

730,254

 

 

$

(11,906

)

 

$

 

 

$

 

 

$

730,254

 

 

$

(11,906

)

 

The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2021, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

 

 

Less than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

Fair Value

 

 

Unrealized
Losses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

$

469,386

 

 

$

(763

)

 

$

 

 

$

 

 

$

469,386

 

 

$

(763

)

U.S. agency securities

 

 

208,568

 

 

 

(325

)

 

 

 

 

 

 

 

 

208,568

 

 

 

(325

)

Total

 

$

677,954

 

 

$

(1,088

)

 

$

 

 

$

 

 

$

677,954

 

 

$

(1,088

)

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Stock Compensation (Tables)
6 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss

Stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development expenses

 

$

8,139

 

 

$

10,145

 

 

$

15,249

 

 

$

14,296

 

General and administrative expenses

 

 

7,008

 

 

 

6,002

 

 

 

13,353

 

 

 

11,522

 

 

 

$

15,147

 

 

$

16,147

 

 

$

28,602

 

 

$

25,818

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Summary of Computation of Basic and Diluted Net Loss Per Share

The following table summarizes the computation of basic and diluted net loss per share of the Company:

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net loss

 

$

(76,788

)

 

$

(193,399

)

 

$

(138,834

)

 

$

(235,582

)

Net loss per share, basic and diluted

 

$

(0.71

)

 

$

(2.10

)

 

$

(1.28

)

 

$

(2.58

)

Weighted average shares of common stock, basic and diluted

 

 

108,644,329

 

 

 

91,939,439

 

 

 

108,469,760

 

 

 

91,188,160

 

Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share

 

 

Three and Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

Options to purchase common stock

 

 

11,526,322

 

 

 

8,906,194

 

Restricted stock units

 

 

1,681,891

 

 

 

505,393

 

 

 

 

13,208,213

 

 

 

9,411,587

 

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Nature of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ (906,934) $ (768,100)
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail) - Fair value on a recurring basis [Member] - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Investments:    
Total assets $ 810,407 $ 929,845
Liabilities    
Contingent milestone payments 40,863 45,258
Total liabilities 40,863 45,258
Investments [Member]    
Investments:    
Total investments 730,254 677,954
Investments [Member] | US treasury bills [Member]    
Investments:    
Total investments 478,880 469,386
Investments [Member] | US agency securities [Member]    
Investments:    
Total investments 251,374 208,568
Cash equivalents [Member] | Money market funds [Member]    
Cash equivalents:    
Assets, fair value 80,153 251,891
Level 1 [Member]    
Investments:    
Total assets 80,153 251,891
Level 1 [Member] | Cash equivalents [Member] | Money market funds [Member]    
Cash equivalents:    
Assets, fair value 80,153 251,891
Level 2 [Member]    
Investments:    
Total assets 730,254 677,954
Level 2 [Member] | Investments [Member]    
Investments:    
Total investments 730,254 677,954
Level 2 [Member] | Investments [Member] | US treasury bills [Member]    
Investments:    
Total investments 478,880 469,386
Level 2 [Member] | Investments [Member] | US agency securities [Member]    
Investments:    
Total investments 251,374 208,568
Level 3 [Member]    
Liabilities    
Contingent milestone payments 40,863 45,258
Total liabilities $ 40,863 $ 45,258
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Additional Information (Detail) - ZebiAI [Member] - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2022
Jun. 26, 2022
Apr. 22, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Contingent consideration payment description The Contingent Milestone Payments are payable in shares of common stock based on a fixed amount assigned to each milestone and the average closing price of the Company’s common stock for the 5-day period prior to the milestone achievement.    
Number of shares that would be issued upon milestone achievement 4,751,258    
Average stock price upon milestone settlement   $ 17.89  
Level 3 [Member]      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Business combination contingent consideration liability, milestones payments     $ 85.0
Business combination contingent consideration liability, contingent earnout payments     $ 100.0
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Beginning balance $ 50,258
Change in fair value of Contingent Milestone Payments (4,395)
Ending balance $ 45,863
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost $ 742,160 $ 679,042
Unrealized Losses (11,906) (1,088)
Fair Value 730,254 677,954
Investments with a maturity of one year or less [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 497,790 298,301
Unrealized Losses (5,612) (366)
Fair Value 492,178 297,935
Investments with a maturity of one to two years [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 244,370 380,741
Unrealized Losses (6,294) (722)
Fair Value 238,076 380,019
U.S treasury bills [Member] | Investments with a maturity of one year or less [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 332,729 189,406
Unrealized Losses (4,150) (228)
Fair Value 328,579 189,178
U.S treasury bills [Member] | Investments with a maturity of one to two years [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 154,076 280,743
Unrealized Losses (3,775) (535)
Fair Value 150,301 280,208
U.S agency securities [Member] | Investments with a maturity of one year or less [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 165,061 108,895
Unrealized Losses (1,462) (138)
Fair Value 163,599 108,757
U.S agency securities [Member] | Investments with a maturity of one to two years [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 90,294 99,998
Unrealized Losses (2,519) (187)
Fair Value $ 87,775 $ 99,811
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Investments - Additional Information (Detail) - DebtSecurity
Jun. 30, 2022
Dec. 31, 2021
Investments [Abstract]    
Debt securities unrealized loss position 112 88
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Less than 12 Months, Fair Value $ 730,254 $ 677,954
Less than 12 Months, Unrealized Losses (11,906) (1,088)
Total, Fair Value 730,254 677,954
Total, Unrealized Losses (11,906) (1,088)
U.S treasury bills [Member]    
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Less than 12 Months, Fair Value 478,880 469,386
Less than 12 Months, Unrealized Losses (7,925) (763)
Total, Fair Value 478,880 469,386
Total, Unrealized Losses (7,925) (763)
U.S agency securities [Member]    
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Less than 12 Months, Fair Value 251,374 208,568
Less than 12 Months, Unrealized Losses (3,981) (325)
Total, Fair Value 251,374 208,568
Total, Unrealized Losses $ (3,981) $ (325)
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Acquisition of ZebiAI - Additional Information (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Business Acquisition [Line Items]    
Fair value of contingent milestone payments $ 45,863 $ 50,258
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and License Arrangements - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Collaboration And License Arrangement [Line Items]          
Revenue from license agreement $ 365 $ 844 $ 784 $ 1,796  
Contract asset 4,764   4,764   $ 4,537
Other Liabilities [Member]          
Collaboration And License Arrangement [Line Items]          
Cash received for milestone payment 15,000   $ 15,000   $ 15,000
EQRx, Inc [Member]          
Collaboration And License Arrangement [Line Items]          
Collaborative arrangement, rights and obligations     During the three and six months ended June 30, 2022, there were no changes to the Company’s Discovery and Collaboration Agreement (“Collaboration Agreement”) with EQRx, Inc. (“EQRx”) from August 2021. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.    
Genentech [Member]          
Collaboration And License Arrangement [Line Items]          
Collaborative arrangement, rights and obligations     During the three and six months ended June 30, 2022 and 2021, there were no material changes to the Company’s Collaboration and License Agreement (“License Agreement”) with Genentech, Inc. (“Genentech”) from December 2020. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.    
Genentech [Member] | License Agreement [Member]          
Collaboration And License Arrangement [Line Items]          
Revenue from license agreement $ 300 $ 800 $ 500 $ 1,700  
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Stock Compensation - Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 15,147 $ 16,147 $ 28,602 $ 25,818
Research and development expenses [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense 8,139 10,145 15,249 14,296
General and Administrative Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 7,008 $ 6,002 $ 13,353 $ 11,522
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]            
Net loss $ (76,788) $ (62,046) $ (193,399) $ (42,184) $ (138,834) $ (235,582)
Net loss per share, basic and diluted $ (0.71)   $ (2.10)   $ (1.28) $ (2.58)
Weighted average shares of common stock, basic and diluted 108,644,329   91,939,439   108,469,760 91,188,160
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Anti-dilutive effect 13,208,213 9,411,587 13,208,213 9,411,587
Options to purchase common stock [Member]        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Anti-dilutive effect 11,526,322 8,906,194 11,526,322 8,906,194
Restricted stock units [Member]        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Anti-dilutive effect 1,681,891 505,393 1,681,891 505,393
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Commitments and Contingencies Disclosure [Line Items]          
Accrued expenses $ 22,108,000   $ 22,108,000   $ 13,557,000
DE Shaw Research [Member]          
Commitments and Contingencies Disclosure [Line Items]          
Research and development expense 2,300,000 $ 2,100,000 4,700,000 $ 3,900,000  
Accrued expenses 300,000   300,000   0
Prepaid balance 0   0   4,400,000
DE Shaw Research [Member] | Lease Agreement          
Commitments and Contingencies Disclosure [Line Items]          
Milestone payment Due 0   0   0
Other Third Parties [Member]          
Commitments and Contingencies Disclosure [Line Items]          
Research and development expense 1,600,000 $ 700,000 2,600,000 $ 1,100,000  
Other Third Parties [Member] | License Agreement Terms [Member]          
Commitments and Contingencies Disclosure [Line Items]          
Milestone payment Due $ 0   $ 0   $ 0
XML 44 rlay-20220630_htm.xml IDEA: XBRL DOCUMENT 0001812364 rlay:OtherthirdPartiesMember 2021-01-01 2021-06-30 0001812364 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001812364 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001812364 rlay:EQRxIncMember 2022-01-01 2022-06-30 0001812364 us-gaap:USGovernmentAgenciesDebtSecuritiesMember rlay:InvestmentsWithMaturityOfOneToTwoYearsMember 2021-12-31 0001812364 rlay:DEShawResearchMember 2022-04-01 2022-06-30 0001812364 rlay:DEShawResearchMember 2021-01-01 2021-06-30 0001812364 us-gaap:CommonStockMember 2022-03-31 0001812364 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001812364 rlay:ZebiaiMember us-gaap:FairValueInputsLevel3Member 2021-04-22 0001812364 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2022-06-30 0001812364 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001812364 2022-03-31 0001812364 rlay:GenentechIncMember us-gaap:LicenseMember 2022-04-01 2022-06-30 0001812364 us-gaap:CommonStockMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001812364 rlay:OtherthirdPartiesMember 2021-04-01 2021-06-30 0001812364 rlay:ZebiaiMember 2022-01-01 2022-06-30 0001812364 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001812364 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001812364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001812364 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2022-06-30 0001812364 2021-01-01 2021-03-31 0001812364 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001812364 rlay:DEShawResearchMember 2022-01-01 2022-06-30 0001812364 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001812364 us-gaap:RetainedEarningsMember 2021-12-31 0001812364 2021-04-01 2021-06-30 0001812364 rlay:UndesignatedpreferredstockMember 2022-06-30 0001812364 us-gaap:USTreasurySecuritiesMember rlay:InvestmentsWithMaturityOfOneYearOrLessMember 2021-12-31 0001812364 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001812364 2022-06-30 0001812364 2022-01-01 2022-06-30 0001812364 rlay:GenentechIncMember us-gaap:LicenseMember 2021-01-01 2021-06-30 0001812364 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001812364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001812364 rlay:DEShawResearchMember 2021-12-31 0001812364 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001812364 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001812364 us-gaap:USTreasurySecuritiesMember 2022-06-30 0001812364 us-gaap:USTreasurySecuritiesMember rlay:InvestmentsWithMaturityOfOneToTwoYearsMember 2022-06-30 0001812364 rlay:GenentechIncMember 2022-01-01 2022-06-30 0001812364 us-gaap:RetainedEarningsMember 2021-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001812364 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001812364 us-gaap:OtherLiabilitiesMember 2022-06-30 0001812364 us-gaap:RetainedEarningsMember 2022-06-30 0001812364 rlay:DEShawResearchMember rlay:LeaseAgreementMember 2021-12-31 0001812364 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001812364 2021-12-31 0001812364 2021-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001812364 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001812364 us-gaap:CommonStockMember 2020-12-31 0001812364 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001812364 2022-07-29 0001812364 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001812364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001812364 us-gaap:CommonStockMember 2022-06-30 0001812364 us-gaap:USTreasurySecuritiesMember rlay:InvestmentsWithMaturityOfOneToTwoYearsMember 2021-12-31 0001812364 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001812364 rlay:InvestmentsWithMaturityOfOneYearOrLessMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001812364 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001812364 rlay:DEShawResearchMember 2022-06-30 0001812364 2021-03-31 0001812364 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001812364 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001812364 us-gaap:USGovernmentAgenciesDebtSecuritiesMember rlay:InvestmentsWithMaturityOfOneYearOrLessMember 2022-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001812364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001812364 us-gaap:CommonStockMember 2021-03-31 0001812364 2021-01-01 2021-06-30 0001812364 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001812364 rlay:OtherthirdPartiesMember us-gaap:LicenseAgreementTermsMember 2021-12-31 0001812364 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001812364 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-06-30 0001812364 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001812364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001812364 rlay:InvestmentsWithMaturityOfOneToTwoYearsMember 2021-12-31 0001812364 us-gaap:CommonStockMember 2021-06-30 0001812364 2022-04-01 2022-06-30 0001812364 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001812364 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001812364 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001812364 2022-01-01 2022-03-31 0001812364 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001812364 rlay:OtherthirdPartiesMember 2022-01-01 2022-06-30 0001812364 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-06-30 0001812364 rlay:OtherthirdPartiesMember us-gaap:LicenseAgreementTermsMember 2022-06-30 0001812364 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001812364 rlay:InvestmentsWithMaturityOfOneYearOrLessMember 2022-06-30 0001812364 rlay:OtherthirdPartiesMember 2022-04-01 2022-06-30 0001812364 2020-12-31 0001812364 us-gaap:RetainedEarningsMember 2022-03-31 0001812364 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001812364 us-gaap:USGovernmentAgenciesDebtSecuritiesMember rlay:InvestmentsWithMaturityOfOneToTwoYearsMember 2022-06-30 0001812364 us-gaap:RetainedEarningsMember 2021-03-31 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001812364 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001812364 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001812364 rlay:GenentechIncMember us-gaap:LicenseMember 2022-01-01 2022-06-30 0001812364 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001812364 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001812364 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001812364 rlay:ZebiaiMember 2022-06-26 0001812364 rlay:GenentechIncMember us-gaap:LicenseMember 2021-04-01 2021-06-30 0001812364 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001812364 us-gaap:USGovernmentAgenciesDebtSecuritiesMember rlay:InvestmentsWithMaturityOfOneYearOrLessMember 2021-12-31 0001812364 rlay:DEShawResearchMember rlay:LeaseAgreementMember 2022-06-30 0001812364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001812364 us-gaap:OtherLiabilitiesMember 2021-12-31 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001812364 us-gaap:RetainedEarningsMember 2020-12-31 0001812364 us-gaap:USTreasurySecuritiesMember rlay:InvestmentsWithMaturityOfOneYearOrLessMember 2022-06-30 0001812364 rlay:DEShawResearchMember 2021-04-01 2021-06-30 0001812364 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001812364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001812364 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001812364 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001812364 rlay:InvestmentsWithMaturityOfOneToTwoYearsMember 2022-06-30 0001812364 rlay:UndesignatedpreferredstockMember 2021-12-31 0001812364 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 rlay:DebtSecurity iso4217:USD shares shares iso4217:USD --12-31 false http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember Q2 0001812364 10-Q true 2022-06-30 2022 false 001-39385 RELAY THERAPEUTICS, INC. DE 47-3923475 399 Binney Street 2nd Floor Cambridge MA 02139 617 370-8837 Common Stock, par value $0.001 per share RLAY NASDAQ Yes Yes Large Accelerated Filer false false false 108898083 107736000 280119000 730254000 677954000 288000 403000 4764000 4537000 12751000 13229000 855793000 976242000 8922000 6543000 19828000 20780000 2578000 2578000 2300000 2300000 889421000 1008443000 4296000 8276000 22108000 13557000 2002000 1844000 83000 248000 15413000 396000 43902000 24321000 20019000 21056000 45863000 50258000 15000000 109784000 110635000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 300000000 150000000 108810478 108810478 108210318 108210318 109000 109000 1698368000 1666887000 -11906000 -1088000 -906934000 -768100000 779637000 897808000 889421000 1008443000 365000 844000 784000 1796000 365000 844000 784000 1796000 60511000 45147000 112178000 75769000 123000000 123000000 -11855000 -11855000 200000 -4395000 17465000 14422000 33533000 27156000 78176000 194424000 141316000 237780000 -77811000 -193580000 -140532000 -235984000 1005000 180000 1701000 406000 18000 1000 -3000 -4000 1023000 181000 1698000 402000 -76788000 -193399000 -138834000 -235582000 -0.71 -2.10 -1.28 -2.58 108644329 91939439 108469760 91188160 -2688000 -76000 -10818000 -128000 -2688000 -76000 -10818000 -128000 -79476000 -193475000 -149652000 -235710000 108210318 109000 1666887000 -1088000 -768100000 897808000 195799 883000 883000 27233 13455000 13455000 -8130000 -8130000 -62046000 -62046000 108433350 109000 1681225000 -9218000 -830146000 841970000 182113 859000 859000 79859 1137000 1137000 115156 15147000 15147000 -2688000 -2688000 -76788000 -76788000 108810478 109000 1698368000 -11906000 -906934000 779637000 89906835 90000 1167367000 64000 -404228000 763293000 437230 2055000 2055000 84489 3000 3000 9671000 9671000 -52000 -52000 -42184000 -42184000 90428554 90000 1179096000 12000 -446412000 732786000 218365 1123000 1123000 22239 16147000 16147000 1883487 2000 61946000 61948000 -76000 -76000 -193399000 -193399000 92552645 92000 1258312000 -64000 -639811000 618529000 -138834000 -235582000 28602000 25818000 1931000 1879000 -1227000 -701000 123000000 -11855000 -4395000 -115000 -74801000 227000 -3462000 -478000 -4964000 -73000 -186000 -22000 -4611000 -867000 9540000 8261000 -165000 -106266000 18500000 4651000 855000 151945000 646239000 87600000 464673000 25132000 -68996000 -207553000 1742000 3176000 1137000 2879000 3176000 -172383000 -185877000 282697000 448524000 110314000 262647000 669000 1077000 3000 662000 2330000 62990000 107736000 260069000 2578000 2578000 110314000 262647000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Relay Therapeutics, Inc. (the “Company”) was incorporated in Delaware on May 4, 2015 and is headquartered in Cambridge, Massachusetts. The Company is a clinical-stage, precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the Company believes it is among the first of a new breed of biotech created at the intersection of disparate technologies, the Company aims to push the boundaries of what’s possible in drug discovery. The Company’s Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s lead product candidates, RLY-4008, RLY-2608 and RLY-1971, are in clinical development. The Company also has over five discovery stage programs across both precision oncology and genetic disease indications.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s product candidates are in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has devoted substantially all of its resources to developing its product candidates, including RLY-4008, RLY-2608 and RLY-1971, by developing its computation and experimental approaches, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred net operating losses since inception and had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">906.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million as of June 30, 2022. The Company expects that its existing cash, cash equivalents and investments as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue its business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into license or collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all.</span></p> -906900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2. Significant Accounting Policies</span></p><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basis of presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The Company’s condensed consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiaries, Relay Therapeutics Securities Corporation and Relay ML Discovery, LLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">All intercompany balances and transactions have been eliminated.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certain prior period amounts, specifically including certain current liabilities, have been reclassified to conform to current period presentation. Such reclassifications have no impact on the Company’s condensed consolidated statement of operations and comprehensive loss, as previously reported.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of June 30, 2022, the condensed consolidated results of its operations for the three and six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The condensed consolidated financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The condensed consolidated results for the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. (“ZebiAI”), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments thereto require that credit losses be reported as an allowance using an expected losses model, representing the entity’s current estimate of credit losses expected to be incurred. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company’s condensed consolidated financial statements or disclosures as of and for the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of any recently issued standards have or may have a material impact on its condensed consolidated financial statements and disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basis of presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The Company’s condensed consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiaries, Relay Therapeutics Securities Corporation and Relay ML Discovery, LLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">All intercompany balances and transactions have been eliminated.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certain prior period amounts, specifically including certain current liabilities, have been reclassified to conform to current period presentation. Such reclassifications have no impact on the Company’s condensed consolidated statement of operations and comprehensive loss, as previously reported.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of June 30, 2022, the condensed consolidated results of its operations for the three and six months ended June 30, 2022 and 2021, and cash flows for the six months ended June 30, 2022 and 2021. The condensed consolidated financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The condensed consolidated results for the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. (“ZebiAI”), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments thereto require that credit losses be reported as an allowance using an expected losses model, representing the entity’s current estimate of credit losses expected to be incurred. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company’s condensed consolidated financial statements or disclosures as of and for the three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of any recently issued standards have or may have a material impact on its condensed consolidated financial statements and disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.225%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.805%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of<br/>June 30, 2022:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80,153</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80,153</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80,153</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">810,407</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Contingent Milestone Payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.225%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.805%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of<br/>December 31, 2021:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,891</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">929,845</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Contingent Milestone Payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Contingent Consideration Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2021, the Company acquired ZebiAI.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s Level 3 contingent consideration liability is related to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">85.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of platform and program-related milestones (“Contingent Milestone Payments”) potentially payable to ZebiAI’s former equity holders. The contingent consideration liability for the Contingent Milestone Payments is measured at fair value at each reporting date pursuant to FASB ASC Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 480”). The Company determines the fair value of the Contingent Milestone Payments based on the probability of achieving the milestones, the related timing, and, to a lesser extent, an appropriate discount rate. Significant judgment is used in determining these assumptions. Due to the uncertainties associated with the development of platforms and drug candidates in the pharmaceutical industry and the effects of changes in assumptions including probability of success and related timing, the Company expects its estimates regarding the fair value of Contingent Milestone Payments to continue to change in the future, resulting in adjustments to the fair value of the Company’s Contingent Milestone Payments, and the effect of any such adjustments could be material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company also has a contingent consideration liability related to the fair value of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in earnout payments (“Contingent Earnout Payments”). Because the Contingent Earnout Payments were not accounted for as derivatives under FASB ASC Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">("ASC 815"), they were only measured at fair value as of the acquisition date and are not re-assessed at fair value at each reporting period. The Contingent Earnout Payments will be adjusted when the contingency is resolved and the consideration is paid or becomes payable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the change in fair value of the contingent consideration liability (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.817%;"/> <td style="width:1.0%;"/> <td style="width:35.183%;"/> <td style="width:1.0%;"/> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Change in fair value of Contingent Milestone Payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4,395</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The “Change in fair value of Contingent Milestone Payments” in the table above was attributable to changes in the assumptions noted above between December 31, 2021 and June 30, 2022, primarily changes in timing and interest rates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Contingent Milestone Payments are payable in shares of common stock based on a fixed amount assigned to each milestone and the average closing price of the Company’s common stock for the 5-day period prior to the milestone achievement.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Accordingly, the number of shares of common stock to be issued upon a milestone achievement vary dependent on the Company’s common stock price. The settlement amounts of Contingent Milestone Payments are predominantly fixed. If the milestones were achieved in full on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the number of shares of common stock to be issued would be </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4,751,258</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> based on an average closing price of the Company's common stock of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">17.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the 5-day period prior to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.225%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.805%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of<br/>June 30, 2022:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80,153</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80,153</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80,153</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">810,407</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Contingent Milestone Payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">40,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.225%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.387%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.805%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of<br/>December 31, 2021:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,891</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">929,845</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Contingent Milestone Payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table> 80153000 80153000 478880000 478880000 251374000 251374000 730254000 730254000 80153000 730254000 810407000 40863000 40863000 40863000 40863000 251891000 251891000 469386000 469386000 208568000 208568000 677954000 677954000 251891000 677954000 929845000 45258000 45258000 45258000 45258000 85000000.0 100000000.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the change in fair value of the contingent consideration liability (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.817%;"/> <td style="width:1.0%;"/> <td style="width:35.183%;"/> <td style="width:1.0%;"/> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Change in fair value of Contingent Milestone Payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4,395</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table> 50258000 -4395000 45863000 The Contingent Milestone Payments are payable in shares of common stock based on a fixed amount assigned to each milestone and the average closing price of the Company’s common stock for the 5-day period prior to the milestone achievement. 4751258 17.89 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4. Investments</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.235%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:8.823%;"/> <td style="width:1.0%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:10.483%;"/> <td style="width:1.0%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:9.211%;"/> <td style="width:1.0%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:9.439%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">332,729</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4,150</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">328,579</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">165,061</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,462</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">163,599</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one year or less</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">497,790</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5,612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">492,178</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">154,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3,775</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">150,301</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">90,294</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2,519</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">87,775</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one to two years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">244,370</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6,294</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">238,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">742,160</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.309%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:8.712%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:10.372%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.339%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.458%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">189,406</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">228</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">189,178</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,895</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one year or less</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">298,301</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">366</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">297,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">280,743</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">535</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">280,208</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">99,998</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">187</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">99,811</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one to two years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">380,741</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">380,019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">679,042</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Company’s adoption of ASU 2016-13 and the related amendments thereto on January 1, 2022, the Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive (loss) income. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company held </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">112</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> debt securities that were in an unrealized loss position as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022 and December 31, 2021, respectively. The unrealized losses at June 30, 2022 and December 31, 2021 were attributable to changes in interest rates and the unrealized losses do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:16.544%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:9.850999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:10.636%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:10.328%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:12.216999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:9.850999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:10.636%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Less than 12 Months</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">12 Months or Longer</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7,925</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7,925</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3,981</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3,981</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2021, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:16.576%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:9.733%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:10.827%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:10.200000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:12.228%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:9.733%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:10.827%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Less than 12 Months</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">12 Months or Longer</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">325</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">325</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.235%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:8.823%;"/> <td style="width:1.0%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:10.483%;"/> <td style="width:1.0%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:9.211%;"/> <td style="width:1.0%;"/> <td style="width:1.203%;"/> <td style="width:1.0%;"/> <td style="width:9.439%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">332,729</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4,150</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">328,579</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">165,061</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,462</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">163,599</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one year or less</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">497,790</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5,612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">492,178</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">154,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3,775</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">150,301</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">90,294</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2,519</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">87,775</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one to two years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">244,370</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6,294</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">238,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">742,160</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.309%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:8.712%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:10.372%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.339%;"/> <td style="width:1.0%;"/> <td style="width:1.202%;"/> <td style="width:1.0%;"/> <td style="width:9.458%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Investments:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">189,406</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">228</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">189,178</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,895</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one year or less</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">298,301</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">366</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">297,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">280,743</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">535</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">280,208</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">99,998</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">187</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">99,811</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments with a maturity of one to two years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">380,741</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">380,019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">679,042</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table> 332729000 4150000 328579000 165061000 1462000 163599000 497790000 5612000 492178000 154076000 3775000 150301000 90294000 2519000 87775000 244370000 6294000 238076000 742160000 11906000 730254000 189406000 228000 189178000 108895000 138000 108757000 298301000 366000 297935000 280743000 535000 280208000 99998000 187000 99811000 380741000 722000 380019000 679042000 1088000 677954000 112 88 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:16.544%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:9.850999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:10.636%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:10.328%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:12.216999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:9.850999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.322%;"/> <td style="width:1.0%;"/> <td style="width:10.636%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Less than 12 Months</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">12 Months or Longer</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7,925</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">478,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7,925</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3,981</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">251,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3,981</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">730,254</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2021, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:16.576%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:9.733%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:10.827%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:10.200000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:12.228%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:9.733%;"/> <td style="width:1.0%;"/> <td style="width:1.313%;"/> <td style="width:1.0%;"/> <td style="width:10.827%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Less than 12 Months</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">12 Months or Longer</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasury bills</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">469,386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. agency securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">325</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">208,568</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">325</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">677,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> </table> 478880000 7925000 478880000 7925000 251374000 3981000 251374000 3981000 730254000 11906000 730254000 11906000 469386000 763000 469386000 763000 208568000 325000 208568000 325000 677954000 1088000 677954000 1088000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Collaboration and License Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Discovery Collaboration Agreement with EQRx, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2022, there were no changes to the Company’s Discovery and Collaboration Agreement (“Collaboration Agreement”) with EQRx, Inc. (“EQRx”) from August 2021. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended June 30, 2022, expenses related to the Collaboration Agreement were immaterial.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Genentech, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2022 and 2021, there were no material changes to the Company’s Collaboration and License Agreement (“License Agreement”) with Genentech, Inc. (“Genentech”) from December 2020.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended June 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue from the License Agreement, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue from the License Agreement, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022 and December 31, 2021, the Company recorded a contract asset of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, both of which are classified as current assets on the condensed consolidated balance sheet. The contract asset relates to the amount of revenue recognized for which the right to payment is contingent upon conditions other than the passage of time, such as the completion of future milestone activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded an other liability in the amount of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The liability represents the cash received for a milestone payment in 2021 under the License Agreement. The amount has been excluded from the transaction price at both </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022 and December 31, 2021 and, therefore, excluded from amounts recognized as revenue, since the amount is subject to repayment to Genentech if the Company exercises its option to participate in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the profit/cost share under the License Agreement.</span></p> During the three and six months ended June 30, 2022, there were no changes to the Company’s Discovery and Collaboration Agreement (“Collaboration Agreement”) with EQRx, Inc. (“EQRx”) from August 2021. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022. During the three and six months ended June 30, 2022 and 2021, there were no material changes to the Company’s Collaboration and License Agreement (“License Agreement”) with Genentech, Inc. (“Genentech”) from December 2020. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022. 300000 800000 500000 1700000 4800000 4500000 15000000.0 15000000.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6. Stock Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.312%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:14.068%;"/> <td style="width:1.0%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:14.486%;"/> <td style="width:1.0%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:13.959%;"/> <td style="width:1.0%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:14.376999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8,139</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10,145</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15,249</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">14,296</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7,008</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6,002</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">13,353</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,522</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15,147</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">16,147</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">28,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">25,818</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.312%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:14.068%;"/> <td style="width:1.0%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:14.486%;"/> <td style="width:1.0%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:13.959%;"/> <td style="width:1.0%;"/> <td style="width:1.699%;"/> <td style="width:1.0%;"/> <td style="width:14.376999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8,139</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10,145</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15,249</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">14,296</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7,008</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6,002</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">13,353</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,522</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15,147</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">16,147</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">28,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">25,818</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table> 8139000 10145000 15249000 14296000 7008000 6002000 13353000 11522000 15147000 16147000 28602000 25818000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7. Net Loss Per Share</span></p><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share of the Company:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.164%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.356%;"/> <td style="width:1.0%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.455%;"/> <td style="width:1.0%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.356%;"/> <td style="width:1.0%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.455%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">76,788</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">193,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">138,834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">235,582</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.71</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.10</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.28</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.58</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted average shares of common stock, basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,644,329</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">91,939,439</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,469,760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">91,188,160</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s potentially dilutive securities, which include outstanding options to purchase common stock and restricted stock units summarized below, have been excluded from the computation of diluted net loss per share for the periods indicated below, as the effect would be anti-dilutive and reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9.0pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.623%;"/> <td style="width:1.581%;"/> <td style="width:1.0%;"/> <td style="width:13.4%;"/> <td style="width:1.0%;"/> <td style="width:1.581%;"/> <td style="width:1.0%;"/> <td style="width:13.817%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Three and Six Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,526,322</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8,906,194</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,681,891</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">505,393</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">13,208,213</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">9,411,587</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share of the Company:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.164%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.356%;"/> <td style="width:1.0%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.455%;"/> <td style="width:1.0%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.356%;"/> <td style="width:1.0%;"/> <td style="width:1.053%;"/> <td style="width:1.0%;"/> <td style="width:9.455%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">76,788</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">193,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">138,834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">235,582</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.71</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.10</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.28</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.58</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted average shares of common stock, basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,644,329</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">91,939,439</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">108,469,760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">91,188,160</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table> -76788000 -193399000 -138834000 -235582000 -0.71 -2.10 -1.28 -2.58 108644329 91939439 108469760 91188160 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.623%;"/> <td style="width:1.581%;"/> <td style="width:1.0%;"/> <td style="width:13.4%;"/> <td style="width:1.0%;"/> <td style="width:1.581%;"/> <td style="width:1.0%;"/> <td style="width:13.817%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Three and Six Months Ended<br/>June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">11,526,322</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8,906,194</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,681,891</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">505,393</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">13,208,213</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">9,411,587</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table> 11526322 11526322 8906194 8906194 1681891 1681891 505393 505393 13208213 13208213 9411587 9411587 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property License</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022, the Company amended the Amended and Restated Collaboration and License Agreement (“DESRES Agreement”) with D.E. Shaw Research, LLC (“D.E. Shaw Research”), specifically to update certain of the Category 1, Category 2, and Category 3 Target lists thereunder. However, there was no change to the Company’s accounting treatment or incremental amounts recognized in connection therewith for the three and six months ended June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the milestones under the DESRES Agreement at June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, concluding </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> such milestone payments were due.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded research and development expenses of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million under the DESRES Agreement for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended June 30, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded research and development expenses of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million under the DESRES Agreement for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had accrued expense balances of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had prepaid balances of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Other Significant Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has certain other research and license arrangements with third parties, which provide the Company with research services with the goal of identifying and developing product candidates, and the Company is obligated to pay certain development milestone payments pursuant to these arrangements upon the achievement of certain specified contingent events. The Company assessed such milestones at June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, concluding </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> such milestone payments were due. The Company incurred approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of research and development expenses under these agreements for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended June 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The Company incurred approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of research and development expenses under these agreements for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p> 0 0 2300000 2100000 4700000 3900000 300000 0 0 4400000 0 0 1600000 700000 2600000 1100000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">9. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In preparing the consolidated interim financial statements as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and for the three and six month periods then ended, the Company evaluated subsequent events for recognition and measurement purposes. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.</span></p> EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 136 172 1 false 29 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1 Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 7 false false R8.htm 100090 - Disclosure - Nature of Business and Basis of Presentation Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 8 false false R9.htm 100100 - Disclosure - Significant Accounting Policies Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 100110 - Disclosure - Fair Value Measurements Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100120 - Disclosure - Investments Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestments Investments Notes 11 false false R12.htm 100140 - Disclosure - Collaboration and License Arrangements Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangements Collaboration and License Arrangements Notes 12 false false R13.htm 100160 - Disclosure - Stock Compensation Sheet http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensation Stock Compensation Notes 13 false false R14.htm 100170 - Disclosure - Net Loss Per Share Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 14 false false R15.htm 100180 - Disclosure - Commitments and Contingencies Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 100200 - Disclosure - Subsequent Events Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 100210 - Disclosure - Significant Accounting Policies (Policies) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies 17 false false R18.htm 100220 - Disclosure - Fair Value Measurements (Tables) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurements 18 false false R19.htm 100230 - Disclosure - Investments (Tables) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsTables Investments (Tables) Tables http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestments 19 false false R20.htm 100250 - Disclosure - Stock Compensation (Tables) Sheet http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationTables Stock Compensation (Tables) Tables http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensation 20 false false R21.htm 100260 - Disclosure - Net Loss Per Share (Tables) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShare 21 false false R22.htm 100280 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of Business and Basis of Presentation - Additional Information (Detail) Details 22 false false R23.htm 100290 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail) Details 23 false false R24.htm 100300 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 24 false false R25.htm 100310 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail) Details 25 false false R26.htm 100320 - Disclosure - Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail) Details 26 false false R27.htm 100330 - Disclosure - Investments - Additional Information (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetail Investments - Additional Information (Detail) Details 27 false false R28.htm 100340 - Disclosure - Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail) Details 28 false false R29.htm 100350 - Disclosure - Acquisition of ZebiAI - Additional Information (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail Acquisition of ZebiAI - Additional Information (Detail) Details 29 false false R30.htm 100370 - Disclosure - Collaboration and License Arrangements - Additional Information (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail Collaboration and License Arrangements - Additional Information (Detail) Details 30 false false R31.htm 100390 - Disclosure - Stock Compensation - Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh Stock Compensation - Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss (Detail) Details 31 false false R32.htm 100400 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) Details 32 false false R33.htm 100410 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) Details 33 false false R34.htm 100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 34 false false All Reports Book All Reports rlay-20220630.htm rlay-20220630.xsd rlay-20220630_cal.xml rlay-20220630_def.xml rlay-20220630_lab.xml rlay-20220630_pre.xml rlay-ex31_1.htm rlay-ex31_2.htm rlay-ex32_1.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rlay-20220630.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 136, "dts": { "calculationLink": { "local": [ "rlay-20220630_cal.xml" ] }, "definitionLink": { "local": [ "rlay-20220630_def.xml" ] }, "inline": { "local": [ "rlay-20220630.htm" ] }, "labelLink": { "local": [ "rlay-20220630_lab.xml" ] }, "presentationLink": { "local": [ "rlay-20220630_pre.xml" ] }, "schema": { "local": [ "rlay-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 396, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 8, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 12 }, "keyCustom": 18, "keyStandard": 154, "memberCustom": 9, "memberStandard": 20, "nsprefix": "rlay", "nsuri": "http://relaytx.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Investments", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Collaboration and License Arrangements", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangements", "shortName": "Collaboration and License Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock Compensation", "role": "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensation", "shortName": "Stock Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Net Loss Per Share", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments and Contingencies", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Subsequent Events", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "rlay:BasisOfPresentationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "rlay:BasisOfPresentationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Fair Value Measurements (Tables)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Investments (Tables)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_7fbe0acc-c220-45ab-af37-92deea82e412", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Stock Compensation (Tables)", "role": "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationTables", "shortName": "Stock Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Net Loss Per Share (Tables)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Nature of Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_303ff03b-56fc-4ede-afea-3ea3b006a5d0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail", "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_303ff03b-56fc-4ede-afea-3ea3b006a5d0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_7ab8ad15-602c-400f-ad14-828c4d97b713", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_7ab8ad15-602c-400f-ad14-828c4d97b713", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_7fbe0acc-c220-45ab-af37-92deea82e412", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "shortName": "Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rlay:ScheduleOfChangesInFairValueOfContingentConsiderationLiabilityTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail", "shortName": "Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_DebtSecurity", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Investments - Additional Information (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetail", "shortName": "Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_DebtSecurity", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail", "shortName": "Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Acquisition of ZebiAI - Additional Information (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "shortName": "Acquisition of ZebiAI - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Collaboration and License Arrangements - Additional Information (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "shortName": "Collaboration and License Arrangements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "rlay:CashReceivedForMilestonePayment", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_ff65a965-491c-41ec-99b9-6b8aad70a42b", "decimals": "-5", "lang": null, "name": "rlay:CashReceivedForMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock Compensation - Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh", "shortName": "Stock Compensation - Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "shortName": "Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_1c95274e-e44d-40be-994e-88ec4c33d6b5", "decimals": "-5", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_01b17191-3b6f-402e-bf83-5e0c83ad9dd3", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_83dd4ca2-9280-4720-b4c8-783b0dff77bd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_dc9c2367-39bc-4e25-9219-dab0baba03ad", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_6cbc8772-5862-4ebe-bd06-1d8f28119441", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_8d737188-4858-4e6b-9bfd-566eca1a5f97", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Nature of Business and Basis of Presentation", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation", "shortName": "Nature of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Significant Accounting Policies", "role": "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rlay-20220630.htm", "contextRef": "C_4931e3be-04e7-41b4-b6a2-c3e358c19a80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 29, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address Address Line1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rlay_AcquiredResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquired research and development in process.", "label": "Acquired research and development in process", "terseLabel": "Acquired in-process research and development" } } }, "localname": "AcquiredResearchAndDevelopmentInProcess", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rlay_AverageStockPriceUponMilestoneSettlement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average stock price upon milestone settlement.", "label": "Average stock price upon milestone settlement" } } }, "localname": "AverageStockPriceUponMilestoneSettlement", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "rlay_BMRHampshireLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BMR-Hampshire, LLC.", "label": "B M R Hampshire L L C [Member]", "terseLabel": "BMR Hampshire, LLC [Member]" } } }, "localname": "BMRHampshireLLCMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rlay_BasisOfPresentationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of presentation.", "label": "Basis Of Presentation Policy [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfPresentationPolicyTextBlock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rlay_BinneyStreetCambridgeMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "399 Binney Street, Cambridge, Massachusetts.", "label": "Binney Street Cambridge Massachusetts [Member]", "terseLabel": "399 Binney Street [Member]" } } }, "localname": "BinneyStreetCambridgeMassachusettsMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "domainItemType" }, "rlay_BmrHampshireLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BMR-Hampshire, LLC. [Member]", "label": "BMR-Hampshire, LLC. [Member]", "terseLabel": "BMR Hampshire, LLC [Member]" } } }, "localname": "BmrHampshireLlcMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "domainItemType" }, "rlay_BusinessCombinationContingentConsiderationLiabilityContingentEarnoutPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination contingent consideration liability, contingent earnout payments.", "label": "Business combination contingent consideration liability, contingent earnout payments", "terseLabel": "Business combination contingent consideration liability, contingent earnout payments" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityContingentEarnoutPayments", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_BusinessCombinationContingentConsiderationLiabilityMilestonesPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination contingent consideration liability, milestones payments.", "label": "Business Combination Contingent Consideration Liability Milestones Payments", "terseLabel": "Business combination contingent consideration liability, milestones payments", "verboseLabel": "Contingent Milestone Payments" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMilestonesPayments", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_BusinessCombinationContingentMilestonePayments": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail": { "order": 1.0, "parentTag": "us-gaap_NonfinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination, contingent milestone payments.", "label": "Business Combination, Contingent Milestone Payments", "terseLabel": "Contingent milestone payments" } } }, "localname": "BusinessCombinationContingentMilestonePayments", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "rlay_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsLossOnInitialConsolidationOfVariableInterestEntity": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed assets loss on initial consolidation of variable interest entity.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Loss On Initial Consolidation Of Variable Interest Entity", "terseLabel": "Loss on initial consolidation of VIE" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsLossOnInitialConsolidationOfVariableInterestEntity", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "monetaryItemType" }, "rlay_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentAsset": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed in process research and development asset.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Asset", "terseLabel": "Acquired IPR&D asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopmentAsset", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "monetaryItemType" }, "rlay_CashAndCashEquivalentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents fair value disclosure.", "label": "Cash And Cash Equivalents Fair Value Disclosure [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosureAbstract", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "rlay_CashReceivedForMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash received for milestone payment.", "label": "Cash Received for Milestone Payment", "terseLabel": "Cash received for milestone payment" } } }, "localname": "CashReceivedForMilestonePayment", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_ChangeInFairValueOfContingentConsiderationLiabilities": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement.", "label": "Change in fair value of contingent consideration liabilities" } } }, "localname": "ChangeInFairValueOfContingentConsiderationLiabilities", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "rlay_CollaborationAndLicenseArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and license arrangement.", "label": "Collaboration And License Arrangement [Abstract]" } } }, "localname": "CollaborationAndLicenseArrangementAbstract", "nsuri": "http://relaytx.com/20220630", "xbrltype": "stringItemType" }, "rlay_CollaborationAndLicenseArrangementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and license arrangement.", "label": "Collaboration And License Arrangement [Line Items]", "terseLabel": "Collaboration And License Arrangement [Line Items]" } } }, "localname": "CollaborationAndLicenseArrangementLineItems", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rlay_CollaborationAndLicenseArrangementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and license arrangement.", "label": "Collaboration And License Arrangement [Table]", "terseLabel": "Collaboration And License Arrangement [Table]" } } }, "localname": "CollaborationAndLicenseArrangementTable", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rlay_CommitmentsAndContingenciesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Line Items]", "terseLabel": "Commitments and Contingencies Disclosure [Line Items]" } } }, "localname": "CommitmentsAndContingenciesDisclosureLineItems", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rlay_CommitmentsAndContingenciesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Table]", "terseLabel": "Commitments And Contingencies Disclosure [Table]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTable", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rlay_CommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock [Abstract]", "label": "Common Stock [Abstract]" } } }, "localname": "CommonStockAbstract", "nsuri": "http://relaytx.com/20220630", "xbrltype": "stringItemType" }, "rlay_CommonStockRestrictionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock, restriction period.", "label": "Common Stock Restriction Period", "terseLabel": "Common Stock Restriction Period" } } }, "localname": "CommonStockRestrictionPeriod", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "rlay_ContributionTowardTheCostOfConstructionAndTenantImprovementsForThePremises": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contribution toward the cost of construction and tenant improvements for the premises.", "label": "Contribution toward the cost of construction and tenant improvements for the premises" } } }, "localname": "ContributionTowardTheCostOfConstructionAndTenantImprovementsForThePremises", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rlay_CowenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen.", "label": "Cowen [Member]", "terseLabel": "Cowen [Member]" } } }, "localname": "CowenMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_DEShawResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DE shaw research.", "label": "D E Shaw Research [Member]", "terseLabel": "DE Shaw Research [Member]" } } }, "localname": "DEShawResearchMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of new accounting pronouncements not yet adopted.", "label": "Description Of New Accounting Pronouncements Not Yet Adopted Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted" } } }, "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rlay_EQRxIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EQRx, Inc.", "label": "E Q Rx Inc [Member]", "terseLabel": "EQRx, Inc [Member]" } } }, "localname": "EQRxIncMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_ExpenseRelatedToAcceleratedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expense related to accelerated stock options.", "label": "Expense Related To Accelerated Stock Options", "terseLabel": "Expense related to accelerated stock options as a result of Zebi AI" } } }, "localname": "ExpenseRelatedToAcceleratedStockOptions", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "rlay_GenentechAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech agreement.", "label": "Genentech Agreement [Member]", "terseLabel": "Genentech Agreement [Member]" } } }, "localname": "GenentechAgreementMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_GenentechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech Inc.", "label": "Genentech Inc [Member]", "terseLabel": "Genentech [Member]" } } }, "localname": "GenentechIncMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease assets and liabilities net.", "label": "Increase decrease in operating lease assets and liabilities net", "negatedLabel": "Operating lease assets and liabilities, net", "terseLabel": "Operating lease assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rlay_InvestmentsWithMaturityOfOneToTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments with maturity of one to two years.", "label": "Investments With Maturity Of One To Two Years [Member]", "terseLabel": "Investments with a maturity of one to two years [Member]" } } }, "localname": "InvestmentsWithMaturityOfOneToTwoYearsMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "domainItemType" }, "rlay_InvestmentsWithMaturityOfOneYearOrLessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments with maturity of one year or less.", "label": "Investments With Maturity Of One Year Or Less [Member]", "terseLabel": "Investments with a maturity of one year or less [Member]" } } }, "localname": "InvestmentsWithMaturityOfOneYearOrLessMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "domainItemType" }, "rlay_LeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Agreement [Member]", "label": "Lease Agreement [Member]", "terseLabel": "Lease Agreement" } } }, "localname": "LeaseAgreementMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_LeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration month and year.", "label": "Lease Expiration Month And Year", "terseLabel": "Operating lease agreement expiration date" } } }, "localname": "LeaseExpirationMonthAndYear", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss on extinguishment and reissuance of preferred stock.", "label": "Loss On Extinguishment And Reissuance Of Preferred Stock", "terseLabel": "Extinguishment upon modification of series C preferred stock" } } }, "localname": "LossOnExtinguishmentAndReissuanceOfPreferredStock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due upon specified regulatory milestone achievement.", "label": "Milestone Payment Due Upon Specified Regulatory Milestone Achievement", "terseLabel": "Milestone payment Due" } } }, "localname": "MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_MilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_NumberOfMilestoneTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestone targets.", "label": "Number Of Milestone Targets", "terseLabel": "Number of milestone targets" } } }, "localname": "NumberOfMilestoneTargets", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "rlay_NumberOfSharesWouldBeIssuedUponMilestoneAchievement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares would be issued upon milestone achievement.", "label": "Number of Shares Would Be Issued Upon Milestone Achievement", "terseLabel": "Number of shares that would be issued upon milestone achievement" } } }, "localname": "NumberOfSharesWouldBeIssuedUponMilestoneAchievement", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "rlay_OperationsAndComprehensiveLossStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations and Comprehensive Loss Statement [Abstract].", "label": "Operations And Comprehensive Loss Statement [Abstract]" } } }, "localname": "OperationsAndComprehensiveLossStatementAbstract", "nsuri": "http://relaytx.com/20220630", "xbrltype": "stringItemType" }, "rlay_OtherIncomeExpense": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other income (expense).", "label": "Other Income Expense", "terseLabel": "Other income (expense)" } } }, "localname": "OtherIncomeExpense", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "rlay_OtherthirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other third parties [member].", "label": "Otherthird Parties [Member]", "terseLabel": "Other Third Parties [Member]" } } }, "localname": "OtherthirdPartiesMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_PaymentRelatedToCollaborationOrOtherAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment related to collaboration or other agreements.", "label": "Payment Related To Collaboration Or Other Agreements", "terseLabel": "Payment related to collaboration or other agreements" } } }, "localname": "PaymentRelatedToCollaborationOrOtherAgreements", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_PercentageOfPaymentRelatedToCollaborationOrOtherAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of payment related to collaboration or other agreements.", "label": "Percentage Of Payment Related To Collaboration Or Other Agreements", "terseLabel": "Percentage of payment related to collaboration or other agreements" } } }, "localname": "PercentageOfPaymentRelatedToCollaborationOrOtherAgreements", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "rlay_PotentialDevelopmentMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential development milestone payments.", "label": "Potential Development Milestone Payments", "terseLabel": "Potential development milestone payments" } } }, "localname": "PotentialDevelopmentMilestonePayments", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of restricted stock liability to additional paid in capital", "label": "Reclassification Of Restricted Stock Liability To Additional Paid In Capital", "terseLabel": "Reclassification of restricted stock liability to additional paid-in capital" } } }, "localname": "ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash and cash equivalents at carrying value abstract.", "label": "Restricted Cash And Cash Equivalents At Carrying Value [Abstract]", "terseLabel": "Restricted Cash And Cash Equivalents At Carrying Value [Abstract]" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "rlay_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement [Member]" } } }, "localname": "SalesAgreementMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_ScheduleOfChangesInFairValueOfContingentConsiderationLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of changes in fair value of contingent consideration liability.", "label": "Schedule Of Changes In Fair Value Of Contingent Consideration Liability [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Contingent Consideration Liability" } } }, "localname": "ScheduleOfChangesInFairValueOfContingentConsiderationLiabilityTableTextBlock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating lease presentation in consolidated balance sheet.", "label": "Schedule Of Operating Lease Presentation In Consolidated Balance Sheet Table [Text Block]", "terseLabel": "Schedule of Operating Leases Presentation in Consolidated Balance Sheets" } } }, "localname": "ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "rlay_SeriesCPreferredStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Series C preferred stock issuance costs.", "label": "Series C Preferred Stock Issuance Costs", "terseLabel": "Series C preferred stock issuance costs" } } }, "localname": "SeriesCPreferredStockIssuanceCosts", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "rlay_StockIssuedDuringPeriodAdditionalSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period additional shares issued.", "label": "Stock issued during period additional shares issued", "terseLabel": "Additional shares issued" } } }, "localname": "StockIssuedDuringPeriodAdditionalSharesIssued", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value preferred stock net of issuance costs.", "label": "Stock Issued During Period Value Preferred Stock Net Of Issuance Costs", "terseLabel": "Issuance of Series C preferred stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of operating lease presentation in consolidated statements of operations and comprehensive loss.", "label": "Summary Of Operating Lease Presentation In Consolidated Statements Of Operations And Comprehensive Loss Table [Text Block]", "terseLabel": "Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss" } } }, "localname": "SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "rlay_TransferOfActivePharmaceuticalIngredientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transfer of active pharmaceutical ingredients.", "label": "Transfer Of Active Pharmaceutical Ingredients [Member]", "terseLabel": "Transfer of Active Pharmaceutical Ingredients [Member]" } } }, "localname": "TransferOfActivePharmaceuticalIngredientsMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rlay_UnauditedInterimFinancialInformationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaudited interim financial information.", "label": "Unaudited Interim Financial Information Policy [Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "UnauditedInterimFinancialInformationPolicyTextBlock", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rlay_UndesignatedpreferredstockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated preferred stock.", "label": "Undesignatedpreferredstock [Member]", "terseLabel": "Undesignated Preferred Stock [Member]" } } }, "localname": "UndesignatedpreferredstockMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "rlay_UpfrontConsiderationPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront consideration payable.", "label": "Upfront Consideration Payable", "terseLabel": "Upfront consideration payable" } } }, "localname": "UpfrontConsiderationPayable", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rlay_VestingOfRestrictedCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting of restricted common stock shares.", "label": "Vesting Of Restricted Common Stock Shares", "terseLabel": "Vesting of restricted common stock, shares" } } }, "localname": "VestingOfRestrictedCommonStockShares", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "rlay_VestingOfRestrictedCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of restricted common stock value.", "label": "Vesting Of Restricted Common Stock Value", "terseLabel": "Vesting of restricted common stock" } } }, "localname": "VestingOfRestrictedCommonStockValue", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "rlay_ZebiAITherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ZebiAI Therapeutics, Inc.", "label": "Zebi A I Therapeutics Inc [Member]", "terseLabel": "ZebiAI Therapeutics, Inc. [Member]" } } }, "localname": "ZebiAITherapeuticsIncMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "domainItemType" }, "rlay_ZebiaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ZebiAI.", "label": "ZebiAI [Member]", "terseLabel": "ZebiAI [Member]" } } }, "localname": "ZebiaiMember", "nsuri": "http://relaytx.com/20220630", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r42", "r86", "r87", "r207", "r216" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r206", "r215", "r253", "r255", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r413", "r416", "r453", "r454" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r206", "r215", "r253", "r255", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r413", "r416", "r453", "r454" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r141", "r238", "r240", "r388", "r412", "r414" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r141", "r238", "r240", "r388", "r412", "r414" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r206", "r215", "r242", "r253", "r255", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r413", "r416", "r453", "r454" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r206", "r215", "r242", "r253", "r255", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r413", "r416", "r453", "r454" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r41", "r42", "r86", "r87", "r207", "r216" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r142", "r143", "r238", "r241", "r415", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r142", "r143", "r238", "r241", "r415", "r442", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r19", "r145", "r146" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r75" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Net amortization of premiums and discounts on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued Liabilities, Current, Total", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r46", "r47", "r48", "r403", "r421", "r422" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r45", "r48", "r55", "r56", "r57", "r89", "r90", "r91", "r305", "r417", "r418", "r470" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r267", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r89", "r90", "r91", "r264", "r265", "r266", "r314" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r256", "r257", "r269", "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": { "auth_ref": [ "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs", "terseLabel": "Net of discounts and issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r257", "r262", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive effect" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r84", "r130", "r133", "r139", "r166", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r303", "r306", "r325", "r350", "r352", "r391", "r401" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r39", "r84", "r166", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r303", "r306", "r325", "r350", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r316" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r151" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r152" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r149", "r175" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r148", "r150", "r175", "r393" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r252", "r254" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r252", "r254", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Acquisition date" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Issued shares of common stock" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Average share value of 5-day", "verboseLabel": "Closing price of common stock" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "verboseLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r287", "r288", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration transferred", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r287", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Aggregate fair value consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r73", "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedLabel": "Change in fair value of Contingent Milestone Payments", "terseLabel": "Change in fair value of contingent consideration liability", "verboseLabel": "Change in fair value of Contingent Milestone Payments" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.", "label": "Business Combination, Contingent Consideration Arrangements, Description", "terseLabel": "Contingent consideration payment description" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r286", "r289", "r292" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Contingent consideration liability", "totalLabel": "Business Combination, Contingent Consideration, Liability, Total", "verboseLabel": "Fair value of contingent milestone payments" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Description [Abstract]" } } }, "localname": "BusinessCombinationDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition of ZebiAI" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiai" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r284" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Assets obtained in asset acquisition", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r283", "r284" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r284" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedLabel": "Liabilities assumed in asset acquisition", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r283", "r284" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net acquired assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r88", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment additions included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r28", "r76" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail": { "order": 0.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Assets, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r71", "r76", "r80" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash as shown on condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r71", "r326" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r82", "r84", "r103", "r104", "r105", "r108", "r110", "r117", "r118", "r119", "r166", "r194", "r198", "r199", "r200", "r203", "r204", "r213", "r214", "r218", "r222", "r325", "r461" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r297", "r298", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration and License Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Description of rights and obligations under the collaborative arrangements.", "label": "Collaborative Arrangement, Rights and Obligations", "terseLabel": "Collaborative arrangement, rights and obligations" } } }, "localname": "CollaborativeArrangementRightsAndObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r193", "r394", "r407" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r89", "r90", "r314" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively; 108,810,478 and 108,210,318 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r62", "r397", "r411" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r234", "r236", "r239" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract asset", "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r234", "r235", "r239" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Conversion of preferred stock into common stock upon initial public offering" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r213", "r214", "r218" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r34", "r206", "r320" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Letter of credit expiration date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r159", "r181", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "12 Months or Longer, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r159", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "12 Months or Longer, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r159", "r181", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Less than 12 Months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r159", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Less than 12 Months, Unrealized Losses", "terseLabel": "Less than 12 Months, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r156", "r177", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Total, Fair Value", "totalLabel": "Total, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r157", "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedLabel": "Total, Unrealized Losses", "terseLabel": "Total, Unrealized Losses", "totalLabel": "Total, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": { "auth_ref": [ "r176", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r155", "r180", "r184" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Available-for-sale Debt Securities in an Unrealized Loss Position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r158", "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Debt securities unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r74", "r188" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112", "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r55", "r56", "r57", "r89", "r90", "r91", "r93", "r98", "r100", "r116", "r169", "r229", "r231", "r264", "r265", "r266", "r275", "r276", "r314", "r327", "r328", "r329", "r330", "r331", "r333", "r417", "r418", "r419", "r470" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r316", "r317", "r318", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r316", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r208", "r211", "r212", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r317", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r316", "r317", "r319", "r320", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r208", "r243", "r244", "r249", "r251", "r317", "r359" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r208", "r211", "r212", "r243", "r244", "r249", "r251", "r317", "r360" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r208", "r211", "r212", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r317", "r361" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r208", "r211", "r212", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfContingentConsiderationLiabilityDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r322", "r324" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value on a recurring basis [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired", "terseLabel": "Assets obtained in asset acquisition", "verboseLabel": "Assets obtained in asset acquisition of ZebiAI" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r153", "r154", "r162", "r163", "r164", "r170", "r171", "r172", "r173", "r174", "r180", "r182", "r183", "r184", "r210", "r227", "r313", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r461", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r187", "r389" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "terseLabel": "Intangible asset", "totalLabel": "Finite-Lived Intangible Assets, Net, Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]", "verboseLabel": "General and administrative expenses [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r29", "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Acquired In-Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the assets (liabilities) created through trading commodity-based derivative instruments.", "label": "Increase (Decrease) in Commodity Contract Assets and Liabilities", "negatedLabel": "Contract asset" } } }, "localname": "IncreaseDecreaseInCommodityContractAssetsAndLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "totalLabel": "Increase (Decrease) in Other Operating Assets, Total" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentSecondaryCategorizationAxis": { "auth_ref": [ "r425", "r429", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by second categorization of investments, which may include, but is not limited to industry.", "label": "Investment Secondary Categorization [Axis]", "terseLabel": "Investment Secondary Categorization" } } }, "localname": "InvestmentSecondaryCategorizationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r161", "r165", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r424", "r426", "r427", "r428", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r424", "r426", "r427", "r428", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r408" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments", "totalLabel": "Investments, Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsBySecondaryCategorizationDomain": { "auth_ref": [ "r423", "r425", "r429", "r433" ], "lang": { "en-us": { "role": { "documentation": "Investments in the \"Investment Holdings [Table]\" and the \"Summary of Investment Holdings [Table]\" are often categorized at two levels. The first categorization is the investment type. The second categorization can vary. The usual secondary categorizations are industry, country or geography.", "label": "Investments by Secondary Categorization [Domain]", "terseLabel": "Investments by Secondary Categorization" } } }, "localname": "InvestmentsBySecondaryCategorizationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r316" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Total investments", "totalLabel": "Investments, Fair Value Disclosure, Total" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure [Abstract]", "terseLabel": "Investments:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held for their financial return, rather than for the entity's operations.", "label": "Investments [Member]", "terseLabel": "Investments [Member]" } } }, "localname": "InvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LandSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land subject to a ground lease.", "label": "Land subject to ground leases" } } }, "localname": "LandSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Operating lease renewal option" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "terseLabel": "Operating lease option to terminate" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r344" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: interest", "terseLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of the lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letter of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r84", "r134", "r166", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r304", "r306", "r307", "r325", "r350", "r351" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r84", "r166", "r325", "r352", "r392", "r405" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Liabilities Assumed", "terseLabel": "Liabilities assumed in asset acquisition", "verboseLabel": "Liabilities assumed in asset acquisition of ZebiAI" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r84", "r166", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r304", "r306", "r307", "r325", "r350", "r351", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement Terms [Member]" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License Agreement [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r71", "r72", "r75" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r49", "r52", "r57", "r60", "r75", "r84", "r92", "r94", "r95", "r96", "r97", "r99", "r100", "r106", "r130", "r132", "r135", "r138", "r140", "r166", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r315", "r325", "r395", "r409" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r94", "r95", "r96", "r97", "r101", "r102", "r107", "r110", "r130", "r132", "r135", "r138", "r140" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.", "label": "Nonfinancial Liabilities Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "NonfinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r130", "r132", "r135", "r138", "r140" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r340", "r345" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r336" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total lease liabilities", "verboseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r336" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r336" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion", "verboseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r337", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Fixed lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r335" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets", "verboseLabel": "Right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r343", "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r342", "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r43", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Unrealized loss on investments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r50", "r53", "r55", "r56", "r58", "r61", "r229", "r327", "r332", "r333", "r396", "r410" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r43", "r46", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "terseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r44", "r46", "r160" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "terseLabel": "Unrealized holding loss" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r32", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Other Liabilities, Current, Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r67" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisition of ZebiAI, net of cash acquired", "terseLabel": "Cash paid for acquisition of ZebiAI, net of cash acquired", "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r69" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments", "totalLabel": "Payments to Acquire Investments, Total" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r102", "r111" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Deemed dividend resulting from extinguishment upon modification of series C preferred stock", "totalLabel": "Preferred Stock Dividends and Other Adjustments, Total" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r213" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r213" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r26", "r27" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r7", "r185", "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid balance", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r70" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options", "verboseLabel": "Proceeds from issuance of shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "auth_ref": [ "r66" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.", "label": "Proceeds from Sale and Maturity of Other Investments", "terseLabel": "Proceeds from maturities of investments", "totalLabel": "Proceeds from Sale and Maturity of Other Investments, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r70" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stock under ESPP" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r189", "r352", "r400", "r406" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r250", "r347", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r272", "r387", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r272" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "In-process research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r80", "r390", "r402" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r15", "r80", "r443" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Unvested restricted stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r231", "r267", "r352", "r404", "r420", "r422" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r89", "r90", "r91", "r93", "r98", "r100", "r169", "r264", "r265", "r266", "r275", "r276", "r314", "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "auth_ref": [ "r296", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Revenue from license agreement" } } }, "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r128", "r129", "r131", "r136", "r137", "r141", "r142", "r144", "r237", "r238", "r388" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from license agreement", "terseLabel": "License and other revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCollaborationAndLicenseArrangementsAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r59", "r84", "r128", "r129", "r131", "r136", "r137", "r141", "r142", "r144", "r166", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r325", "r398" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Aggregate gross proceeds from the sale of shares" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Sale of Stock, Percentage of Ownership after Transaction", "terseLabel": "Percentage of commission of shares sold" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Shares issue price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of Fair Value of Available-for-Sale Investments by Type of Security" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiSummaryOfNetAssetsAcquiredBasedOnEstimatedFairValuesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense Included In The Company's Condensed Consolidated Statements of Operations And Comprehensive Loss" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Held-to-maturity Securities [Line Items]", "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]" } } }, "localname": "ScheduleOfInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Net Assets Acquired Based on Estimated Fair Values" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r258", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r73" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "terseLabel": "Stock-based compensation expense associated with accelerated vesting for certain stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureStockCompensationScheduleOfStockbasedCompensationExpenseIncludedInTheCompanysCondensedConsolidatedStatementsOfOperationsAndCompreh", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r81", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r82", "r84", "r103", "r104", "r105", "r108", "r110", "r117", "r118", "r119", "r166", "r194", "r198", "r199", "r200", "r203", "r204", "r213", "r214", "r218", "r222", "r229", "r325", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r38", "r55", "r56", "r57", "r89", "r90", "r91", "r93", "r98", "r100", "r116", "r169", "r229", "r231", "r264", "r265", "r266", "r275", "r276", "r314", "r327", "r328", "r329", "r330", "r331", "r333", "r417", "r418", "r419", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureAcquisitionOfZebiaiAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r89", "r90", "r91", "r116", "r388" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Fair value of equity issued in connection with asset acquisition", "verboseLabel": "Fair value of equity issued in asset acquisition of ZebiAI" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r17", "r18", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Shares issued in connection with acquisition, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r37", "r209", "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r17", "r18", "r229", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under ESPP, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r229", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares", "verboseLabel": "Common stock shares sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r229", "r231", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r38", "r229", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Shares issued in connection with acquisition of ZebiAI" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r38", "r229", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r17", "r18", "r229", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r229", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in public offering, net of discounts and issuance costs of $34,707" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r38", "r229", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r17", "r18", "r229", "r231", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Extinguishment upon modification of Series C preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r23", "r24", "r84", "r147", "r166", "r325", "r352" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://relaytx.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r83", "r214", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r231", "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r334", "r354" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r334", "r354" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r334", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r334", "r354" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r353", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r153", "r154", "r162", "r163", "r164", "r210", "r227", "r313", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r461", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r85", "r243", "r399" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "US agency securities [Member]", "verboseLabel": "U.S agency securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r85", "r243", "r251", "r399" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "US treasury bills [Member]", "verboseLabel": "U.S treasury bills [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/DisclosureInvestmentsAvailableforsaleDebtSecuritiesInAnUnrealizedLossPositionDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail", "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r120", "r121", "r122", "r123", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss": { "auth_ref": [ "r308" ], "calculation": { "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).", "label": "Variable Interest Entity, Initial Consolidation, Gain (Loss)", "negatedLabel": "Loss on initial consolidation of variable interest entity" } } }, "localname": "VariableInterestEntityInitialConsolidationGainOrLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average shares of common stock, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://relaytx.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail", "http://relaytx.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=SL6757427-112606" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e845-128460" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e848-128460" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.2(ii))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r459": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r460": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r461": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r462": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r463": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r464": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r465": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r466": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r467": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r468": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r469": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" } }, "version": "2.1" } ZIP 52 0000950170-22-014809-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-014809-xbrl.zip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


PDOL- M&B"!OP=8Y<+'UTCT9MY6YYB/EN1$VOE7EUP8J#B/(E1N1.,W+M^ 9OZ-H'1 M<52'LM7@/5)"#B(CC +-56#]^>TQT:@WZ3*;UNI2*7M$5(6E7S8;22-HB\@X MT]EBTOLQ^#TH@3FVA@/=7O"GE3^<#Y#W<_18A$F/\F$3T>Y?/J;M"D9.0:I<%;6IEP5-]BT,Y_? M01VX1"B/;M5^RM:EA,07%M".VF4F.8IIG"33($E6;F$$'U*[EN[%@TQ@Y/1V M=^VX3,BK-'N@S@=Y')FT01Z--Y*22DF7(TY\6JZ)P@74+VR@Q;]_Q(9/%*N3 M \[22-#9M'=_ZSXS].#I>6*'[5.$./]E@3@O$.>+=?@HGH: 7U"EG&*@^OZZ M8O"J%G4,)Z8MR]]:G6:G+5E1%>)$>63*?TSR$8#7"49B3'X^#0CF=5'99$6LCOV!PJ\7]?'1[Z-.V"9#\C^5GD)6><,96 M%:XA<#%N\A:8.JPWF<7L8);X>C911'5ALP\AJTTLSBWFMIM8"$4 %;M5V"7' MF]=^_&7(UU[Z_;-#6/Y,W26@EU4B,67UR/S4$##)*(R= MS]1-!8.@H]^@A2H)IT89F^,HPC#\\/!,-$EB:HF-/I*E8A+<%/6R^^BV&08] MY&@,C[ !6]K0?)NTLDE:LER[E+XS0PV._9J%\E%ZD::?H'PJM%\PZ?L;O A- M.$L&899Y ?@DCX9LTETWD7;B?NT14UK'V>DTZQRO8)8F6I^:G_ZT[7LL:01O MX]!WG+P*!AQ;>$^+/!K:X=S@& TUL.8COGT,JVI3WLC0^$W#&_WVJZNP+O[U MQ6BIP8Q5^?';;>5^NT\X^&OONW)[E '@[X)[$^S;"UP_STI UGZ[#L8&<^)3 MJRT^BAW5(UU^R8SJ=)8USAS.ZD/N<6)Z[:Q]_?5?OGG^3=CSS[_X\U??_.5? MPXRAUL277[Z0Y6#603JH1S6[_^M_)W5(/J>EU!O1 B.O8("^1A(C/"J>B7XG M\!2*@)AY2?++URO48LV 0'MF8 M+4F;+;OH0M[SLHO.NXLP\:0)L.QC("_QDV9 7L626#7G^#8D8<*9$UNT7O4:7ZIC/;(PE MN_R)WLA/)XOHJ$-ULFC>)#'VN'8NQ1JLY;O?J)(AY1>L.GFIYY-.<1R+:G?Z MPAVZDH%0>[#+!U;$BHDO+^09OJE4*H H&EB(*OV^RG_LJ6N:^?4IJ\[$]4@) M3@Z6A8LA6V:2N -[+M7ZAAM75)#@SEFCXIUP7D[?#DN[8]*W:4=1;V[2_"R> MK9H%#ZED_9[6@&')RDH5;&,E Z5.IN=E.RS":ODYGKZ8 MF&G;G%DEQE@]4-8^=!8[%ZN,L;$C86^;K_4B+$7H3^;EQC[9"UB*AHM9GS+K MGN@1I1V="@+&R"$B"4B<.9$Y2,LD@L.L+I1[_-;K-Q_>O_FP>AFM"V@.[KF! M[>WH.GBGUU>K-U>K#[O\%KH:7=Z&ZY5T/1#\0[H5,LVXN,WO,U%7:84QY4>"KMNOF-[%Q4P],3,UVGN,4?/J))8VL<4>G:]_:N5=ADUP# M".G+50C%KEWG4Z?TQ.VF=B_?'ZZ L.GYD5RM?A$6$^+S!7*NC4,-.FS>Y)T& M+A'D(("#P0&-&.QJ >SQD&TK^8P$#H;R?+RGPT2%0,$+OC3X6-TM M$#9RPG+BHEDB:1]MISMP. Z 7Q*\!8:H B*?&1_0 CF#6P>,5-BMI@H>3*%Y MWYF^6KT>(^7N\T1L\M"=C2(1AP96:9FXI0C7?P#X;FII([+W(9%PT3R#]8'M M8;A2@L4)YGC38Q#[L,A8O."!QS^(DL>!,6J;;4C ;WB#@?1YW'C3CY6T-EKV MJAE.KC,%Y$-N=9( L8!QM)LVR=.K0",>F]./AZ2*DOESN?Q_=.(^,E&3'Y$D&,!GH,P^'-P/3NZ? MY)ZPF?SYJS\HES^1:V,O$(\>T8S^W.G\)W8N/5Z;\)GY?*8E//Z6WRX"'A>_ M8L[8_/N*>?\Y$HHL_M+'G9"3&^!HRII+5FX#](_(E[N#O%C5&Q(WS+6SJF9L MWJ1X:*)C\W34L?15/[HU_"EI?9#W'>LYN93+:%&NR^8 -"IA%#TUJ*H.!+&N M<& *O]^Y_*;$\!1H3#$^GW4>$G4&7L]7J[?(_"(Y9N+SMJHDO(/&@PKOOO== M&PL[X>7L#+^_Z+V2:@3[=+ Q6&X6=P_TOB*S-RIP3,C2UO MS%WU$D9?A1,! M8C'M/X:K[.$^I:^X*'9ZVQL]BLB7!#_XF\MWQVK0^7."($4T0X:*ED8E%3D^!+6G:9*([EPF G+CXJP M)X)+3MBW3D5LH"6\=1NWA=P#L6Z&Q25.'%8:196/-03DT9Y%D8'@3=90,]XV M*?LDN,$L7N?$"+/R_3:NVU$D,9PM*$D$#[_VL#JH+3V9%=(QH=>6KQ 2][QX ML2U;WQ$_;>7HP\T+_BZ]%?Q&L&K/X!MF(C.HJA"W*E*[ GOJ/A%5J%<_8DZ2 MU\17 \+U4OM_CBZ\R\KE+;KX"&D)+GF&!PV_I>'38HT6'71F,5;G>DQ]KQRP M4Q?"70?['O8KA 16R%@D5O#E1IV5$2VIX3H5)OP!%-;L@]E=$ Q=BP9A"Q()0*4,$4E5C_%*['\0T\T2E$]'.$L<\I1/] M)S$P'_H#, :O7H6E0W:H[2L@$H'2Y WXCK)LX>C'([:E$PT)IA5-%_,(=_$) M*W^PJVZ+?P9==+TF4D596RV7F-50]>/C@ M:S0^K\BFY_H3>S"E#OJT_-7448WG%)G"37/ $XA/5#** ]?[3GLTQTPXJFN( MQ$F4MYC_^=4J\LG#O:C"DW-\030LM$9>-?5UBQ9%/RI@N<@''][]]%8-F2(N MPXP]"S88+K]N-BRA-/)I.I$6(U44I$7! 5Q#%:BVWAU-(;T>N%9?AZ4+ 1&N M)D@'8(=,1*2)RS,A33[*S19"TF\^)-YCD)VDXQ MI[%BB-3U(.P))@8V$9[=L8[:[:!^N\37CV]I?>+3.(*1I-8^P<'/G52G-8U\ M]%%5%N'D+QA6'MQJXR(*^[/13[JG:7W;.D]^]PMUN"%1:E:J4I"P!S%)85K4U#SC(N?4 L"($Q7(L!$OQR] MU'7?Q8N!14F9_D10AGWKH>^E',_$1Q\<_Z5E^T+6T;)+S[M+"<28=DXW[1!Y M1PRAL*]BB-M)ZD^W=6S_YNI1L@63]!*=Z%;NVV:LIC8FX._JYI8J_B8^6G;J MA:RE9:<^BIU*2?J))+&*K0W(6DF]J[0)ZV7/7-AJE_GAC)5^2CD$CB(Z;[[8FW1AMR#X59"_[\D)6 MSK(OS[LOJ3+,DCKG4- #\)3J'.)*UZ0_;'0(FCX8N0 MG(:,B!*,BY<4]-T:",L^O)"5LNS#\Q-6WD,21*5ZK)E/@/AI6"NMBN3OQE!5T\2P2X]UG^HQ_J;IE37YANW\JYH'2%JA3V<>[1'LO"^7WOW]YXR M]NF-M-@U3RBR<"&?>T%\V"&(.E?E1VB=I]ZRIBAZZLP^HC4OHHHUU3DR2RN:AEL*$>4>)>WM@OM>ZF M=+?"@@YN$===L)\MMDJ;S!+(F]?>#7O+$%+1WZ =J<*7D;7FZ_ M.0H#(7-=TY^DP[W*@;X'G]1W+5-1D(L'S@',+G:FMOP[A$YLVOP66O"W0%<' M*M;E 3>JS[(-,QIUCDZX78.*VJ2IJ)Y37,^BBCB1X]FEAQC7O)D[#TISSZ*S)IZ0!(V#Z=Z]?(I1(<45 !P'\G-:4 M]-V.!%UXU_F[# I<.=R\WX:U2>S)JLN9Z78#.HSB8WZ-_PR;)&R]=<]T\.)J M(]]EZPY-V^'7?!A0?NWX&UWIZ3IMLV^HI0C;+:&C_Z-S!U1W(C1AI&(=&SJ4 M%46*5&QZ'9N]9-<3F_16;$%LI35VB4A%8R&+1@X/"MW' M'I+HI=^Q8.(US$[\7O@+38>A,XVF&+=^B<3YN/V+[W]\1^;Z^U?OO)X'17@' MR!#20703"^U2RL.QZBF"\2Y!6=95G$W@;_LH=A3^@V;.3A>0X4Z<2_&&^/" M@B45A&:U;VHHQE(S>EQ^1S@7R&4CL M%]ZIT)/F\O,$/F$W)$[)X-2#IOJ2=&^V+:9 "B++(U:=GLO&SR17(K;!465Y MUEC ]<*1!L"J^YUJ6>IQA'D,DW8=2]?UM5^:\Y9<[)*+_D)V0GY!#O\ Z+F5U+'OOO'LO]2T0 M2NE?+&O_(M[.LO;/N_:!'P]27#FQ[E2NZYQ%,QHWV M[7TX&KAS&K)"P,E(P;2VM"2]+("=[0_,4.C-US?I]Z ,CBW9_>)P7;>3!!K>E?\#J0NDONRHEQD#%-EOF-U'FB$$MN\A_[="&B'ZUU;!ZHN*_ 6] MX67_G+D'K/ZUKPL]9V1O^%)X9XORIL2*7-$"5SR J*1(MJ"H/@>O6_ 0B)KY MFQ?0%EL!Q[1GM!TR66+!(%9XKR/.Q=)A<@(^O#M2BX22 !5T6>PL&XI/3I6X M9RM1*,!VZXCPJ2(NEZ@NEF_R0\=F?DFU,VJE*J!_H"J\=2Y;RK5\K26OY/HII'$$VKA5.$@IE!. MV0-%(P/6$K2:PL_H344NT;S8H90-^G=>E'_""N#O+'"UB]_K9ZS'\]XW-4V[ M(4$%&OG#D6Z]TI!ZG@\W+*U=N2X[PR_.I5S8U-OM,ZP68PUOP2L\NH7X:?$* M)T$':&EC!$I:K_#9%K4=@V%#6QG<"$1;$^]G6&I0]4V6&=47P/Z*ZVU@.2C% M92K0%L\43#A;R-7]=@D51"H]TURZ P!(3"2"JH&&M6K0D%\#( MSJ9-VU_KT!%>%%5',J-A#^.CV(,T4(+#Z!WX4K+[NK;O=MN>:O\@);LO/7!3 MC) +-)C:CH>K-GE2Z=7>0I[Y6&K&\CE.?D*IJ!>,:0E[HJ=O5E\GR:8E[_3W MO<&MVR!3O/%=@$F^ GP;H,;:X.:0(XI8./%$,>,8WG(.NKA1.(: %U7EKMU& MEV%J[V0=Z S2CP;K$VX&XW U: I+\=UJU%!-S-77"*[!'@>]A-XPKE*X&*(K ML'#OC2,FU\.6,-+I '$8F(D-=$7 S!9->P $++'Q7A-.*&JK,I%N7E.W1?3K M20&//!;P1,)+H >/JY^1*/O@AL#2)S<-41I%#QT:E=O(>@CO#U9,(A@;;II? MNXECY3ZPPMNH-7BO)9,Z7](T@ 39)_RP1;;BLYQMCU>K] GV(FX_($""!],<& )A+((4;D/ MLT"@:SVL)B![=NORT.LZHL(40:2#0"2[4AE&2Y#<-$;Z, M7064,&G#M&'QBF.CLCJ"?XZ,=B-HZF27@DGV#7>&Q7XE,@D98VWEFQEXN ;E M#%0YL@S9D?L^HH8H+NZNBHK7TZ> M\UK\9?XO_@*]D7!&(S('6Z2A(*O&B6IZ@_6P"[1ZNE&6L'9N-;QL?8A\^'Z0 MV>];[@>#\6C\X^OX4[S9,:(=MDPO@R9:E:FNR5(ZEXDF^P;NU#PJ@+_5)TB)8]1UH=3ZBM: M$&?I$[<6MLU:L@84_Z[!:V6Y5!LA9,YYB=.5OA"**HI^NB\U%X:7VZG,R!Z$ MK(M]5;!H$^U.\.Q$(<^FO:"5\S^%[K/X%%_87*Z8*);C$WP=_]H60]5_*1N^ M X[:\L&X$:OT%DHUWSF/ MX//=:9E+V,S(\CU?%M6%8OWL,9G61_C_2-[C;T]^$QEM&SI]*.9JJPWO2+I% MS1WU9+9J/F9%V-)6!>^[MM#,))E5":VY\4PR]OF-GTS<^*N/NC$D&CN* ]D* MV)U8=RSOSS #$UM3"F8^:V [L'3I0#CCV%IZ5,Q>Q*10U'$4QK8.<[V!#?=R M-KK2=*%IE2:+1?9%(#B_6H-EK+W/H89OEO0H,S!JZIK/3MB_T#.(*?&?-0^MQU:P?F+V;)O0(VHZ9KTHR(IO](+[X6V:3TJ:TA\A;6'=-+11HKBTS&:W' MWSQ]]OAWYU^3?:DJG%.M6HUD*U#9'.Q)>$E 1YH+YY7S,M]$8=0VK'+ M:>TNDHX(A>)!TVCC1^5QRX**BXC,CO:F(>''RA9*M5K =^QD2M;-!9TP%I[P M>N_<$6RR67X:_0CB6U\F<>GDNG43;AJ9.N2>2RK\=$^-P7C:!KD<]3_C-L^'DS5\?M7..-IHM^R7\ MQECID;[7N+YL0WF)5YR=&F=QO[SHBU*/CI12A"F %S1J,]/&*5DNVAT]89FE@5:N:44'$DOJF(P M/^W-BQ=<=Z"?TUDDJ?X5^S5HL&\_O,><@"\T=2=$&,_ MX"4YI67;8SVBP+ M8)MQO!'%F>X:]03$C_95('&.HVQZFCD,+G8O.YWD5 #J7$)@58C@AJXG\ZDI M_![6'(+Q\YLF7>]OPQ9#73JU1V7N_*D MQ389+WV&@MMS._FS.7DN4,R80K VLN%*CH2PY#F';VD*]6_J$WC'Z@F;\A^PBL"5O;6D^MZJS#._EV^<4:E7<_:V-[5U M H!M%"VFS;!+40+6Y9<67+#A*"%4SFD8#/%'T)H_D>#IR9)_J5805V!U E@D MO12>F)TY>\QD$WA@ABADS]+&8F7N>) A7T(_6.LY*&5X4>2AL(L+8(LW@8PM MXCH;FB4A)04GYB2B&NU2NBE=\&@I.>Z>I>$:!L3L.WG"V0Q\==):QUNK/>8G M<#;Y;BPUS^,O,=1W5V;_%^IY<\GD[C!D"AUB9;D.B2B)\HKDP<*(@=. MK'YL>>NG%)=6)!(*G7E/E.O3[J7Y +**K6J.W/*N?$QGI)1UN!#=KVDR2B6R MD;Q9@O8F90/V$AP,)CJ44O'Q:5F83AOFD@9Y)DX*.\L#/>I9-,9[SM[1I)"# MPOEJCD5J?ZS/4);[NL7NL/S["MAT*V];'#WB5_HPD!_%20JZ_C&T9;>14B)9 M>\W7['@'6:R>")X,"H8?KW[Y?;&S_9UG*/+#6^.?.%-D(1T8O_J\32/UOL;5 MXY()KX^)U;2FD2VQ<5(H3U7@&#@BH/+K>6(MPY3'04ZX:;)(-/]TC C@ &20O+NY<9WBA_4# MOHHT"R'5(?5'*79+?#(!!,WKQ^EM_7"259$O>.I)Z!IYM*-"0CS WZ(6)Y1G MCE'MN-&G$P+,GIT%6V'.XY8X"P=]?LJWH8@) LZ.V4\C/=D-YLXNST=YV'QN M1_?G"+9\/(,M9[#EO5F.OXJ[R#D'.E-"./(9K4M3O$4A#SONUXSWY[()]R0= M.8C69U-$\L+8O_I!7W1JZ+'5Q,S_W;5*AS2A&^C%C[)BD.>O@\/QO<3C)97'G]_-L M,C9 2UUQ]5YH(?-AP7TH^.R^:JJQ@R4-S;1PE8L5?V>F:P5]=/!-0FMH!(&W M7)#][%'\X.A9AF=8$N_1Y62;$4E9-W5$7RIY*#(((V0G%Q%&'RD(5/)_DPN* MMP*O>0J3]KUAED^]QZD@B.N''7VIE^3Q#?Z@6XJ8V0[8-GV1+8CNBZYKUB7R M,7"OT#[G2;)WO-6F7>2)V9Q8KC'!&MO*MG#%RMUJ:#M)6:Z 6&#H#*^#\7=- M*Q)FPP]%IH+K)NNB,P)D;$S4/;3Y^V96*,+$7_@1V=7K#XM&_I,<7*,BZ"$;I0 M@28/BUPFV4D1\YZ2'5FL!WW U&D&N: MO.7*[8'%W$I>'1!ZZR6E!O#4INR P6;*^0LVL=>74H7+OU&U%PH6U1WC9U> M'WU@B9;%H4V[C79R7 OFY=8JF4ZV7JW5AF9R\+.#2L MZ( G(D^PJ@+3#^6T$;?0XRBE(T>H(^[QIOM\+0A6ZBYL['3AY@I!1QLDKNC] MF]VVQ2Y<-^V[I:RTJGP7JH1DZ"^3/ >3H(T5//B,H; 6\:E\.Q>)D&TH#2'2 MCI/MOJ &"\?4,E4*V%>QJ@(G5M;8.R[TT]K"T9:<@YG/R?GZ M>W#Q;\O+&JDK[R295H^TL"TS?TSR@9%,!NO_PX$+GYK%'I"$DT%,AA6*48J5 M?ASU22).J"V+97ID\=K';?9HTMA0?)8J??'4:^OLM)?7G[_V&Q)*?&K^2"=D@[XJ2V@F M!#4MZJ/\&6:]8 :H([=BOZ<_2%2]!P'K*"(XX1*A]CJ5'\5 +LCB2GM6R8AU M7D[C&PN>2&J,=FN>"3?9R$U.3ZCZ.T?C D3/"H23*TO"%:1+H1/D:JO9HEM^ M(&=-$[ <"7AH 3A:?$$?3KUY\W2 Q>3\* JN5C1V2-7QALXVY,ZO=W TP*W_Y\#PYNE]MS[Y$.WYM0@6,=P,[X4'7Q\ M0-)O4)GMM*U!NRMI?B]T1K4^*XE8'HTGN3J1Z;%@VCLT.9_K,;AAX()^]XOGB. MME<@%)8C0LW32L\3_$ZI6=HQ16G1/6]I+;RAD;=],"0'&3@-^0 /%N_-6""@ M^J7!(,U_-2FS<\ITX R,N>ND]+48.@6'C(.NL='^B #,0BWA-J!9NRSW+ZTH3O'G>%%RZ0-6M*1O5I+;6/B-JD2"*9[;?5D MIKM*P1W,KS":-*6R.Q68_HOSM&D8WBPL$BG3ROW?C1H*FHS.G/?U-!.LHE"D M('FTO]O38YJVOK,?_U#\^%]9L?HYV8VS55NN0DL>(?Y%MVZ'??1^7V'K38J@ M=_.JNN^KZ@YK('^=(@M.U%ELG7.$G3MS/3=VAFO'QP@)6*QUT)90[^8>^[!V M=%K&/Y9J;\1G.FH7)=SP!;G4(J,RH0XI2=>_:(O=7*EZ>-OADW>JD&=NX9M; MWC M(/9#4-@P=8UUMN!W"5H25::'%IVM8!_;5BR#:^8*G;]MHMK0UV JE4J[$N:8 M*:S2>/68:53^*U7PO2I%!UO,8!YL'#(IA%73O+-5Q]+=Q@*]I@'1_2K)7V^+ MLH6KNZW@PU;:0UH8&,@2(=+0B.#)I0*RPX++=R4Y[FT9^<%@H'JQ44:.86,)V?!0;B>N!T3 .9R (=51WB_;GR M*V'+*@3.OX>=!-*KX!0#W'TH#T$4J^3%F_5C;]+,[C#YO0_#?A?!0 MLH>_S-Q[U,/>D_>'=":\SZ@'(4QJV#Y#9W8BTPFY,1A1K[BCS1Q[R/OF)_'WMYFRR+IB%QBZ$.Q5)??-V&+5W>Z6'A%T%*G#OXL\JHG05FET<[&7 M6/=-L9=8+"X2W?BPY0@B87'_1\1A4I&05Z2L.OKOCTQ=8.I/IBZTG^(HO7QS M8.DRRJK)1G-#*_Z:!I[**U+;,9LW9[GQ.=H?#3VN"&JUVK.N4T\N# MIF-6VA$/IV>;FE#A2>R#8A!67VHPVU)VB5DMCHD5$SF^^>R&V MD&\N5P'W!5U RLN16*X592071M/-8.#">Q,89"MV539F>76C\0&=&)8FH^AY MS]S[/7.':=:_JX+E!%DOKR]D1]0Q+?(BRU(^8,[: ^TWU'MP/*C L&8MEHNN M4%VFI?-'>4U/Z_:ATLHM4@!J&,3O)GTQ)7 ;#-2Z[>XPE_AC%F2VF5-U3\KVQ0M+J'MQUC &..Q MZPC>-$_=SS3HH(EE2T]>VC)*!\B/Z1MTR,5_X$1JVNSQC%U)#A^7 L=8=V4W M2I)'\F*:+JC4]N8E"A<%-!U.I,3UE>#CHRA4>.HDNQXJ27TCQ8Z"0"OCHRN5 M^]*H,211OJ)1"$%'>87T:N"'/%_\=W8^II< $/3(@@AG]SZ&<8Z?OT_R$7C?8%G_>ZH3379( M;:?ZF@6HDG X";JJTI4L*+!6"0<&*(F^M+9HCTS"2:(:T0\$[TE = ,DC=5T MW/*7ZY25[%[WQ(;9 3]AC1VMEJ!)>S4!5%FNIP%*B682N[&*;1W_$R*CM$#G MW]7-=14V%T' B&RYXHUGO_#>'Z-W2:XV LVI?5@/'3UQ:.V,2K-Z6FA)1D B=UQR/ MSB[KP]MKG])E-1F.9*LIL&^%Z%BX6.J#0P/52F'"F&$FB5\#Q[ZBL\AC-06E M<$J -F,OG!)6JCR32P%>-]HGD[CO<&H/>KU#)Q#!F>&"Q\SFAWT5?A#=ZJ;8I-=?!F]A?; MU=2UM)9>O]+8VY/84X*<9Z.7*_D#H[]L995'6D!=P1VRZ9+O)V]L-?3AIH;X MV\SI:R<#J V0?CYT32)=QXOPP^>+P#L4\$^1' 12_O 07*)->65#4]/))O(/ M3\_)T/[FV9'MIG? N^$/VRJ\OPWHXA\LRK$]V #P.SI/:,$^@T$^HR??=7]@ M)E^@?Z?,=WH4/ZH':L^S&8W36=:8._Z7^(\I'@T@E"2A>6B#2TC ]67102IA M@TAZ?&HUVR5.J8NFV4BYKKV"MD*RIP9GU%ZJ'2:"W-*8[=G#^B"-G* M(2/_*#?GB^@"$_QA),DSD@-Q=<2MSB)12;*OH?Z6,P29\F?<<;[N,0SH2^(N4-Z)EZ4UA:%$2K01L<=T_YA5YRYT'*[)U=DNBT[Q7%,1P M_SJ!7\/&%Y<0/\F M;T=2M?%E/$NG'FT1_=_Y])M/O__DTV_*3F'CK&7CI.3TA)"D(#^2(;AI^RF$ M_ODR*D['&TXGP-U5Q>>7K]!$=7T55N0]RS%%X>.B+W8&$^-4)GGT79]I1=N) M838W'=F*[[/R J/U%&BS"O;'(*?L="BZM*F",=(34"QE&R9M%]I:H>]LM@U' MXD[/H>*J*3>1U J+3DD/]-.04YM8#9B5!!05(L'X&E*3\8_-,.2A6)DW' MT?RI,T!;!DX.' 4 S;Y+>'XEY*O1#1+\A(B5VG"R59:&Q9&QR8>CXL-3>5E4 MV_'AXS,5G'[G'QTC*4X/6B#^#$0+1ML;]Q_[973UPZ(_;\.L;_9"9M]KG]QF3)P2[AP_G!9LL3;O]'O^D_SM^XD&MK>+AH: M'RW/[G>Z<0Z\YL#K\PB\I,Q$+EPW"*733TW;FRP..V7/%6.E'ST7$L7'WW[[ M#0*5/__PT_.;@REV[N6WR#))RX2&.0QJV^VMI4#^%IB]IUM?DFLNG0!6\CGX MI)$1P&KR"%<[E0!E4T4K #?5$$;SGO!@^;^'/=W42(48GIF%1^#.B81#XUCI M)&5-Q>@@<":YD(PGX?@YT @Q2E^=+]YXCJ\/F&>0]]^KO.2 M/8T%^I2#X7;[/>WU>IW##);0OI"L^@A$RU>T',";@8O.=6#3&U, *57RG)DP M-\B?O&"#@AR7-5/MLI0+;?--.UP J@D+LV0N:V957G=*L"VN#4GG%\S(C=5D%H,#>*D7O)%+F]<>;I[WAP?Q[H M:19O+$?@.][:1)Z4"60+HA;U'TY2)>S$%PF48AS>@KY$85Q;7'F:R(R*]L*> M,0I]*__:-YNRD'_(07=9,G&AX(V_U,XYIDZDP\/!15VW77/-T$9F;)/.+]:Z MU<.$Q:H[P8Z@$'4$^6#P=+GC=P4.#:Q5>G7,I4UGQG>1-_PO]/(Y49/$M]$7 M)].- ]"IS5\'QG"]9Z;9?#)NF%#?D^C6O:%5%E^D#X640[#9->O&:(,2WQS MEHAAE;_B_"DJF6Z^C_0S"D@5/<7RO:*FN;H,?7P5^D$GZYKUDMR=\:[L8F=R MA5VYN:;9ZKZ2=],*VK/Y.0X,GCQY]JZ'!V^]>_%D,'+>0\F7$H73J^N&H>^7U8[PSIJ5C!GT>UQ)743!9 M? +02N]+/9E.%0>7<9%CV0N#TKMP<^]KK" YH!T77::F Y!/CH$$3T(1;=/6 MX= I@76%89KV!&I26]8XU/MK 8?WEJ*O!5/SCZ%.2-%8)&V&5A@L%)R:187R M?!'RUX7P+HW&/#'ZMK7Z0 %XK!^WIS-Q0(HP+\PZ[;JLU*/L@*NL45]_N[0I MH;O%?A>,3S:M5(G\DM&!ZZJAMWJ9W#]MX$*$"VJ39*2\!G'9KH==!S[H;BE4 M)W0=N:$H#4KV4YJ1I#$EUTSFRH?260DE+B)?H9RW)=#;W8I[M:EF*@WBXYC"C8$I"$;,>?Z(!=B+6H\ E76-E5V%][C M,CBK./A:=PMEEU.2.SE9:) < 15U+2FI;!2"+7LV;\1[L53FC?CK;$0T0^\" MD+V]9J9YKPPU$T)B=P6)OK.-:0T741]+&A)H/M;!-VXBTG:=JW!UC+)%Y ][M!F3MF>:":3W$^9UNP8EZ0>H@N]9196UUV,=(9,71 MR$%"KDH"!=-2ZY>/(!&;KD&@> MA0E0>-8&.6G09D#81IXK$\0=T12M;A]M.L?^<.1K^BGWZNP%U#85MB7BMVJI(4B7@-> MUS5D5^-ZWDRS^75'K^.H0U<8(4P S%^"(X24N9%+-:U_L?YJTH.KPD*N=R;F M@YR2+&;6;B\;EQ*&T\W0 MD<4E6[QIY7ZHI5E6K39@Y=P^C8@Q8J?M&SI5D,/D\64'NQ?%11,]XV.T.[C( M6](=I:!U]GLV>RFH8IO)PRN:9$2;BMX&8>=TOLD-#=XQ]?V!R0 #::[YX(UW M$N/:C#AW5K$#7XXOOH8X6'U@8!$JH_*]+2]!8Q:N<_QDIHZ& 0K'DXX^F_7) MMO3HW0U)%#TW2'[_(R^[S/%6Q08$';VJ;+H<>&3V0/,?VYCNHFEE02Y]$T+> MPC=!Q72ZHV\[(,T^R3)R8T=E)&WE1406L3(M"A#I#B8KTQR_7E>'R7ABIPK< M.$G!UD2[7\^.%;>6YJP140E!=%J5I-::/G!HH>BQ2;P6[T>MC)G%= M'^Y4V80M>R*\3+5I",>,D19AJTN[C"K?6-I+8VP1]-"S.XJRNM7BB W0]ZE\ M2XE25X]L/B$SOB5I)S4%19&W_.!8XY*F :_0--7'+_/BSJR*?H\67L'> +9Q MVDO>N8MSG_ESL9\J4_=3JBW&#[JZ3=GI%F;K%;?Q^!4Y8R0N(/<+W6^\\BQ! M\0GZ8[Z:^V-F"8I[LQR/CW\[ZXWTB_V+_,1WO&#)\XDG=O<11_9"!=>B,S"V MR\6J8=I[KL.(03>0=Q*TRNV\T<)/"[[&^.M8^/9\YNHZ7F&_LB3EZT24]3I< ME70!>GTFX?&2\S?2FFO*I0 M" )[L2T89IH3Q,FZ3XKG/#)VC&?&PP>WYC^MYB10BR^?TY(23>T(G#]>NT+ MQ/V3/:/88D=0X=G@-4E>,*L2K5I9;ZH 'R]YC1-30R'^O0OWP#=]%;N3&*$G MTHLQ.2WBZS9PD4"7_1"RN^1:C:,]#"JD&[;U+A06#0HK@) ]Q=LB>IV\ SH7TNOXJBYAP.L\#X>*!; ME4\_-B\J_D@#O"PZ*8D#<-F&U.#E\(_7ET%)GRVL) ^J/KXA\F&=F)>CFW*5 MS)NI5:C*P!D%K_=U_%)8CHPV3FG$RT>6C3_#?<5%1N@]<0"^@1+.K6PH9L]=BW8!)\&A +KAPA,S7X]G/EX$ M-;!82JBO."> 5! _+^ZPD2+/ZTAZ=K0CW&M=/,0TKUX$$H=26OT M#*O-+K(^K*L@?8V<"YIIIN_]07"WS@]*:$+M&9BL;L\6#.7.2>]G>](@>4?J MILM82>D##I0E3I?&XZ[!YE"[7!]JI?JQ(:"CPBN84[5U]0A$?&*$8Z!_4K_: MQKJL1:M7M#5GO^K!;:=/Z5?Y3@_M7H-QQFEUPW;B/?A^]C>1L M<:O 95,5]479K(MV7=8T"G)D1%C3-D[,6B"U$BX.L2+S:V[!,8HB[=CI6B]_1/H&B;?=(][/SCDVWZ M.;:BOI+/D0]XONY/^9>%3!P7;>IL*LGU*7L11I5_UZD=$6^0%5/!VU5VCI+, M<$;:"A0[+UQS)TBUCI\&]"7AVGS+)X]HG3]ZE#&V%76M+2H3DM["87#BPG8U M"VHG-<&O 9201HJ2?0[(IC1B<*6(H:O:O&BN *&3-XH8"ML 3YC1H"LU%PM MLELCU%NXQ(I/+ML$&@M%#*M[P0&H?.TVH\X<Q]S7/Y6(R5$4K'V34( MEEK7FL&G?=EMT>O.;>=T*B'TGAS[,A\\XFG6:(ZB/1OG^XF:I=WW"V:%YNR' MW2.\EV[PXR3("KYSG@(Q?IBH5&OE!$,HQHGYDD[_"![@E>5?*9\FZF]( D3? MX>U>W?+HW15';V]IF9_QFQ-X+G)"PC& -YSGAT"%*2V9S= [ [S4DW2HJ_(= M'^A8=(H;WF9SF*9<9E-.3Y86&Z"8%2 .U0\M%K@BOO&3)"N5$1B,CR:]43QK M>,M.[)Z//EOH?!O6Z1@71/1\-'RF1\.?S.E3JZ$.D:!!3_DS#)F#G%R/_!5J M",*^LBW;KI_0XX@;GIW$=7+[U?D4&W='$0K6S30CW>@K/]H(ZQ5/'!0DF_P+[&XRPDC&!^!7V&-[ M0\8Z;'+^TX;X$GYI:NJ#W;IL_ -GV7$OLJ]..7G%\M4@OBCY>RHOP?K4P9JSBR M"'NDPVV5PA;X_C[N2V @K>#*^8B6B%\WCU67C'13 &\+/;FWHTA.0/3L>N^(?D$T2W*3*;2VS/Z)A17U.1DQ6E M3[WLE._P[Z R4>O71(H/_GBUZES1V^VF7"M?%UG:BS!G10MK_T3=EI35!5G M(-R+TK4)$AI?%UZ(5]/Y XLI:#+CKPGCCO])]# M((B^C_J&/CR M6U21NPTF8O'IRA\:Z#!KRFV3L#>C1_0J-E3 MR1#;P,0)0_V/YI"73;!:.33-[WK$IF\9U*W Q6D@@7G8K%0_RKI&OB7?9 #4 M-V2@M)JD'1Q, 4I/N-0XDJE)Z0-_T_4E-Z[@(S_AIRYNBT1Z0)8Z&-G EAGG M6_#*DDMWBN*1^'PD@O@R[!5LSE:#Y]-^Y,<(0A^FK.N[6PURA$"?P!XR&OV. ML8>?(\+ZZQEA/2.L[VW!_H^\_$SEARUML3]D)XMTYG>@=%V_R_ZD246R2*E] MQB<.%3E]2L+V) #1G>3+VYV\BG@L1D"@"&F)$O-PJ#DY6%ZRE)YDI6\:IAQD M=@Q.I$8F*TQS$?^A;;%/:/$];J58K#ZTP0!A:W8W0F&>3U\&[KMI;U2*,Y:^KU5I$0EP*QZ"'+W^;NGKSY:2I^\=U6&FR](JLURA>8.)%JS4 M&1BYR5UG&M+YR"G&D9NP$[GB/F_P]1!/CNRD/*(I=YH1]L4XB'&/Y.-E5RFA MF=DWI?!1&RV)NU$J7T@$0Y==,6T(\VER)0XS:8_DS-7YXOM&)U >"]$ JC\N M; ; \NAUJO):Y,I0PL+=;J@M]EV%_CJ(#!C\P"C$O:?IX@A@J\ /E)-IPUR& M"EJ62C4I]GK'H6R(@22%7)<"XIAX( U!N.%F)X+D""T'YEW.8DNP)8&JE)9C MS#0@O&O0^TN;AQW]EYB;VTR&.UZD59@))4'3IR-9=- M9R>#=BT>-Z K H5Q_"81%QU\J-HMK5[,Q*L2'=_*;$UAO5,>* )C)\[U='!/ M'.H>V9J6 W?]<@.L.1?V;2%FOP$!*]+DY@IH)H5%@78 YMAUTG(;A:/VAB>: M-29>[S\'.KBVAYLVN7^'ED<"-%GJE> _/[YPGM'/R[F",I%;F[%H\LO",*3: M!G[ @YB8?[@\/%>_VW\EA]BHJV<@ ^,0 (W>1DY " Z M"\Y1Z$;P6@XH-IN65,92==UKB9>T\30P5_/7I>?A0X\2) M1@G<.ZN6?I)>B./+,L]/43O+=VB&9!%XW(* ,%OA.R.F<]6 M!G[>OV3];^QK>.O,*!_:F[:X/K58I>J@D^I=SASVDFPLJX&PY0-TAJ:ZD!H3 M+_1)/TE[B,D!G!Z ^. 3/1:YT7:=0@FE-79RW"3,1OF^&^5?J=,T;I\;$BZ" MNTUPA:53U*$%]_]UDZXS H3KXL ;CGF5Y%_3&1^^\_=_^O[U$]L/"_WPIQ^> M_I?_+'$$*7'2+TT035=YIIJM-"M_NYS0+TL&S7F?![<][RKO,[61=&M^>(,8 M_/3DWI F5/E4"]29&S!Y>SD#X71U'^5NI=8"[;Q%_384_%5NFDK54B1EBJNB MK*1P;3'/***B8>P&.B9]GH?!3EH-XY"17!6:#/Z#I6IB8BLV"QP6AO-D##*[ M=WTZG T+BT(K%+@M Y5=3P$A]#3L'$EZIS3H0=DRJK45'CF*^U;EII2>XAT+ M1E: JM&_?OCQQ^7MAI<])?TL\3N-!X[VG,*7YK?Q5>8AI'%?:?NU2P:I[TW_ M,,DS-5ZBHSYEZU6ZI=C018V,DEMVSC25PQ"^?=/U9\GZY6T,IXJY27Q,Q]OQ M\5.A#98GX+KL@I)%)KPRK:F:155XZ_IM)(AS<0L-4]'E8.6;']00AE(&'== M+5A6!C8)M7>[T *56Q5#S0R5&:*83T=N.,Y8%\06,+M=7U9D7.29;CAC,R>: MB[,*_U U>1/T3$_(GNXO2M^RP)+PD=Z8'-ZRQ]85N/L2_2_]6K)UYW\N8 ) M.!*0MB1A+Z1WUAN@E&Q(I,+[]*?Q[!S_1Q'[./KIO[*VGC0 TC?8^,R+YKXO MFCOTC=]:.=M YHF*NIWN2F4S&T7>C*,>.5T4>_7"+_!-:C\E%?6(Y,TI;W%'6/V]+ M4R\ M()<"7@9!FDO!;J"_K\%(C7Y:&].%>*@J(Y[_H!LX#> MQA+*QC&!Q,_I;;DV)\M?A='8QN%9\KW)0HQ#LB*"][1F]\BE"^",- MA/3.46%R>@@<2-R/)$XIEV<:EF0=COJ53Q1?;4;C4U3.-1/T0 +^5/)=K'PFP"GMUS/_W<-8AG<8Q+K44N522Q"9V%F505P& MB3=B^MJ2T*X^<$0E/DDC/@?W#VX!?N+@_IA8 (I=IOR5$::I:UFCTTOBBX9" M 58F=.MUE"&P"":1Z;"KZ!CTNT/7AYU6U)2C5\(6H! K]*L=M4ZH?WFLHC0= MQ>"93J,%S)MUB( PBG+&8JZI^\X=&9'A@$NYG&F(=TNMQZFG?0($L'AQ%/!) M3&?B4,9BD0=]/!T1SSXA>)7.MR3MXOL..:R/^H)++]SWA\47Y9>IB;#!15*O M\5A)(H; M3II=$YI?W >-(>7FA8/%^[U4,@]<(2P^$@]+0VC:/:I;]GUZ8V#Z^A%:FT\> M/7XDJ;OG+&VW04C\@G\&MD%=2L]?/%^BPUQD1JV\Z7H:*MO&DDNYYA/(B:-V M2CLDZ2$DYW+--#1TY)*GFH1.20771#K127]"EU. ?'B 8M=PQ;47XFMZ_6C/ M@!9(%TO8$LLJJUCC$)\9_\.!0FQ:&6=@#J2?=D*BQF,65"A #)Q1$J8M2=_1 MSTRL?25FYUHF)%?J3+ ID_.23N37^%747,6[-9UW072XUA A0[LL*GY=9;T= M.OD/,@"5?$8KP5@_Z?-_(!F0TDZ2 $5GQK!+ _DT(^=NNO<,U^UT1^//AD_A MCA)'%QEJ!0:4=;HLW;?@Q8;EU;071:VI*BZ2=VQ?R^XR&->D4%DAT5>\ERZ> MW5A@UEJI5V2J&$;,2=IU6^ZEU4^:EK O@6.QUQO5UWYBJM.7"Y!$,E;EHMB+ M?1H2?!/[3E9 ?GO 5:39@NTGQ"J_?O0;LEXQ T.?_XX^V0]M-Q2UDK"%Q1]+ M '@[\BC^.&PN0H]^=5!E/O[]TK%R%)U^^NV7"P!4SIKM&9.7Q5'R%[8<\S2] M$ _3AEP+MYE+EV%Z;*$U"19-,@#:TW\EN'0 MQ8Y[7#IGCH?]1A #2EPZR^?A!%'=B/';4]?AL;:4$9LLJ]W&L M&.$U.C;P2*7U3,UE]-(C 0B^-E3668!J"J!,'2Z6'*U,G35Y.PA?V/>3!X^' M: )(L@DF4RBN$!8^^!Z3=IE4%E3']KIIWV6N\S(G+)% #>9$:;FB.*!4 M+?+T'L8/,6:Q*L>+/.9*BLTVC M#3XOO_CS^>OSQ>/??_/UEW!SV>F4^FS#>I7+Z+;M0U'I9J0WSIN'_B7K?OWL M1;$A\U"LY=^;9^!:;I(H]2692^&:#N1[-0?N Q$T)>YE#\UNF;;Q'4V((F1; MOG32>+7>HPVM*A:I?K_F6@]]Q=2*$;FH7G'C>CBM?4C=5_6.(GD+KVA,VZ(IR*J-[7: M0UMB;*VTY2>*$,IP\=VC]01SG#GN-SE)R#A@R<;#AHZ2M7;I&=)B4VJF9(TC MC X0%0SFM$/11C)]Y2#FV1@Z,8MI9:+3;#2.$2B4?WA9='H@,GQ\>DZ%,TIX M>$$V)0?A!>Q3N]A69' E/X,<2FNDR71\/(+'W@5Y(^3BKB_Y+!!(@L6IMCN< MY#,"5]#]L[.U]P=(MXP1@"9I^;>6E=U",."]31$'DA)]ZIN+1%>Q\IR_.9QV M>-UD[S;1;"*CX0[!WY,&^PIX=.9QP#I,#&W.B(C#>[)V)S7,:G44P>+E\ M,FEJ%5M!71TR*NI JB%^H;0(R2 _GDY^R!&]284#--T:/5CD@@97@J&@N#?D M+VAP>!/8+CF2]X;/88X!>PKX];)MNAWQ]! @UWCR&SX5R*!U?+SQ4R\%E+^1W& B!LUS[#$.65I?&2L-\3H+ MEJFT67OZR'HE7%R3P]X4:D9/U1?O0OV,&><"V"_'&8D7SU]_]R:RYDV-3OLV MNFPZD&?M!JP^$]GXL5 'X/?Z69I,NL2O7 MO%0?_R:&]FYQK5$4T+L\)U^P6M@%[3Z(SYX^6JI2CKE:3Z:NQX4S;BMI.*RK M;,Q/-/5(T2JG+Q=OB_?T4WJ5K[E/>.NVYY/)W6D4S).KQ%9?7"W>];]LNCU7 MS/C#77&!+AJ 0K0PS4>_)]'7/RJU8$HY708K*HA&0@)Q.98'_I;; ]AR\*& M\9M>V:H,I_FN+:]7;&?X\OS69>+9D>3+OP90D+[YECQ&Y*4GG'29;7CK4[/I M>LO,4=ERJ@>QC!<9BIPS[%]):&)_$DI^]6;0ZW\]54Q*U#R&#V"/Y*=+!O,] M'LNRR,+2A"T.\XM&'!!WKTBGD:I (A%D(\MXPY*;]TR 1)B MJ],S!62P+Z:0#;WR[*G!/.1]OIPPD0RJSE[L77_K*#T;_\JTF057LQ87*X\)ZX";'M0G5)H#YL7_K]\ M^$./X'GOS"=P],<9/C7+-+/?Q2S9*V3)['C\5E-SQ79;MCOSO7P.U[M?R"JA M=,YE9B7.\$_]F>V#SQ$<^KL9'#J#0^_-<32T #:,NQ%4V/"L@PSX8S MR!SVU4$H@&5WQV;:JC[@N]NK"KPYF)Z.4X:@7T$15 MZKY%=<>A&4#'0,&NN!\Z9,,W/,,' /"8)4:>RJIU0@N 1-SZ.-LHGA$=(Q/^ M.;K'1@<&DL@;BMO7O>O'>ADXHVMW$T@DAO7G@=[:XDUHKV2:R)7Z\Y_?+%WH M 4<0HV;2AG6$&S%MJ0B#<,![%>+9-_4:V;^N+PO+S&R:'3OJ:^7V&D#HM;XD M3]E"N+0N4F?Z]WJ(^NP!-V%$%,=2LT/",2:_OJ#(U"FZ&<1%7HJ?)U6"1VR# M4[Y+X+T?R&_F:+0M5Q:K:$)*,K!8*!0K2&C[^T=?+7[8\93)(OO)"D+"%\"( M(9Z(J.*0LNM^VEY"?.6'Q*\J3_=CL^$^.>TQBO'PHZ\XABR=;S#AB0RVI?R=)QTE?T MZU@VAR:Z70DFN]=]KB3'ZRP5BQ5Z8UF53]2*_34I7YOUD(HJ'8^BGR,G4G60 M8KVD5?6RATB@)$"^-M'UI/6>$JRE*W@Q]M*R?3!Q\!)R5)Y_VLE')!>N$NE2 M8XKQQ>:L#[PXNIHMRVWYGAQ?9P=BQ-]:"R:OQK:PJ(^_66.XWT;$\R'GFP>-( M^_*N\)FB.!N*&>=Z(<, ,:'9IZ9P\^/&[P2##$K M'B>%*'@&GH-,,&,P&#L!^V( Q^P8GLH"M]D7PD_LAA,!\OA9C+?\_5+'NI6Q M-F%GQ(,?U9;C>^(M(1G \R7M%([ F)];TX5)TTJV-)^QSJA7S3K.><241;#; M.KDEN0*V=;%2U=;XLDWVK;H*2$F.AH-=.OD M'<3BS;Q#[PS ,;0PV6P\Z14H+CCIF3G)<\>\X9O5##\1(9&'TQ*]!1B](1\G MKF>0]E]>00"67:@[;+$^?@5C7EQWR\6(!BJ"@@V *UD0_OZ( B1K!YN\EKM$ MF\C-W(-JV4V14P[1Q:$.Q9ID1X1B1.OEMS$BBYL:KVV_+5U[JEC,*&F>-%;G M_7&WA2CU+!5@+TRD1Z['*BQO:OP4WPQE9CF;M*=T>8JUJ=.80OQVT7&M8P') MK4=>@WZI:C^=EJ^9S803G@GRV?7Y+[ CE=C>R%4EY>:Z[42=^G##09PRO (= MYJT$ )YQ2_O#A3'AG64D([CYK0#R>4HA8\Y=>JE1(9W6RPPV39NF+H7D^E2? ME/>1BT,C35#>CMF6=%V%Z'U%2A-NXO$L_Y9QD6B3U)A+?4OQNL>YC3^,-NFF MO+)=H!N'-\@?GI[3-OO-LZ.=NRD[FLS#'QC!>9NRF2B%'VPQXW=G0'P^PW8\ MHUVTZ_[ >06P0TYMWK0M_*@>Z&[.9C1.9UECYC"K'W./&Z;7S]I77_WNV\?? MD@E]_.B;I]_^[CY>YKOD$W5*< MJ=_25.G_SAMHWD#_:1MHQ)W0A1Y\";&2YI1LN,6\*-NXT*GAVQF4D\;U^!B;0EF=3>O%WNQPN=M\NONEU$@P0-&I+Z$:7/2Q'<9#J; M4B(@H^_!+^?-Y[Q9[CZ.$=9L3CN@1]C<+ZE.)!;_I/@)PL:N1WBX)8H/ -=_^2M]X+CUAPOH_QR;2GX_ M-Y7(CUU MNBH< &564%C/I-4/;BM]>J7<;:&E<&-MG43A6+T@4]AQO>5@1,C;_D&WQ4@4 MX>5''I7A_LIJH**TM.*'=FTD$\>;)+$$ !&P&1?,FWJ,P4Y*5R=9A)/#>]1; M(UC]'Y\OK9K?20N+0@Y$K;:J(J=#E#I2*^'A0?BV]/G;(,NN[ZQ31U@#F/2* MT=2M^SQEW,0&+=:7H6"H/.2@%)=$"\TF-?7-Z8L$_$^!0ZZ38IEL3BM)BS1M>9MYF,ETI](TR(HHC@"&+G$0O6&ATT898>NQ2;]1EZH-C#'A_4.H& M,+_XT,8#3EQXXW$PG@ 9 DN[H-PX;ONQCNRHH)FX@]$*_9!=7Z^A(BV0>1\U[>:?5SY&Y(EU_Z0%Z6;>< M$:2D#@ )ZS+V#;\AQAM!1.>GVL&,AC8BHO0U\S1L ;M)JD\>L_[+FL7>S,UB M__9FL3?:LC,N?]2C8[K.M3YI!N:5F@&PF(4NE8 AFSM!0+!JX8 MG7>'1'/#%[$5K&U>X'>$"2KZ\0\% *?MRMR2%E4"=,$YNV#B;9@MH=-Y5S?7 MM: +F;J*' @FL*4]5@GREO'9Z'!!4,O+%C,-EVS>"+>J1T M_4XV(+K\E5;'E(@RHJ-5&7TBM?69<'(\7'_[5];&!OE2PK-!L?5 G^!P^TDT M!.>U<]_7SAT&Q2_+KAWV:@=[.QC5R?SNQ:3F;F+6AM@L/)SM($T8W27;S@OI M);JHFE7B4J6;DFV."CB7I?F"908-N"Q;@\_ CK\+!RB>DI&\+/<>14V?-'7- MG$@F3^0(XD9]#O!"5X&'J,97A#@RT;C-A!9;1ZD1"$RLWP+ MV0FI88EF)^ER2J9%F,M.Z-9HA81=%9^7N;E-8T["/+B-_8F5PUQ1U+&2' G8 MAGR?J/JK[[0J%E>L*R*78A>WR0DOG2U8"0>N2"R*#9#6D>6)[;_\T&:/^UH3 MK^NPUYYQ;6P"TQ]3M 8+$84UDTZXI4-O.Y+\V#MV'J,&G94>TZN6KY#C$4FB M;463,Q@;NXI " >N(S@<462[>;')L#CM@[8T6@:7866+D4Q!FG\Q/^*_#Z(D M&,#3"F(:SST4)=*6C-A5]:68TVB8+'R=Y(3-W(!,EU,[X/FFJ2@WFF+1YAQF M?YR=SL_)ODP["FY-QX6,<(X#ZXY#-/XB;[)%DJ78:HNDEQ:2[2@ R339PY@)JQ:371O K6SR27[D[,AED=SGTBPW'N/9] M-2!U$B&9T$-?2EJNZ+)Y4[NP%(-S*:+NVZ&MT$&];G5ONB&HCH7>L*.EFKZ6 MMGJ>ZY@2$:B%\_:(P7FI#.BF5??D$>=YZY@D@'DQYI6R1CAJR0$Z)MBLHQ[% M2>&*R<99)4"R[63>+LFM2+F7R*W)K%DP:HT2.R]H%_0L2M -[55@B0\:TY*Y M:**=VS5U23,Z6OKVX*Q@9G>>]J'0ZT+$:_"=X>:SXC?;*KV6L[(: MG\65S MBZ=Z:/IAT^9_18[79&P$Q=-ATBR_"^<4YDFIG"$S\6_M2Q>2*EG/F MK,?DUE;V>M,;.Q/&(RRL8GVIQ2M[O5P9\;Q[M*@N88/X:;VP!B?/:W<+,#)G MQC IFM:;T7>U)W;EN:V3V)MY,>O#FB5;!F7@=^N"TV=8+AG%&[WIT"&OF@9: MW+R6319S$_[)7M$R=Y@ZR]F*6HRR&KJT)>P\,JU+NJ>U[)L 5LZF7:2U$2T7 M_:N78&S#XB_&CZ\74+T\S0)R&>AH%K,I/%^\3'.8K&!&HT@[M<7C+3.^F]CK MR^ITS0")3>3\]KW]>6KDG6?.STGVZBF!\XCQ]4M3<]IEZQ^8#(/+\&BJ%WN? MECGGW=-A)G"YAD::$'=^K1AF3WWF2'_R,4>(5A\.X%VA& *9=&9#,MV6LLU. M2'=JY=Q;(J (DO!OEB,C32LWF%G*K4J 2(R%\+(]O*1BFD@3<8IQD-M6IY\. MU".U$C R/WJTW!K^PYY ]<+QD-FX>5YT.QM_>C30?#'K5F6/S@5LZF;PC1TU MABAZJH:H!@92E2U.'8BBNYQ]L$T4]%W)M2;/_87S?KCE2^=L]\31E)Z^]#HA M<:7#,YI<[L=V3F001#B87US50 '7>4CLH,$_@^:$T'&4V].9J'0ZIM2.C#;N MAG9Z=XD.E'@*27M3OMSZYUC:,EQ.7].':*:W/:7"*Y9N,L3/EKL5"R &T S9 MS5 *[91FQ*>6/DZ^WM7TRWHVJ*2!FFLGLSEP >W1#\M)IL16L.OJZI MS4FV%3?7/%!QT89@I*F]U,R<2/B6;@/X)\0H99@[1-^2[>(M(_&:NS0N-*"Z M@5 6X+6_,PX0,7ND)#"L9*I51JQDHH0;$<:[G1YCP)C,'Q41 2)C%N]:P,!5 M7U@VF**RLAO58D]-;/HN5)([LB7\="6R^3N WS@#A_CP5/50<. 1("$)-O C MAXO#^8+MWJDA&E-?S)2O#E&&NXM:)+2?ABZFC$S#+V; %=$GMU F0;W!00#F MQ3HN 9G4NI?P/+(%1B9>3IOYUF&:ED%$!*X-OGB4E$EVUU>I(2P.D]L?/ QE M9.FAU"GAY05B,IZLJ:#F/&*FQK8KVM5D MP^#%F!W+$ J!4;2<*AJ]BDM+OQOM0GWPZ5Y-8JO:T'8"4CIYFN7<,$HT(G"F+0XUGA.V<38C9P M4_)7N"?$+!UZ6&C!6@[7!%[Y%7"Q?!6D@J6OQ,J0J0R1Q,\[2\%%RN(H#L3) ME4V/ [![1W,_=C,S)I%L5G3&EXN+$XR(TC>4OXK@.J9>N#XPP_EHOU;9Q>?9 M-TTE8!.:AD[9_14CO?(&F7^_Y.RRJ#P9.6KT?P7IGZ.'(#G%X"&Y2& ),1:D MM]Z;-$#1KZVY[896S;@-3'50^K"^K%D-Y>!J0(#3:RTE>=[L-6#;N:GV][,F M&GHJA0B=.L33TV#RAKI$\;8O=:''HYL\#[KXH 6A[^F8&]H07ZN F,9:LZ*& M YW7!2]O!DE55:@O8C4>=LJ??%,6ZBY"COD8N__'6*8%L$R>NXMBBP5(R>/: MOXIK/M179=O4JIJZ>%'L5FVYN:!-_B/YJG0:D/7KH:6.BI9Z:)=DSV@)MH@- MSCE3%RLA6KG,MV[:J-9](4/ARC5W9$J;T$3P+(]R 9&;UO&=)Y@%[3STF](0 MV;P#*RBWT;79JZ44QWB,>5+@5 MF?A05&H#V-4],UAU_L49]->-2(5:W+WG(K.-],.PZU M_4W9B02ZBV FE:OY]?EC?O;#'YH!N^,TGG-F4UHC-:0CGG[Q^E5G%<08^P+R M4%\PM)C6\XX7)$K#R5>>T'S+OB- >[KY/[P)-\0 8'O=WX(>;# M--J.QIS<'S]"GO*B+^+PJ\-('FHIV8FE2TUD.>5,Q$^'ZIXP*?"@K!(;%Q R M0S3XQ#.G+FF#]&"RELXH+Q?ORO4[WL4,S0[5]FRC+H_#L_- (4W,RP<]Q&^Q M8"=OJY1V0#TMI#WWLEQQ\$26?,-.#.O/@>L!HEI+\5D&R'V.IXBI0!I)!DN" M!SE1P'9H[="LD"_'\3XC0F2(2JR71C\YR^=,#V [(>\%B<^%COCZJJFN@A$] MR*FEZ8AL"0!^DV186$A1OC4.-=DI96<:_$7)9& !:?J"7E;\530A="@F>%I/ M&TT2Z*/+GY9"2\=G43NDM"17-$LD.2+-BM'"'WIE>OB[>K8F-L.XU(T\GIH= M!16JC\ML+I8S2]9U-?2*5.0J@F! M[<9L9\+V\B06D@5@WQAI)JA,LP"I0>45YD8C,LOL@8E1:Q$I@P8D+M@:UMW? M,,;<=&Y:%,8A\--U\G*$M1F*I_PK1/<:4:FHQ:H=+A6&C\H:N),R(7BE(4HQM'Z^T) M3RH##6G!!L$>(D)EH&)]4%-N"Q#&3=(UO*HT$AVZF/XRXHR4DN-)9>"SPJ9Y MFU5:3*)P.;2IEL.^!#"7:%#56WZDP%Y^K G92Q=54->T9.A07K?E#EP04O5) MRIELD +]05;FIMAQ._"26S:$L68K5$YQ"X3W=*\.>3&TT>( *?>%,>48Q=(R M:?6E?3 AWFC6I,[WJ/"_W;%[N M,?CS,P0@?_-H!B#?JS7X<%,SOS+$5.#'\ 0TNX>N'_,)J/% !6HGW$()^,NYN65&$("H.F:3NP/G M=ABEFPR98Y'(>O1&7;-]Q*^8(R R\ M^V4*?R3=^*VT\VT+V^VCZS$ W4E@N/WBU?B**+Q!L7<8'E(3<1J%3*-J:E?G GN89 YQ?L(-2.NS)]- MK_;OP4A;B@[5Z$,SX'Z\^(QIV!4%XJ#P4@6RK4*8>A+(O;M#'=H+K6&K,IRP M:[5D$273_W EKAY8',90(??J.L5: %O0:%%,)!X^3$N6H9ZQ;MSK]YY$6GW; M_.;T[]S>>5LQKXF["TT*' GFHXR:?**1!L::WK[LX_&;2^<&%\<\>RU#7=)[ M31QR3;[X^"+_?UB5SW]@*YHXS<3I\E_4NGZ7;+"L5#C?R4U?)B]YJ;;7W/D( M$1]C7T(R;K8_%PD^BS\FW6S[\>KG3?.W6Z<=#C%;FT!+I4(^\")M>&@;IEDOR)' M=&G1%U/=:>X0&:G4_+$VP)ZEKN:-=3]>_;RQ[G9C530\M"G&&-1DP.J,V42R M#Q,AJZ0&.AI(<<58JGGCW(]7.V^R M0A]R",!X,>E"EG--20SW\5FK,!S#_J)AEOS*>6_=C[<_[ZV[W5NB#J,XH<@. M,V)[L4ZD*,)C51=.BM;* Q9/NMB+/^^A^_&6YSUTQ]F(JBAW'1I=C71N,U9P MH5,EL"S*R[' IBWU]T?45QAW^VM'9E<.>@G:)B5 MP"";L.H7S:KR#8<<1]4HJS6QM[4;5DRS@#,/_<]:HN.X:UUTE_/6NA\O?]Y: M=[^U6*O',A9,#- ?%IV(S"L$10(L0=9T4>.]B 1G15Y\5CS$IJP&Y5QHKFO5 M=-4M1M[D^IV>AO-6NQ^+8=YJ#W&K>6@@'8UR0I9;ERNT4ZW9[4#I2SN/*0I8 ML9$N>,7,*&45,@@'"!J8FV6(XC=@,3F%9YOW\#U99?,>OML]#+QK4U7%2CL# MEU,(5([W*MIZ-8"]CI9%N6,$"JP 0EZ9O)$N%Q#@8V2N,#M8&<#C/AS"V?6& MP+&]:!G$+[<-H@8('E1ANE":B6UQ10-7].\P;]M[LK#F;7O7,"MPZ0J ,K6S M)&5&5G:IA2#8(=M3WQ .P2D@O#*(60UOWE#WXY7/&^IN-U19PS7M>A4"+Y-, ML$-<+3,9_\"C$?'29E:RQ2C%6L+\"&Q71>?>=;ZW&<1'=/ MI5V,V%GI'>[2;49LNN:=0EP!=I!4O,\]V%5 MW,7)?*+"BMP?_%Y,B"F>AT$(6BXH_(GPPLP!LTS#](7/[]X]^[S[=S/119#\ M>+I=;;F3[-"1!0Y&\LY$VHXN)6S)Y^Z3SE8-$MZ6\7-@A_9<.,P2!&*65D1, M5IR-%=( ..UBKY/"35;A<:W%?@6>; U>1JD3]Y0<.EF1_.(QY6H3TK^I[5&T $15:#Q>@L MYPA"J#8B)!4Q&0];_-X*[(>97?#!+==/Z +\"7*0GA].UR<=3RK8E@0#>CX> M=9TBA2V@^,B"9^EH7(\ MAUZN[>+-J1_K]\@H%+P4Q9>UEHU<*44$5SQX)T#/0M?76+5E/&@09L4GG%*% M]?ZO\XM!),;T:EU0V%'7*]!!=/M@KP7#("^.!WJ^^&OY+ER7+ SK1-'S76!: MJHDQ+(*;3@@ BAJA_&6L(R/CEMP)7KHU8(H:HM"!'>U;4PKI&M/8B"]7>6^4 MYW$LM"&\C+9(Y61B+:X-[NPNNPIQ J&DCJ_29MV*F(C?#%']UPP(_6U;L2S1 M*O37@>S=ZZ'KR@+/^O,[9H\,TT$LS5]5;D,*@W:(B2^!*Q(?F>R),XD[84Q5#5)1M2.NVP-/1+\=*M.K.UT8_8(6MG9V+(\BO@DJUSV&5%JMEE9 M#GFHA72)15N\.4_@![PAKF'IWJW8Y#:C(\'6"#3;^NNF?=( M.MI;EER*R\E9P\PCA3E8&AFE2:P%%LNQ!ZG7=,YUQLWU#J@Q2+=V0X?YC**K MN]U0ZZYPV^Z>LJ3.;NZO%$\(^RA"VA-LK&E"Q58=/)SA:#I"B@& M7A;_4[0;'JJM?+G:-05,%C6ZQ(F79]3.M70%A(M5L=LA[(O7RP*M2S[$[":K M,N%*> J*3=D4(@ 8?WTT!#BEYJ^GFV/ D84.7+@7@4-0SA2;&ML4H[)Y\7Y6 M1-%O>D82R6ZH2NFMS>(]OE>!SV-OX#\&UI[CT&=T83@"H^33]*]'1,-L?([F MW\VX=[DN0[6!^UB%V+*1+A?%Z1"YTY^BHZE7"._7(41%."-5YS7/+\*[J!/D M[:."%O3[A.]:%?RV,:B.1OI^>@BS\;R;B7U.!K$9+BZEK"3,>7!@Z?1-B5.. M=NK.=!ECF8K7WQ4$8K&RDV) :K'5:I6LT(VJ1_">T@:G7'1CM,TFS9S;9E R M3>.QWB?.2+#R;K&A:(?M T;)H:,I;CJ"BP23P*[:-+A$G(IT]2V8O]UYXK8J MV[#F?;FF_VTYMX#V?W@W/*954*G.3/-S*GC77DB,580.HDU,QGKI)H,CL$FS M_9^[B:=0;[,>7ZR@_2-34"RQLS)B%-; M4H/DM0RMI)7966H=AU#YEF M96#&SMB,N=#/56G$,+UX_0H298?CW$^].5$]^8!V]DB4C5/!%EVLBJY4 MS!T:LR+PO5F.W#-)7E00%;)ZS#E?>TQ*/+[H M;/RK5OBE.*0UJRZSQ$(L8*8]%9 1HB]=.1^I-U>:/%U ;]H,[G DSS MJ_AO4U&'U4MSY^=D657SF+%6/HG+2:?WK7R%#T@,3>H+22:T;2 #(4"@XBBL M,K^,PCK-TXCKI4GD-5R\C;A7BH&F?UIT- @)2 47K<@<$26>LYUU29XE.;-M M#Q24<&A) 9OSMR(LFV.KD)RB.G?WD/[%#X;+D*CP6,S2,=>6-B,P4\: MKZ:^HZ9%P7T=6J37U@6RA.5NWW"9FS%,6[#R*59')& S.[.5>?.$?1QNP@EG M:+@@:X[CUTRKU$6[$M="6/@*B!H!- B"O<%',9$XQJH>A[J^!0M?BSJ(FJ1W MX[8LZ5'+KU.DQ>*+N*:/?*I<9/MC 4K/NPSL@ *+TWY%[[Y)G1UE2U/*M5]4 M?+X<:V<"<.B .OQB\Q'\V9(O1_->QZ#&QS1\L_%1*,683)91L"I7@3.M.BQT M)"3P2WJ.U#NQ%:PQ"HR<"N^V!\$T205'6'X:;A"!W1A)&G^"C3<2Z[0 :!4$ MBWC#M##.3RM/!N;A;HHE)M0V%$>9HZVD>FZMF*MM;E60)9J"*^J>%WR.1/)Q MA68>Q,?%?I_ GL]^R7WW2SY9G\=1>PIGH5X(Y]T;YKR;6U/N]TK0+?8K-S&] MY6H:^6=WMEIFRW%?+,?M*P-OA69=,-(G.313)W_%QQIG4^EP-3Y-<\4@6B[G M6J+D9+\(?V7!:''6NL!JT,RMR43QW=0=SQ=O$E?HNBJXSVIMN!4YY]G5N+"R M/4.'K%/%*,TX31QV*R6AY[\X#Z\/QNN@X-@#YOU_Q)Y2'#VOSQ@J]HUXZQ$+>,V5UVW% 7($T65X[ZM"(CCV MMRD>H%U5LN-_>M])GT+7 'BEP40I@>BPHL5$O]F&%C! >J8??GJ%^.4O SW" MDT=/'J%A.=F1__V$7NTOO$7[_YZOSI[\@4M0 !R2"_7?) GRAL76<;(/Q; M&B^.$-' T)67A;-EK:3;(K4 MC*/ (8JK)9\$A*3V-<1\\H@C3*+F.*BYF_X.:^$G-X!;]++8/FP@-=8N:UKX MLEQ6O$VY6^AH'"PG'_^8UEZ$B4X#MQZ:R;-\X]>;7SQKGKC1/Y%V@[5.$"2F>Q%!.! M'1G8V 4^:RYTM3/O]KUYI?.&N6/!![\Y-#X>A#D!'?6(B MP5>1L$BS0!":I MWGXJ.\C31H@\RWSXW).W/>^ENX]HVK!NAU):FD$UPADLQ:FP5/0^M!VWME7S MKK@G[VW>%7>_*X!S@I2? ;L_+JYXUUQSH4PC$/ M&&ABWEY?LA8E$@:!9FPGB0(G/NGFOW9O5,.^UN]UK75$)="3O4Z@'1EJ!E/8TN,1HA@5*(A7@V&OK6!/U M>UHBCB!V%5&7FU>TD,/Q;1F$+6RH@&G(IW,J\'ZLGGEOWNW>9+A7P@?E+9?1 M\70UI@34B;P>V(7EE<1UC#;3?A_14)X/N?OQJN>-=,?=R\EU!,@A$KPS6Q>( M%M?8+,4!_J(2 L_;XYZ\P'E[W.WV4,U'SRX'@BH1IY-0H,@):(99I/4N M*$">SA0@LTCK;*QG8^T7N:'X WW4@.:?)IMF21OLCVPYM%%G3^9^O+YY<]Q] M229KF'&=,?!IRFXA5,'K9]Q0N_A>OB:?;9[!H:%=9M'U MRW'BXJBOR/43Y;G$V)HFFD?:B<<_1Z.1;\4ZT7^:VDXC^\E*Z$][SD@JR0DM MF_ZPQYVR/E65S>%8,FMQ=5]R+,ICI2J?<$V$U+340MN/&ER-W[ICW3/Z-P@5 M0>^.U>YI551VQ=.I*//+5"?L3#1Q[W?='?8,/Z\72L=M3>.N$W"R@XNY:="U MVC&+3MC,[7=W92"5(T?)TD^_E4U#U^/78DVITVQ6]EO\R$HO5E=1\RDU%Z9W M;X:>H7(LFFR]ID<=?DBE:76HG;A. $EZI5A\)FP6^X^;\:)S?@K MT[*\+%G0H=Y\.D'I^6!]> ?K'Y7I[#K*="0H"]<9C+Y[7727[/')DC'^,#,W M69F==>N[$$2<9Q .1?LB<].%=:EZD"4?'4QWIX1P!YB,IF(F"!;E83>6O=*9 MUN3!+=E/JT6&2*EFWD(Z["DL4CE..J8VMUF9HG 5M2035J,-H%AT5'PJ"!H* M-+!T:8U&]);X"#1?U_TQ8=]81"]7Q817$-J=0$F2_.@FK&C?7;0A2#>-\&0& MYA@(D>14-V-\4I!)&L7EAW;8).7*!W9=])V.-_1\?O]+1N742O^3IDQ]QF>> MZ7^[I_2#>*Z+%_25MJEF?^F^+Y,[%CP*[\-Z0-S6<- **ND-A49*#D/A8\T. M5)6'L$IA1(%50;^J2L""Z5+MF@.W7&@0ZVPA6NZ)6UX/; )]2S!#.RE^& M.BR>/A(2LV5$Q;*+%%M*/MFN8.)ASN@$D+ROZ%!DFF@&VE_3^=A=EOO(7EU< MD-=T03^"BP/FZ_= W).;]_4WYT]_8Z-CO;">NU6@^^#YTS(O2CB[_ CA0VD& MB!/T%X'S'REF,>KHM/-&C(]@7]YNBS)N0=G=* $-/12>61M>=VDWK&ACZ\ES ME <#KS0_Y15K%N8<:RQD9%SW<>*C!BKCIUFFJ;W@T7,VIJG*C;J)G,:BOV,. MA44_YZ5T#C*K+C*-_]NCF4K4/>M7\#RP0"Y21@@)23 M:D,Y3I(,O.VHQHT9#@4%IN*S*;AJA)0-N@(%W>YBXNTZONSZA#[V27;2(^>^ M[(Y'$9?L8L<[\TAE;K)(=.2JKPXST=A'#/??#VUQ(9LHZ:1JP;459WA7O),O<.X:K8=;MZ6@ M&,41Q&Z/,\&H"U7(&%36(U*GLTIO >W\#[ACOX9 M!\8;S0X]_?T3$\3[@?,TS.?RF@.:(2Q>-!N$,H^__?TW2TCH,0%%V,1F^1]> MOY"B8DP3\R5A*"\:0(@B;#EE/B1$BM#E+[0SH#IP6,78/!'KNV@#*Y9Q.JA> M?/WH-Q9:?;$Z+*Z*:@A?6M8O79IUY?IN$?X)@3YXF04K+X2P.(2B5>VU+Y>: M(HI#=C!5MP/I#.6K\?O0>_^"C>A^/=J3?"AOMQVGK_@N3=>?Q;0[TH"C36LX MWX0P7HPGM6:Q=/'2/4^ M7HJ(XV:Q#1N4)C\X(4=IV/_]U3??G#]9T(JM$ X4"D6;,'V2\/O@+:2(D2:* M(6>W67B%1]D#[O=PZ]@?:$[[Y<;B@1M8X(?9P43I5I:?'#$ M:95>E73[E7$&=YI;M=["D!:P2*:L;9&N#M-QP9O07I7K(.)KK]\L8]45HWW+ MTL=#>R#WD3F+N>I]OGBA_BG7?&GG5,5UM_A">[WT3['VVH:^;;05PG&%?WEJ M[8J-:M[IGWA&I_73H$(_ZJ6;$SB? MT8Y]G@A0UVEU^PWK]B>O>-F>$7>\"H(^J3E-BS2@;"2-W7Q$9SOFEZC,+P42 MO:V:ZVGY4)!+3JF'+G[H3=9]Q88A;,HUQU?7EP9ZH<,0V)MKAFSP60B3 ,.% MCV1$O(\W@N2I:5;CTVA\&[CM29,**KL1A<7)(@)4-/XJ6:G=4%V8&)]J"(B] M"^_+KM?:K+]?WEN:VEDAVKAFHQ4L'I[H.;,4@5RNM' 58Y9.J%$(3DN' D^9 M'<#T0M23Y[NT/%263"QK"EO_!^RZ.VF_#4#HY&]5)'R.EH1P\N)^0-GL&<*. MM\IO*#3;\\7_;0:1M6\O)-',!P0_.L""R$ELKLI.)I\":L,/E;NDTL W3Y6( MJ979Z#PR#@3&SRE:2 O(A-MKR>@SYNPE7#B4_/'R!=L0U^1U:5DYHB M]E^%P^+Y&AOIR:-'3\S9T=TA2?H*O=<5-D^(T=B;[UYX*609^&[?\$8UH6UU M252,JJ7E9[).(<^Y#)GR^N)\X?J[C\SE*3,Y-3@Q'T%"/93OZGJ( MMT+AE^%'G08C^@2 ]=URK!;3Z5/SHML'K#S>OA3A!1Z*&C9GB+=ENSM?O&6" MBLLR7&7F :-U\XX/C#.TC;5 J1(OX[& S%#V!2[48EIZJ*KHU7NH/RA F\1O&C9'6(09\<<0; M#N(E!M51T'.CSY>;6"5Z7$N$7O#JZ6DW@UEH;ZM#9R]0?B40RT P8D M1ZTM6/T2C\N$I; 8MLU';=&7H=N7NE14EVAQ+EYS1NY M_?AM$9J[9AX[^=4:2%A]%NG)H M6]=SGN&&;H_/C,PZ(N/DOM"TWVW'WH:8FR2X,,Z[PX:VT3TO,L@D<)0?)_-QBE<%(%13T MD*:T_12;H![0?])$1R].IJIC7Z' MQ\'^3SHR$9Z*$TGA_#ZLRVV9BJTI#.4G[ Q\26$]$'XK.CO"E''97-.\5=49VE.ALH(@7*H3&RX8U?Q39I:A8X/>3'Q)8:F' M4]=4 [M7>&=*@Z-$=PW(2SD&MV$8\43D M."TJB:5QCW\,FXNHP;ZAV>WH%V?:$,%#IR-P6]#1?K#"-/T(V*%-0;T;(AU M1$Y J^]+_A[MU6KHM"FXOVYPRP;"-\U>EK.@&(>Z&/K+1A8<.U=MN0FC>67N MGS4O59H 'J1[+!G/Y/QJ><:_F24_=O)/S-6)DP(CCZ-!YH]G5WT..1P^);3\ M83@7GR-,[^L9IC?#]!YD\9-LUHO+HNV#V*X_'KAV_9E9K >X6NZ42;HOSV)+ M,IR>+CL@=;E8,DC\*O$Q7]+*N@9 K+C6G (J . _IO"\*XWV8XC@$P6R.!:; M"5Z7I?@"B039J'@C09.T=G:6'1V3(Y-76A7K(.B4'2?*\"P"/7)^[ARP/;B] M\ F-#)O#+2T,)JZ4QBX-:> "2B,3*IY]D(2MZYC*V\%B$\_4958'Q:[5:(MR M>TQ3L#=SD.54&H[_C+_MH$C O#5%N\D)CV*J,N?Y ?N.D5!3N'!%ST7AS?GB MC1(P29HM,PB(2&;FG9D4829%^+65U:=VME#?O6Z9KA!$(QTRJ>+W:KW*))ZK:N(: M'22,R(-F\ (A(+@N+='!_B\]>[)XIBWWEUO/5?IE3<$\6[6P2 M[M@D;*Y0<*/-P02Q&0*&L4;^8&4@5-,56@YDX=5:"T#\S4@1K#FH8],P;ZI[ M\MKG3?6KG[-<,!?Z&Y-Q.3XY]9B5).M&I2UQRDVF9L/[==B+H)N4:&E7HH'2 M4& X>N,9A[/5 ^6JXGJY&/9*16W,WSPD/BDK0$^9+JF_;L[ZRY+9<;YX\MNG M7T8F;T=[;I)U\FQ*CRU$0#BO&0G:5U(XP4 4OS#)*S[;B7NRDF<[\6O:"6.W MFMR$N4?\,=NOD40Z+(%FSUF>\3CH-@#&I]OY=FN%+:U]!MR@K+^P9# KNM^C ME3S;B;M7=%?D5HJ(I\I3C32Z<-V+.>5I#RD97ZW:<(RL:G?@13P=P9OV;68C MHC"(I.#&=X"VJ\+L6GY^[CT$;+'5YCK[6(?O&%9R=I691?C.1>=3F\ J;^%* M)E8@I@9*B&U;TH295D]NT*U?XLFCI_::(ZS!].=>Q(;.O[+_F8 ,EA6.E)=3 M3.ZR.',_N+E&D\WCKW\3@8\3PCS^9#*P:'$*K^':2(] '+_TQ)).IQMKVA'T MP=K5.6AC%(L#IGM,Y]U-DW.?B#> ]$6/:XA)\ZB7T^RE"UA?-'OQ9X;YF,KZ M10$PZ$C'"CPH_(,C\!]3C#.=YT&(:[K>$?6[VKR]+O6 ND_BBQZ@71"9^LK;"<;*^;)I."6%D[PQ*1/4NZ5?;$K=9Y5LQG+T-(LX] M!BAH!#0%4^C;HN[40[L51D&F1H9V*P$@-/*MV41^;GC;!W@0W#5G^ WV2?HQ M>%E'?YXWGI!Y()A_OV8<^A5478>=9";4F%?"1B3%O:*W7(?9G\U4AB/G6!)1 MPI-,2H[R5PU@D9 X#/,7@%P:&7N$H$[&B3+,]""_>#/HY1ZV6^2[Z3^ /ELN MAAI!\G6PRC28N<@[5WT,5-!\;HLC^ I--7W<'T+C\8*W$'^%20UIMT3__DVO M7D1TH4K99I!3%E*1X_T&.3[\$CC2JBAWDI[_XO&7T@%$/OF5C"*=*FCM$:F= M%2KOB?@M7!;5]AG%__)SRQ5T76A-I8IO@I.%O@Z*'_X"FF1H\^)8VY:;@;8? M/=QFX CF.A7@[.!:FK1CDO)A)KOF$.S4ZH1'?8I/C<;W] /CR^J1]2$Y$Q_T M5/D[\%7_)>]/1WW#LH(PT1=??> YQAYX[-4R'!"UG>OB>0UMF M3 # Y$/[$87O*^GH/TC#.1/BY"_6&JQN.:7QS7ZOS)!'+S:+\3Z$IV(>GMFC;9;%V@M]'"$D\" M@M9^'4*7WA0FUX8XS1<$)@:\YMGUOO>N]Z?M;N9^X(M:E"FTU_67KG,+!F_: MY,C/@=@K6H:B\EZYL$_E<#R$F3@X;8\#YRI>Q3)G3OM_[5UM4]NZ$OY^?X6' MF%!J@A M M+VV]BSFTJ'LHCMG.+_J'1NJ>8L&#Q0M3OY>8:=JD3%/*-#5F.=['D3&(\L@? M71H+C@QM.Z; ">3F'!ZK/!SZ#)+Y"K,S%_Y)'[?FT@MSWE7)8.2K2]2P?:90 M:XI="4 ;(W&^SMQ:U0 "Y%D+X/:$FDQPRQM3'#/:(F%B@!YCE/J[*K-*YC%ZP& 8UOC"!)Z%&E15*4 -WA8-2<[A+*R@)I_" ME$C%TBW/UW>>?2 Y4YVG1;.Z&?2:H9-=DXJ.V% 2I2'!6$8ENIP9FB/O2@/E M6TNFZ( +-95ZYH5&WQQ"6@X$*$.9N'GWH6'T&1K!R9"=>H"7)BM?\6M'S&RXTHT"H0M)O#%C+,EQ[>-UC1OTD^9G M/T_-JM<#KA\V%]S5J8L2Y>ECJ*X8%PXU,WZN 3S_82R$SW8JC%,K3<9KV3"Y ML_ZJ#\H(723OF.FD]()CK"\MS+3IO:V(W0"P1!(Q-,@J,#]2J'PN M)H^H+0*N4?# ,$EW+.G+U/J=\<7%FN3.3068P&L%,X+03 _T,I:+?788T$L> M\1\D(^?NT* ]UQ\80N!!W\R0O00*M*N(268U+[I3,S#$)-M'MPQPY^']"/'[ M-)A!@-G@EC12*I<6W0HEP\.*4K'50XGS@T%2=F1$A:L_.1W&Z +&FP': $)4 MY[&L$L_R>"2-@KDK&+,>RDZ_C-L6K2?R?5B>^WX'KM=>UB[38$9* M?!DS 2+4D&-:[L.@8/4>_Y6N6BQ&CPATII\W MR*[U78:YOLEHLUM7(;198Z2M71JVK"MKW & M+IU*6BR6HQP<1M1C_QY)&'X-M2-\4(K5 U"GE_%9JSB<#UU>_@\J]_Q M"0H>M_9^1]9E=Q9,AZI$(;AIIU;M8!<$ M_WD0,WW+!,86,+@KP&^%O<,SHG9[[ZY*VX0J"#'2" %HEID4R/B/%[@6FU?^ M5BBQF2)I$-QCF"*^!08BV^I"R KN'V-EA$ 5901_7E:\4=]^U^Y"[:.<8'X& MA**O(4@Z-Z055XO!APU@7=^MD1*>2Q.9FQ/5^,,%MK)MN#F.?FYH2\_57(/Q M8UI4\I2R_+JZ<74S6FH6=74Z$52:OT8B1^1Z/WCQARSZ9AFHC/ MWW+W4#;E5%%^Z@4H&L F,>_$?,+ &:D@\ MY6;RP>9:MM-T7N&@$O>.9X2D:OMKGFE7[9;3F'M(_! M=DW-]P'*?KE/:W3@ M1@A%[M@=N6_#+U9KP0^XMSMDOEH@T/*Q?+4T_P?2=4P:,GG='';$JUXC:EC(@.FXR?GH?9SGX<>HC#MS2B,X8[%NNV4 MY;"SH0E\OH"@N<;F&47/K''$1V)+29))W*E4;FYN[)@/[:OP1Z4;#<=0G;/" MW2L655R6L$JU6G5:3JW>W,'")+24H\02>X;.EC['^T,1"Q*=4A3/ JVO/T&.S%EH6V)B M]NKM>JOQ1D5?13]^2_VI57,PXEK-A8L8G0Y-!V-T.C1@)GZ"PU2L@H!8J8!8 MC8 8 ;%U#O][12$W@\1R,*S:;E2=@VI-(()JJ]FN1 )O[ D0=OEK* Q^4VLT MS %A"T +P9BFURX]0,O?B'MSG_R!!TY-(?<\+,*-I4 KA!M-F0GRWVT7;*P3 M;"38:([HG\I_5]LR_]U*7/A1$H45@0!KV^ZB,W3]OX2MAS9^VOA-$SW!VJV" MM8[MO"5@:YJ2O63MTK65$ M>"P:L(#'>U]O?3[57ZE5JS7#0"IYH<@?:/A,$'#:,N!4(^!$P,D@T2\#IU_S MY94).'W*N/%,!TYYW/1\/M8BQ&]34IGQ((/@GBDS07!OJ^!>S7;>$MXCO&>0 MZ!?Q7NU%.\H@OGM?/.BTK.]VW^[9&71SZHWJ6GS7KC8)WQ&^(WQ',T%I(5L& M\)RJ8Y^<]0GB$<0S*3>D1!IT$H K']_/#^U3H(XP5*Z1^$PA42-YV(P+#+E M0:Y%>9FO?JCJZX+:4 15%90X ?(HJ)HE$.H12YB%]_\&7):/ M@ I[**>$7<58,XY?#[CK*KKD[!LS@;H+&87[,EQ$9(PUC[1DC#E)D@ MI+%-&R4@C5[WE) &(0U#16^X JU!&CWF#U-?1O5.O>!_ RC;2;BC--:.<(?"'<0[C!4](8KT!K<<<1'7N ]#G8L[*[[=OUY=UX3Z"#0 M8:CH#5>>7O@#LJO9U5U)+Z]'T%@"2=4LMKP<1H%<%\B;\<6$#,23B<8L/,,L M7B#?AI^A329>=B')1A%PQQ:<&MZ^^1EZ$?_"Y_''NR;Z54X6]\OOH/:XUYA$'1V%PMX7W *DA#S M]%S.K\43\+_A,+P68YY:R=B+K3]2%HG=SY]:YWP21@G0^B/[OU/=^P/)*6X\ MW\=,P4'V&9E;.#S$0@#R/^ZA)78\:Y)&DS#F6*(@XZAH9>P3]R J8[+N@6WU MT^%X<:PK^B*&-( $Q[N*'G@!#%H,5W36"Z[BU;QILU[4\[W8!@I;G MOM^)Q6]8DD8\?H8E.0A]MY %V3_YYUGWN5+-"^OUQ??SXWXQ&Y-#YGWG0YZZ M"0Q%Q/]*O8B#DS.^MP65+V869BSLD@M5>C"!WY4V/Y*67EI.T!A9S0=.)0,^ M9OX(; ]\"$VE>B !-)&",<7OL309AY$8L%LF@+=NBW2*W2+Q_*;;5MV%;G6$ M]$)]K(+>"J1[BXWL^FX9I(CY_R]U#V9131?FI%\0Z]=DDYIV83QC A?EC M%WY[9]'+]\.+!3#TO63:T>^OZ^'Q\ MWOUV_/WBI-??M4[.>N4E.GQAVV*F<'7C8ITO9R9,0A$4KOG5>3X2.+=C==.K M-$ZL?5ETGF*?I88EI'2F*]W':6=C.@:S=__ XPHYFS+OI7215_H5J]\]^^WD M7];OMO6M>W%\^L!,0SJIFP*$2/ID$DLU2UNN(V2KBE6J/@O^Z_U .R4."?ZN M]<4^6NLJ(6M%FFBZ]#>M6&2M2$?(6A4=Y8]X[('$\')=;^SQT7)5*+)>I)EE ME_ZF%8VL%^D(6:^"E>KU3TH9_C29A<+3YN@>A:<-F F3X!Q%RB@\3?B0PM,E M4SH*3[]4& KAZ8O/7[]T^U:O>W%RUOWSSZ_D,RDI$B+IDTTLU2QMN8Z0L2I6 MJ2[&XL^QU6.)%["__P[)4)$2EEWZF]8I,E2D(V2HBJ;$PF#T)V&E@J''? I& MDRYNB_0WK5IDKTA'R%X]73"Z.QR*;HH#UI6V6GB]:O; DE4K!_7B-E ^$>V8 MHAUK/Y)V[%UE$+K3#_]X5QDGU_Z'_P-02P,$% @ KH0$5>#"/-P:$ M4J< !$ !R;&%Y+3(P,C(P-C,P+GAS9.U=67/C-A)^SZ_ ^B63VI4E>V:2 MC"LS*?E*5&5;7LN38U]2$ E)J*5 #0#:UO[Z[09(BA0I'I(\IG>9AXQ,H!O= M_36.;H#@3S\_S3WRP*3BOOAX<'38.R!,.+[+Q?3CP>=1IS\Z&PP.?O[TS4]_ MZW3(^>7@AMRP1])W-']@YUPYGJ\"R7YI-P397705$Z9OJ%SIA;4 M81\/0DTD\^A2/QGYL<'>]V_!;E1KR<>!9I>^G)^S"0T\_?$@$%\"ZO$)9RZ8 MUF-HDU2%1#%@(=2)JV5'+Q=,Q>VAY9[&TCOTY;0+Q5TLQI9[G=Y1Y_@HHF0B MF!_'5#$%5NRR)\V$XF./=; :D\;6JG.,D%MR)75,/*%J;(CA(3(XPI;>QBU) M,$").6Q%L&9*C<>WH4B]H^X?UU?66:+*'A?_SE<:ZK_M8O&8*A95#U1G2NDB M*W-8D".WRWC:/HHYAU/_H0L%IOJ7=['D4.SJ/&OVWG=M8;(J+Q ^8[!K: Q_*L3M=C!1YVC8S#! M(3 [("+CS 7B=G<3(L)K*R%BL+<5(@()6W^_J=U<5"NUJ"+J3$_I,D\K_*NS M\K]-[6_J9I5%6-.ZN*-7L$+)2+&E:9(=TIHG?%+'1#F]NIXXV;Z./SOV9Z%M ME[K'A,ZBZDOV!2U4J\B%9SC<176*R(&2"C$K#'QP,%('CA6/'5]5Q(5E=/(%&P$#!H M;5;W-E&K:4J[;%)7:2#A@A>K?![7:9K"#O7J*@PD3N"5@'RVJE199>1^#^4$ M?WR^&Q0NQ;J:/OG"GR^M4'?PO[^BU7GT;U^X%P($6@Y@L)!S(\T!X;!VJUX] M$C$2<@7WIZ,>_@>A0"(JB']2X1++C238_=1=9[+&/E#,'8I/YO=Z=PJ)PRH% MA&L(5:9+NW(N6?@P@FK/ (Y 61-+G/G"A>F:N? #(BONPG/WE'JX@!O-&-,J M@6,=JA(XCQ#.F!_!."QD29(\2A4$)UL>FZZZ"_0ZQ3: 'V%:(/R&V'1(V M9*N0J"GR)FP,0O36"?;5M6^IA'HSICEHNUT_3[,H<82W6W5Z\B;5R'JX62XB((SF)#/_#G8:H:AVP.[\E7U<;\&RQ+_>%?1/U8MXL"Q:M.L!5*M M$FRV=9A-#E,=V)'VG7_/?,]E4EU\"6"U=60=9#<6)0[Q?BN'2#;T+;%-M3[P M'#Z0,X'LCUV);WR_-]]H)YAGFF#.J)I=>O[C=G/)BKK$$W[8RA.0/3'\6[SW MC?=V"\L*K$H\X<<=/:$=">JE@>*8[H9B\#: 3Z!M"]QW'#X3F8GH+_8O'HE +W- )1@@I,7LND/6J@J0G7F>QX=^S9-! N,*^[@JK O)173@J&O M"ET)E.\R4*:8FC5)R)8D^;;85L9V/O>%B>LW8+@J+\'J?0Y62&RS!BTBY9M/ MQE"8@05_3BSYBRJ48/)]=@F(+$B21XM,U3"-:4R(WS(YFD&@FQ^/K=4IP>>' M;.#%M$F[$V!!#(\6GQIC&;?+,+-_8F(;)C8&5T7U2W#[,7>L"YF%&RD)=BV$ M57?>\[?3R^#(YB\L76OWJIF)8*S8EP#4OWC8N)[+5"I&Y3@G_Q!S()9%"] ^ M4D?;IY JII*.LPF)9"HI)Y-$WD2_VC3P3DFE>SKV-B!;5+\$SVP.8T."B;RQ M#%L4M\@T%6"7K56"6#:ID6#1HK2']%,!6IMKEZ"6S5_DIJ):_':)DI/ E5'BY!>-9 MS@CT7=>(2[W$VQSV\/<.QP>*N)8X0#914N=D M4XC>U>\KQ4PZ[(K3,? 0P+VP#S@%%7YE3-) MI3-;%KC?BPM5XKW9O-*F,"G],D9\\X&5/-RFBF6/2%U"=9(C;FB16(>P2QA: M5 ,YZQE+$L3JM/UA+_VA[O!9FTFQO[W-9LPV^UL[,#[GP.C,F!MX,#.>S7!3 M60W$:IB9Q+E]/(FIN!N^01'U\/HCWCY:*W&MRD>*<"@+Y3''.ZU$A(O42#59 M;7!HDI(K'NC:06F7W-%J%EQY0O\!K(GKYDM?CJB7K'ZZ1!&&DQ'.'L4NN/=& M2CRO\+S4VL29\K!8D@X,;QV4)44Y7A)C=GPO(12H];@:,5["EJ7S7FVJ$I\H MSF:VD]N>X8TZ$EA203+;!&6Y!^S&N,1) MLLG3-2=)C0_8/D$!R$H"G+6H("LAPIQ0*$;K3WM(F]==,]=D4>(CV71M?H*] M'5*>T07B9<0-TV&LCI4DONUN9+Q0FL_QW:%XG:'J><@.+90X4#9UO,F!$NL4 MS"Z'H7TD!S&"8 @?BY)8SJC6SY[AU''=H6='EB6>E,UU5SNKW(Y-SW&:N;YO M5"(M\8'\@6Z6?9_UVE3TP1WO3E)LLOGO GK%L=+W"9.Q#W,X1[0<52 M;74G1^E6\]>7J,0OLXGLG%WM=.+'5.C862U5+12>1-+##P+RDU"!;U7MBT?Z MN1>/M)UBQUWV>-&$M@VL2883W%5PP.+GW L E36:HKW"O7$O=M9WV2QXSFY^ M:CV6$,%L+*(09KX-Q<@]#M!ZUWZ\JR\T=]'.T'%7H??%DQT=+J4_3WG(!96" MB^DN'K>?%DN\,)LP+_/"I%C))$0D&$')UGTU$J[US&=Y\6.;9> 6K$I\*9L" M+WQ=I%TG[N\,4P%J&TXV%5*4 )W-:\>7-18CVIZ$VN)VSG )*:;V8LV$309B MNSOV"AWC*[1;XE[9C'C>7:"Q>-$UH,D355SL=!M@ZZ_/>9OLKI?)EOE/-EN^ MPUVRK0-L^7)=^92T"X,2%\AY(WS]I;S_V\GJI^[:5QO"!ZEO.Y@O.X3?$C)@ MX4WU?^$M:#BPPS]X+>(#]="2\69$8G-CK+2DCK;?F\ ;Z&L3VLOIS7=O3N 9 M#/0#&,)1C0.B $S-M?G/:-U#8H&JKM*%6?TRBEJG +%:Y%X1;"N7&VRQBE^ MQU ,!]8]^=VNK\^HE$L0U'2^=0-L3=XX0T2[EOCY-3Q C!D[/&/L+[#>0-Q* MWV%XB[55O'+UI*+0$6"VD,MG5G5"/?/M$$,\MG>? R4;X1T]I2Q":H7-_:(/Z0'"ID\CH[V,%^%$R7FZ% X>AM"^BX M8RZ,66!NX4)=/.#:9/OF2?A\&RH(Y/#15<#X>B@&N M@:FW"O=--OPW*@VS@= ,%N;ZPGS]I\#*+R!+4[ KG47V::YX&LV?90V'YX"I M6KNO!A)&3%WQ81VV([X]2ST M$B%9M'Z'AFY-XSEA6TZ=I*Z1H%]%UT*MA/W@,3"Z]Q^I=,T1$J4-?, F<,+0 M^IX)\+L!1&O^@TWT@KM#Y5O)YEPE'&&/'%^/=X2'6>Z8A]GP>[_O.%!'VNP] MN,-P80+>R$B5JS?& N7#QT! ':K8.;/_#D1Z?R/O[=N;U52T-?DK,I%1!+#G MMHEKZ"HX2_X)TV5DAL(J256G^,@4O_088E=F%T\(5<#5S,SV H)\#@L#-(VY M!6#"I R].]:U/N$K GM]*7 >F%A_M&".^53\'9MB4MJ7JS"L[\PX>TCE"W;E M\GJ6'QLCMNX'GGO*!M!9F9M*8^7X\5:DJ7RG(7SIL6ZH9X""T!U:OR'0C:(>IL_1Z;A"N\S \C-VF2LW7I'@D/G// ]RRL^F %:9V M1K0U8AO4(VK>/+E! 9,92B,+,=QPDN\(._%X12[R>3&1_EJ6#,9';"2R16&5 MQJA:FB;Y#<8X #(YV"5R9M:I(Y6KU6V>ZQ?+;;RWFHIAU<:@6R'H"8_Z)TY=9G>M1-4[M4RX$6XXTK%?U&9V/)7>G[!J6,]29 M!8IIK:X9AGOQ-E/E^NOK7M>?4_[<6?)2=>?R5SI?J!D'6#QG3;?\PF8JQJ(M5ZP M]K"1@O_"!/S-G%D<:*=UV%S>;'4R8.25-%*%Q#U,OW,]N\8K?2'B'4Z&@MW[ M]X\^[G&LS27U:%Z=VBC]4%XQ54/M+$TCU;;;>/E]+[^LD6J87)V&6=*]I=)> M(9S49&-Q(Y7!VQ#5!DSRRQJIQCU$"VJ"^PM]!U^;OH5(<$X=%I@OR _$%$,7 M[#MI#6N3-5+YS\)EBD\%9I8745Y$8029UK:\7B/5LS=WI55)/VNLV/W!/0P& M=&$<2F7FZ<(JC52J/%J_3V:M*E??(L)U]<^>]*F7.,=1I>:Z.^NHZ*73=>=,.9(O[![,#7M,?-Q.^@)^.G9/ M[L;7?S+==_T%#)\;#+$?7HTUU6[WBQN/SYALOSQ?@>FJOO1_:M.NHQECNLQT M^^#97-,]WW4)&^SZ]1ILK-$_"QJXT()K7JG@\_A3)(G7N#<,@EN1OK@A["O: M"KK4G'[Z+U!+ P04 " "NA 15E*.IV9,M./6-'&MGI M=OO2H4G(PI8B70"TK?[Z/0 I7D$2I$03=#J322+I'!#?P<&YX<(??GI9.\83 M(A1[[NG@\& \,)!K>39V'TX'GV^'D]OSJZO!3S]^]<,_AD-C>GGUR?B$GHV) MQ? 3FF)J.1[U"3*^N;WYUOCU;'%M7&/WCWN3(F/J6?X:NO3]\_\_Q^&0\3K!YCQN"'U;,^,;ZUN!<\&S718ZS,2ZQ:[H6-AWC M=OO0?QE7KG5@3!S'6' N:BP01>0)V0=!FPX@.'&V,%XH/J'6"JW-:\\2W3L= M)/"\W!/GP",/HZ/Q^'@4<152\$_#+=F0?S4\/!H>'QZ\4'M@P&BX5#Q;X2%; M\I<<_?.QH#[\\.'#2/P:D5(L(X1F#T>_WES?"IQ#&"$&4D.#'[\RC$ B@P6@OT.()<(U@0.BMOUZ;9#-;7OH,OKS!+E[[:_';W-SP[M(I8B9V MZ%$5RCTTW0)@!=E'O]+9.][QO_+EV-8(Z-PE\LT(,6Z;3%F[I0]H20CP_+TU,?C$=']W 9(3/HEOQ M=-TZH FE8(Q -:^Q>8\=S#"B(8<]85$C,W>!+)\0<,!G)L6" 3TA!UK:DOR, M0=&)M=H$$UY)G/IUM_V!N7*?$&49?%''EY,GZ(UY[Z!+C]R:3I+\;','O9LM M;SDVS)H)NJW'MR^XB?6GCRGFMG2V_ W=8Q-'"#XA%JH&)R+XEYDC= %_US S'P"&1VQ$3@>08SXCGGF)A!,^^11Z MZCWR7H#C'ND!5X8S(XB>X$EX\)(QG%B6Y\.HP43A7JG'(&7H9#+H'S*88[?, ML_Y8>0YTG?*YQC85<'N#4PW9'%P!@@$,!%%L6+2#UV08P8NO<1 3BIS696!, M$<3GB6$]U'Q8BZWIG'B0LK/-''P= WQ<#H\<+ 0HO8%787?"HH3[((*0+?'F MD^=:&3.D.]#*(""1P/0&E+)K)#ZR2WR([CC5S8WG2@SKH'I,L1U6]J,1[B/TLOP9X!+38O_!;'7N4^:M$2G4 MYF/-(5=7"R1H!5,R[NL'2AF\!41!!%L,B7J()-([UMF;5L6S;!6K)M#T#9Z: MXYS8-@YZ/#>Q?>6>FX^8\36E$.*[7BAGR12$+/H1D%V\//+2(P048ESEY2W= MP2J&"AG%+4.I'41%K;4L?\V[AH+A3*V!7[D6V%E>]PF2\1]/>:#W"Q MJ;W$+K!= SR8I,QT'S $]P%YTI?H#E!M>!=\Y<)%]H5)7(B-:&*XIVB)+1P# M_JX&8,=+HW3X+B>/I)=>.$P*. 7&I4GO!="P9WR=XW"$'$:WW_!5FL/A^##< MU_1UJ5URS'OD%-FNSKJJN*0AA:#&V_$HE(J_N\X56_-,1R6$W4FT8.U$+F$Y ML0X2KQ:U%MTL+8 4]UW.UAD@90@Z=5JZ_"+MM8RR.VM>MI BM^$E'!U*OVS% MI& 82E@Z Z*P+")%4\W7&:34\H>T\TF*+EU5T5I&D;7*0IG<(JL M\_! O@!1&B1(672;MN50*I@T 9.KK2M@R?)T!J51!5T*L$E+'1H"E;)Y@7%0 M8-4*6%PA5P84L70&I+@6+@512-Z=D2BI=\LM1#%#=_ZGJ)PM=ST%U%WF'-7% MZJ(2"PQT)6.P MB7Z4+:9?P^?7V5Z_R\G)KE<"KB'T0J@@8HYZ&Z<\J3V_9;R?71O$PE,*&+P7 M"T@G:_ZI)WMG=Q!+ 5?]O6VO6NRL"3A;]%1EUQ-@L;+61UO8EB9Y9U5"5D3= MN9G=[^GLKBV,"#X@5O>VX@YBCS!RE&]W9HA OA(0"OY^&--(HT)P19N8$#^T MRT\-\O.\GJ@9AQPPCQR?7Q&R/8=YYV)2UD *M[ W_LY&8*K4'/TMJ=NA"_D/VSYW %_@C!/&]LYH9'S?DJ*<$4?IKZ_$S_'!'LV6=HZ1%4I.4Z[JB1 M@"\36$:%>@)2W6?QD],!>8:D#^<[=O!7D5_J&5)%>Q8+)(]NJ!^\:D-=H=!] M&,.:EJ?61DW=3YDIS=1?3(+Y>N8V?KYP&>0S5RXX'].)LP=X$O=.,Y(RR4=: M*W@I?F&#SU>F^P#0$_? 5"RO)8_Z:KVS7FGP/R(7J!RPTA-[C5U,&>=YRDWQ M]SH69=3\K:QN7\S4X7852?HJ12"C[+YXDM6RHK))1-?E&FCS5+IHF;1QBQV* M(9UPYS"%/W?=P7I9?QF66BUU/Z/RL5G1G$I0=M9M:3"9Z7":IEN_T6QY5.\U MT1;K#+6DL?OSNMS+6)4NY+25K5E#G0U@9:8C':LJKKZM^L5W$G>=GO+MT] 9F-A/ MH"CVV>8SY:%Q%-.(&^T+C[WWLT#, 6<.(:9W6(*>I;](4 8N$E 3OO \1<&_ M\#F(72&(%1-R 8-]L5PB2WKJNH[4>R+4 DCAQ>)4'&-GIZJKZVGD8["EZ%827L"@H81N#&9N$]^M@PS MM[RFZ7Z?UFZ69HH@=;9PVK[H#EG;N25U;#T1ZIZ-]O;8' JJS[G!*VQOZ8RJW.LNW]K)AU1M]CJ M@>H.%:TOHMI-2W9:^G__!J?/'O8$?/=VU27OM?*GXB,Y?/\V34BQ+$3-P.:G ME<,E1MD;FR+Q?/C2Q),^^AG'_'VM(JA8DKP4TJ='9!J2NFM?^_V#>U41D03% MW.&M:%M9'+U-1:DVKN&]9+$D=+\ M 5!9*Z\B66A^U62^Y;%-+S$*]S2$@M" M.>YXY4TA-='G=XRH-O#WSA>U2S1?OW0AN8WS%3NAF_*7+#^H*;^L@2YOP*M: M/Y-BJ^;3;=Q*2E%JXR9KH+MQJ['>)Q] ]0:T4,[D$EZE1B:(N[N.M& 53MKY M F)]U*OZ-L92%CU4J'K5IEJS*MOH#&IZ,4:*)$6BCW*55OO5E*VLB4[O!FU2 MQ9=";MC8WC8>*M?=4[VOQ?KW[M!=!^E+W1VJ5MJ6#I@2JT; %.O4BEC56M,( M?K8.K8@SP[:W"=>X1)R?=7Y88*>2H:RPKO@VH9YL_=Z[>-+$ MC39H]J:LW4:5^N_79+4 +:N44@P9(CWL;WP#;I0.W8"_@,_"[,87X@:5?=.1 MA6HAASUA<4[E+OAQ6GZ ]LRD6##PO!A:VI+\C"$>@I1Y$URIV[DE#Y!%W8LE MHVZEIPMXI(W3F?+X34 M;$&W&"&A37%D$)=1)T_@QWDAX-(C?#4I07ZVN8,.S9;A)1O:^/Q,CZ?HGB7N M 0F6(WA.2ID(8Z0'&LK;B%][\)%XE,87D/ B>>EUJ7KN)>Q29'Q%(2\RW:., M-B06\Z=;:W2JZE5CC8;"R(8@=9O1%;"J>6@B!<6V>R>:C!G8JVC2;6LCFN+Y MKH2^D%VW"$.LIU,<; #X#=UC$T>1QB>T7<(+%]W%KJ*9>T$97O.AC$(1JDEX M(0GW%LCR'ERN:5A/_M#@8;3PB<[I']^/I/9-NQ675>N8\/9-Q M_ )!^5EQG?*!ED1;_:[BG9[29DFI90^N5)1JMP]:2J^Y&VY7HHW[]2:F=.E& MJQ8>]":$5KWIJ:VGO0GQI=QGZ^)+/DVW;!Q<'3<\7P6FA]> M7[.XF<>.SX1[3/)HDHFG3KE&U9$[+W&L;^4Y$"E1 4<6H?7S8M<] )^3<.N@ MH)YB?G30M6GTCG3[?_Y.MQ!V=B):71QE9Z856M$#K@J8+H^SJ6N9%$>-!CJW ML\U?/-ZY)6WMO>,)WD\@W[MGY#RA&\]EJYZ\@_,U)/-?2*KNGKU^W/7[:@(! M0X2D!;LO5B27GD]D];4O6"+X"?7CYL37D,ADR1#)B47+=^G5%4+( M_'#EA<2?__KF>X,7A(D;!E].+CZ.&\R_G'R;G@ZG5Z/1R5__\E]_ M_N_3T\'U[>AA\(!>!T,[1N<.<&OSU;! VN M0SOV41 -3@>+*%I^/CM[?7W]X,S<@(1>'-$.R0<[],\&IZ?KYJ\PLMCO@VLK M0H//'\\_?CP]_^GT_+NGB^\^?W_^^>./'[[[Z>/%_YR??SX_SU4+EROLSA?1 MX(_VGP:L%NT[")#GK0:W;F %MFMY@^FFT_\=C +[PV#H>8,)JT4&$T00?D'. MA[1-CW+PV=NP\4;(-^Z"^V$O"\G.7[>GK'W(<3SLX_GYY_.LEK<$NQ? MIYMBI^RGTXN/IY\N/KP1YV1 1R,@2=\2G6R*LZ].E%7(%_[^+/V8%=UK^O53 M4O;BYY]_/DN^9D6)6U:0-GIQ]H_[NVD"R2D=S(@"C$[^\E^#08JFB" M9H/UG]\FHWWJW" ZD/?I18CSUI%;\D.RK:\\Q\^G9]% MUEL8A/[J+*%[0O_SZS2B>RG;AJ_"P*%=(H?^03=@UZ&_.Y>6QU;O=(%01!XM M3,LM4.3:ULY:Q+2STTTW"2M*&N^ :3%)V5GL0WR%Z,) GZ]E#I(H;<:VN)N2VUUO+Q7^SO!C=T^[IOQ/HIK'O M6W@UGF4G]Y 0.G^&@7/G6L^NYT8N(NL:SC#*&AD'$V3'&%/)Y=(B;E(!O2"/ MMK0I\HN+,%W4B]4UBBQ7;HK#(U?3P P=QV72C^6-@EF(_4044@>D1/.Z9B25 M=)S80^/9U<(*YHB,@NTHSN@&$-$Q3/<$XM+UGE"^&7R54TTA'=U#.0I>$(EV MULB6W.$+I8;M-[OOCEZHE21[=0MCZ:(MA5]YUNWCDJ,@+I6B"4P&OT M'*TI9IV/9[]"SV[EJMN M;VK6N!:FLWG]@*+UH<,*829X4C1Z1RF M^V!R'MM,9!MBS'9/Q6>:FLX. 8KOAT$BG:IDODZCG6ZA"1&4GB5%/^E[>VHF MGYC=Q,E_OWEC?])]T/9B!SFCX&G!^%E:P8I42OGCY?J89>(;JX710G[OA4-K M]_..[A/)F8'P=$$UP6S_&%*IQ7&99>X%;0^;F[>4PUL<^HS4.++2W>?&P@&5 M,"!V'A*A14&>9,TO3"V)SOB$PAZ/HD/#>QA']\=X-7#_V4X:L54)T M6YBD6^Y^EYC&SP3]'M.^;UXJI)!*?A4T79?AF46>$WMJ3$[GEK5,>43(\<]N MWB(VC:C"7ZR=,G]@ MG561[Z 9'>R4@."W0F'$R*3GQZ8)UL?AK+B,Q V17F@7*/.8/RLLL;Q+HL5^ MV05K_?.68(H'&M$_LT&A8C+ROIP("IYI)SJQA%81G!;23^R59Y&-Q7GXYE8" MO5=>&PMY2JX+GJ8=VDL*FDCTKQOO7WWB]S=C]LNOW^AN0-QYP'8!>J[.$*8J M.&$]WA<\8FO2Y.IH@_9Q0TV"&=W(QCB9M4YB0-C(V1RX)2L#82XAA@SC:!%B M9E"38FJO$BAF1H3$M1A95P#%Q#B.6$ #BW^IP4F^EKZ-:6N%J;ET9&I"8$MR MT8AJP&%#N%QXI>&07[U0A%4*C&REYR$NLF1A^V008@?A+R?,@9[$4WQF^@=R MOIQ$.$;;'\,@HK+VC9<(.51(1W/VQX:X=3!'K3BD&0Y]H:2ZH37DBH>#)79# MYD;ZD$P4LO_=]#XEU(YU&+P/6 ,NE[Z/X#G MO9MU_R-XOFLM^C^?[?!.^_KM(+Z$=O'+VBW=>V/2^Q(4$YL.-7/2AD'BTI/P M)Y36T<;*#C5""WUY67-);^%?4&\F*G5 \,OIG_N]'^W 4R5X03AB_ONB&%TQ M<<2U-$ZCW0.3.W_V"FHC>ANQ\6BYSBBXLI9N9'G"$1#7T8>_I%4:D,-F:-NQ M'WM,]!I'"X0+L5&C@,IQ2#P2TO7UKHI4*;B.V5TGJA:Z8:HA/N'D*AP"#F%08Y7NO62)/8UMPUO(V4;C%UUF]"@2/T4SK]BQU6TUY="]JD2G!-OHT3BQ"Y>4/8=DFC+2VV@C%;2F M; _Z&R+L7L-X-J%_8->.DJM7&R-%,@AEFY!,M0/1F&)5G\AU/8U*Z+_C]17D MIY"C728T[MV'FZ#T8BH5D?"+:Z-TSDR0'WB;Q6 MJ Z-P;7[K3&')?65+=WUU+W; D0TQA#N;Y$4B$S"?KC3-N'70$#C1&_95%%K=> M^/H+ M781IN7<2)O\UHTQ%CM<\%AP?(7@,I()-6X%P!#&G0@*CINXZU;AME M+.TJ-99_V1-OW[=J;$RQ]"*O<,["!,#$BR7@ LH[#R0^8 RY_'27]X8;"T:- M[:Z>T]S8.'OIZ<%SJQO+>?NY(.&$/O+[!VU]]$=^-4'2:W_DEQ1D'?Q'>F=! M0=R 6F1^@H6,1.R!6OY_AL)_BV %Q0(X3(VS9C"#8DS@:27-8AT4PV**M%X= M!Z$8&#"BJWPXA6($P(BG-8(U%$, 3@3M/KA#,8*FB*\ET1R*D0 CP38(^U , M!2R153J61#$*X 37+@)/%-L6P4FVRN-.% ,&3NS=B3R!>[F?\YR7M@"G0JIP M)WTE9 _IW7@E<25MX4=WB%*2XGJ-B(W=9,Q%5_M%-=1=G,@>C)!-S)Y/%9T0 M\T2GW27M\[<=/M2WKVKP"(YR T?_M3MH]*=?IVELUE<4SK&U7+!W<,"O-D\\["57)L7 MES5O3BC/L2!%^@0MU\:#X9S.@S2%2QS0,WAIX6CU8/F(RXI\7773W<>_6/Z2 M+%QZ&'FV8&Z7%CPHM+M8<.9P:;'CFP/J4Y1W^':(Q %VL,XUBR9%_K)7'^^M M*'G$4(A4FY8,C+*6$TSS*H!0^C,V]DX>APYD3>-0DQ(@,K#DY3V@0 CC=J7D M/X9%!6C@>2^+6E?#//1H=>DX3@G-. .#CQI,$"JV@]H"V79[*)>/@:)0N1>( M1.C-X-< "SP,O&U!*0Y=[1 '-+#6E3 .IRG A+2+3;=\3AH;0=U4>*^I'\&U M\B?/ 6Y-_=GSVO=)7#C:>?'>#:@$[M)3-GVCF[U+G7+N(K*NX0RCK)%Q,&'1 MLE3=" M;1_:+ 0JV!"Y.M2UK\^(LB4XXV:[R(;/),*6'7'XEZRLSKH:$SJI"*&GW#-= MX&R;R1YFCNY=#Y$H#+(79TO-KO5:T#]S+U?[&U"R,PD2]4I6UL]6E;_0K]<)?)/J%YZ;S*4\/W([N>KN>@#; M=:=_']CN5>(]8+^<_K&_7.4DDUN,?H]18*_D=@)N3?ULE9%66U#;K7F<;.E? M/Z5"@V#APQJYS"^M)S)SI&?:MX M=3UE!O'RT9&N@W"H'%(6ZAU!YA(9 .%3H MR@01I0_#(UB474>*E.]RQ[:,JP(MJD2D/8\_>%PDUZ9B8(YIP54'?%0* MUGN!%$!1D5M.XHB*/!AJG?+@01.N-3VH'<%"["*R(P^W*! "*&A2Z[0Z-J+X M3$H;WSMXG$1+\W! '<%J5!&CD8>3%^)@+$"=>R$DXBJ, Z]=-,:N&4(RQ,$X ME)K%.' TNP- &B1<(45PV MS,18"#L3#YH>H<9F=.ED3_O4S013!0N,/4U@TX<)&P2Q759H@_DN*;B)QS=8 MPP00PA041 ?"?.\5R*SCF6YA@@9AILFJ8S#?T84Q[41F2;/3S&V?'"M]UHKO] M?F/A((PCQ2#SV]>^>U=S,<38HK^FAN9MBNN*W;UYN\HFPD/,)M9XEKY*^_

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end